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ABSTRACT 
 Understanding how defense signaling pathways regulate neuronal protection in 
the compromised central nervous system (CNS) is essential for combating 
neurodegenerative disorders. This is apparent in the intrinsic activation of the 
transcription factor Nrf2 during periods of oxidative stress, a hallmark of 
neurodegeneration. This regulator of the antioxidant response induces the transcription of 
genes essential for protecting against oxidative stress-induced damage and is a prime 
target for drug discovery. Delayed-release dimethyl fumarate (DMF), currently approved 
for the treatment of relapsing-remitting forms of multiple sclerosis (MS), is believed to 
mediate its effect via the Nrf2 pathway; however, the exact mechanisms of action are 
unknown. The primary aim of the studies outlined in this dissertation was to identify the 
molecular mechanisms of Nrf2 regulation and subsequent cellular protection conferred by 
DMF and its bioactive metabolite, monomethyl fumarate (MMF). For this thesis study, 
transcriptional profiling studies following oral administration of DMF were conducted to 
characterize DMF pharmacodynamic responses in the central nervous system (CNS) and 
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peripheral tissues to understand the functional effects of DMF in vivo as well as explore 
the necessity of Nrf2 in this process. Data from these studies confirm earlier findings that 
DMF activates transcription of Nrf2 target genes in the CNS and periphery; however, 
tissue-specific gene expression was also observed, indicating additional levels of 
transcriptional control beyond Nrf2 activation. These findings suggest that there may be 
unique cytoprotective and immunomodulatory capabilities of DMF within specific 
tissues. In the CNS, a novel Nrf2 transcriptional target gene OSGIN1 was identified to be 
significantly upregulated following DMF treatment in vivo; however, the contribution of 
this gene to the pharmacodynamic properties of DMF or MMF has not been previously 
described. Therefore, the in vitro effects of MMF on OSGIN1 expression were 
characterized, and the necessity of OSGIN1 in mediating cytoprotective effects against 
toxic oxidative stress in human astrocytes was evaluated. These data identify a potential 
mechanism for MMF-mediated cytoprotection in human astrocytes that function in an 
OSGIN1 and p53-dependent manner. Overall, the experiments described in this 
dissertation allow for a broader understanding of endogenous cellular protection and how 
it can be used to combat CNS disorders.  
 viii 
 
TABLE OF CONTENTS 
 
TITLE PAGE ....................................................................................................................... i 
COPYRIGHT PAGE .......................................................................................................... ii 
READER’S APPROVAL PAGE ...................................................................................... iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES ............................................................................................................ xv 
LIST OF FIGURES ......................................................................................................... xvi 
LIST OF ABBREVIATIONS .......................................................................................... xix 
CHAPTER I: INTRODUCTION ........................................................................................ 1 
1. OXIDATIVE/ELECTROPHILIC STRESS ............................................................... 1 
1.1 Sources of ROS and Electrophiles ............................................................................ 2 
1.1.1 Cellular metabolism ........................................................................................... 3 
1.1.2 Xenobiotic metabolism ...................................................................................... 7 
1.1.3 Cell signaling ..................................................................................................... 8 
1.1.4 Immune defense ............................................................................................... 10 
1.2 The Role of Oxidative and Electrophilic Stress in Neurodegenerative Disease ..... 11 
 ix 
 
1.2.1 Multiple sclerosis ............................................................................................. 13 
1.2.2 Parkinson’s disease .......................................................................................... 15 
1.2.3 Alzheimer’s disease ......................................................................................... 17 
1.2.4 Huntington’s disease ........................................................................................ 19 
1.2.5 Amyotrophic lateral sclerosis .......................................................................... 20 
2. THE NRF2 PATHWAY IN RESPONSE TO STRESS ........................................... 21 
2.1 The NF-E2 Family of Transcription Factors .......................................................... 22 
2.2 Nrf2 ......................................................................................................................... 24 
2.2.1 Functional domains of Nrf2 ............................................................................. 27 
2.3 Activation of the Nrf2 Pathway .............................................................................. 30 
2.3.1 Keap1 ............................................................................................................... 33 
2.3.2 Nrf2 targets genes ............................................................................................ 36 
3. THE ROLE OF NRF2 IN DISEASE ........................................................................ 40 
3.1 Nrf2 and CNS-independent Diseases...................................................................... 40 
3.2 Nrf2 and models of neurodegenerative disorders ................................................... 41 
3.2.1 Dysfunction of Nrf2 in human neurodegenerative disorders ........................... 41 
3.2.2 Nrf2 and Models of Neurodegenerative Disorders .......................................... 43 
4. COMPOUNDS THAT REGULATE NRF2 ............................................................. 46 
4.1 Naturally Occurring Compounds ............................................................................ 47 
4.2 Synthetic Compounds ............................................................................................. 48 
5. DIMETHYL FUMARATE ....................................................................................... 51 
5.1 Origins of Dimethyl Fumarate ................................................................................ 51 
 x 
 
5.2 Structures and Interactions of DMF ........................................................................ 51 
5.3 Therapeutic Effect of DMF in Multiple Sclerosis .................................................. 53 
5.4 Preclinical Studies and the Mechanism of Action of DMF .................................... 54 
5.4.1 Anti-inflammatory effects of DMF .................................................................. 54 
5.4.2 DMF and the Nrf2 pathway ............................................................................. 55 
6. OSGIN1 .................................................................................................................... 57 
6.1 Background ............................................................................................................. 57 
6.1.1 Characterization of the OSGIN1 gene ............................................................. 57 
6.1.2 Transcripts (Splice Variants) of OSGIN1 ........................................................ 58 
6.2 OSGIN1 Function ................................................................................................... 61 
6.2.2 OSGIN1 balances cell growth, differentiation and death ................................ 61 
6.2.1 OSGIN1 as a regulator of inflammation .......................................................... 64 
6.3 OSGIN1 and Disease .............................................................................................. 64 
6.3.1 OSGIN1 and cancer ......................................................................................... 64 
6.3.2 OSGIN1 and cardiovascular disease ................................................................ 66 
6.4 OSGIN1 as a Transcriptional Target of Nrf2 ......................................................... 66 
7. RESEARCH HYPOTHESES ................................................................................... 68 
CHAPTER II: MATERIALS AND METHODS .............................................................. 69 
1. MATERIALS ............................................................................................................ 69 
1.1 Animals ................................................................................................................... 69 
1.1.1 C57BL/6 wild type mice .................................................................................. 69 
1.1.2 Transgenic Nrf2 -/- knockout mice .................................................................. 69 
 xi 
 
1.2 Antibodies ............................................................................................................... 70 
1.2.1 Generation of OSGIN1 isoform-specific antibodies........................................ 71 
1.3 Human siRNA constructs ....................................................................................... 73 
1.4 Primers and Probes ................................................................................................. 73 
1.4.1 Purchased primer/probe sets ............................................................................ 73 
1.4.2 Custom primer/probes sets ............................................................................... 75 
1.4.3 Primers for 3’ and 5’ RACE ............................................................................ 75 
2. METHODS ............................................................................................................... 76 
2.1 Pharmacokinetic Measure of MMF Exposure ........................................................ 76 
2.2 Acute Oral Administration of DMF in vivo ............................................................ 77 
2.2.1 Time course in wild type C57BL/6 mice ......................................................... 77 
2.2.2 Dose response in wild type C57BL/6 mice ...................................................... 77 
2.2.3 Modified time course in transgenic Nrf2-/- knockout mice............................. 77 
2.2.4 Tissue harvest................................................................................................... 78 
2.3 Cell Culture ............................................................................................................. 79 
2.3.1 Primary human spinal cord astrocytes ............................................................. 79 
2.3.2 Reverse transient transfection .......................................................................... 79 
2.4 Plate-based Cellular Assays .................................................................................... 80 
2.4.1 Compound handling ......................................................................................... 80 
2.4.2 H202 in vitro stress response assay ................................................................... 80 
2.4.3 EdU proliferation assay.................................................................................... 81 
2.4.4 TiterTACS
TM
 Assay for Apoptosis .................................................................. 81 
 xii 
 
2.4.5 Cellular extract preparation and Nrf2/p53 activity assays ............................... 82 
2.4.6 Immunocytochemistry ..................................................................................... 82 
2.5 RNA Extraction ...................................................................................................... 83 
2.5.1 Tissue RNA extraction ..................................................................................... 83 
2.5.2 Whole blood RNA extraction (RBC and PBMC) ............................................ 83 
2.5.3 RNA extraction from whole cells .................................................................... 83 
2.5.4 Measure of RNA integrity, purity and quantity ............................................... 84 
2.6 Quantitative Real-Time Polymerase Chain Reaction (PCR) .................................. 84 
2.6.1 Quantitative Real-Time PCR using the Qiagen QuantStudio 12K-Flex ......... 84 
2.6.2 Fluidigm BioMark
TM
 Real-Time PCR ............................................................. 85 
2.7 Northern Blotting .................................................................................................... 86 
2.7.1 RNA probe generation ..................................................................................... 86 
2.7.2 Northern blot analysis ...................................................................................... 87 
2.8 Rapid Amplification of cDNA Ends (RACE) ........................................................ 88 
2.8.1 3’ RACE........................................................................................................... 88 
2.8.2 5’ RACE........................................................................................................... 88 
2.9 Protein Isolation ...................................................................................................... 89 
2.9.1 Protein isolation from tissue ............................................................................ 89 
2.9.2 Protein isolation from cells .............................................................................. 89 
2.9.3 Protein quantification ....................................................................................... 89 
2.10 Western Blot Analysis .......................................................................................... 90 
2.11 Thermo HCS Arrayscan Algorithm Creation and Analysis ................................. 90 
 xiii 
 
2.12 Data Analysis and Statistics .................................................................................. 90 
2.12.1 Transcriptional profiling time course and dose response studies .................. 91 
CHAPTER III: DELAYED-RELEASE DIMETHYL FUMARATE 
PHARMACODYNAMIC RESPONSES ARE TISSUE-SPECIFIC AND NRF2-
DEPENDENT ................................................................................................................... 92 
1. RATIONALE ............................................................................................................ 92 
2. RESULTS ................................................................................................................. 94 
2.1 DMF treatment leads to increased levels of MMF in all tissues of interest ....... 94 
2.2 DMF-induces differential gene expression across tissue types .......................... 96 
2.3 The magnitude of DMF-induced gene expression is dose-dependent .............. 106 
2.4 DMF transcriptional regulation in whole blood ................................................ 114 
2.5 DMF-induced gene expression is Nrf2-dependent ........................................... 116 
2.6 DMF transcriptional regulation translates to protein expression ...................... 120 
3. Discussion ............................................................................................................... 123 
CHAPTER IV: OSGIN1 CONTRIBUTES TO THE CYTOPROTECTIVE 
PROPERTIES OF MONOMETHYL FUMARATE (MMF) ......................................... 127 
1. RATIONALE .......................................................................................................... 127 
2. RESULTS ............................................................................................................... 128 
2.1 MMF induces Nrf2 target genes and is protective against oxidative insult ...... 128 
2.2 Loss of Nrf2 abolishes MMF cytoprotection and depletes OSGIN1 ................ 132 
 xiv 
 
2.3 Loss of OSGIN1 reduces MMF cytoprotection in the presence of oxidative insult
................................................................................................................................. 137 
2.4 Identification of OSGIN1 isoform induction in the presence of MMF ............ 141 
2.5 p53 is downstream of OSGIN1 and contributes to OSGIN1-mediated 
cytoprotection ......................................................................................................... 154 
2.6 MMF time course of OSGIN1, p53, Nrf2 and NQO1. ..................................... 162 
2.7 MMF inhibits cell proliferation: preliminary studies........................................ 166 
3. Discussion ............................................................................................................... 175 
CHAPTER V: GENERAL CONCLUSIONS ................................................................. 184 
1. General conclusions ................................................................................................ 184 
2. Study limitations ..................................................................................................... 185 
3. Future directions ..................................................................................................... 186 
CHAPTER VI: BIBILIOGRAPHY ................................................................................ 188 
CURRICULUM VITAE ................................................................................................. 215 
 
  
 xv 
 
LIST OF TABLES 
Table 1. Reactive Oxygen Species and Electrophiles ......................................................... 3 
Table 2. Characteristics of Neurodegenerative Disease .................................................. 12 
Table 3. Nrf knockout phenotypes ..................................................................................... 24 
Table 4. Conserved domains of human Nrf2. ................................................................... 29 
Table 5. Classical Nrf2-regulated genes .......................................................................... 39 
Table 6. Natural and Synthetic Nrf2 Inducers .................................................................. 50 
Table 7. Antibodies ........................................................................................................... 70 
Table 8. siRNA constructs. ................................................................................................ 73 
Table 9. Taqman Primer/Probe Assays ............................................................................ 74 
Table 10. Primer and probe sets for 5’UTR transcript variants of OSGIN1. .................. 75 
Table 11. Primers for 3’ and 5’ RACE. ............................................................................ 76 
Table 12. Gene selections for Fluidigm real-time PCR. ................................................... 99 
Table 13. Transcriptional profiling time course statistical analysis. ............................. 105 
Table 14. Transcriptional profiling dose response statistical analysis. ......................... 112 
Table 15. DMF transcriptional time course in Nrf2-/- mice. ......................................... 119 
 
 
  
 xvi 
 
LIST OF FIGURES 
Figure 1. Reactive Oxygen Species Generation via the Electron Transport Chain. ........... 6 
Figure 2. Conserved domains of human Nrf2. .................................................................. 29 
Figure 3. Nrf2 degradation under homeostatic conditions ................................................ 31 
Figure 4. Activation of the Nrf2 pathway. ........................................................................ 32 
Figure 5. Human Keap1 protein domains. ........................................................................ 36 
Figure 6. Metabolites of dimethyl fumarate and monomethyl fumarate. ......................... 52 
Figure 7. Genomic structure and protein isoforms of OSGIN1. ....................................... 60 
Figure 8. Regulation of OSGIN1. ..................................................................................... 63 
Figure 9. Epitope locations of human OSGIN1 isoform-specific antibodies. .................. 72 
Figure 10.  MMF exposure in peripheral and CNS tissues following a single dose of 
DMF. ......................................................................................................................... 95 
Figure 11. DMF transcriptional profiling time course in peripheral tissues: 
kidney/jejunum. ...................................................................................................... 101 
Figure 12. DMF transcriptional profiling time course in peripheral tissues: spleen/liver.
................................................................................................................................. 102 
Figure 13.  DMF transcriptional profiling time course in CNS tissues: OSGIN1/BDNF.
................................................................................................................................. 103 
Figure 14.  DMF transcriptional profiling time course in CNS tissues: NQO1. ............ 104 
Figure 15. DMF transcriptional profiling dose-response in peripheral tissues: 
kidney/jejunum. ...................................................................................................... 108 
 xvii 
 
Figure 16. DMF transcriptional profiling dose-response in peripheral tissues: spleen/liver.
................................................................................................................................. 109 
Figure 17. DMF transcriptional profiling dose-response in CNS tissues: 
cortex/cerebellum. ................................................................................................... 110 
Figure 18. DMF transcriptional profiling dose-response in CNS: hippocampus/striatum.
................................................................................................................................. 111 
Figure 19. DMF transcriptional profiling dose-response in whole blood. ...................... 115 
Figure 20. Transcriptional time course with 100 mg/kg DMF in Nrf2-/- and wild type 
mice: peripheral tissues. .......................................................................................... 117 
Figure 21. Transcriptional time course with 100 mg/kg DMF in Nrf2-/- knockout and 
wild type mice: CNS tissues. .................................................................................. 118 
Figure 22. DMF induced Nrf2-dependent protein expression in peripheral tissues. ...... 121 
Figure 23. DMF induced protein expression in CNS tissues. ......................................... 122 
Figure 24. MMF induces Nrf2 target gene expression in human astrocytes. ................. 130 
Figure 25. MMF protects human astrocytes from oxidative challenge. ......................... 131 
Figure 26. Nrf2 knockdown. ........................................................................................... 134 
Figure 27. Loss of Nrf2 reduces OSGIN1 expression. ................................................... 135 
Figure 28. Loss of Nrf2 abolishes MMF-mediated cytoprotection. ............................... 136 
Figure 29. OSGIN1 siRNA knockdown. ........................................................................ 139 
Figure 30. OSGIN1 siRNA knockdown inhibits MMF-mediated cytoprotection. ......... 140 
Figure 31. Optimization of OSGIN1-52kDa and OSGIN1-61kDa antibodies. .............. 144 
Figure 32. OSGIN1 knockdown depletes OSGIN1 isoform specific immunoreactivity 145 
 xviii 
 
Figure 33. The OSGIN1 61 kDa encoding isoform is regulated via MMF and Nrf2. .... 148 
Figure 34.  Immunocytochemical analysis of OSGIN1-52 kDa and OSGIN1-61 kDa 
antibodies. ............................................................................................................... 149 
Figure 35. 3’ and 5’ RACE of OSGIN1 transcript. ........................................................ 152 
Figure 36. q-PCR analysis of identified 5’RACE transcripts. ........................................ 153 
Figure 37. q-PCR of p53 siRNA knockdown. ................................................................ 157 
Figure 38. p53 protein is regulated by MMF in an Nrf2 and OSGIN1 dependent manner.
................................................................................................................................. 158 
Figure 39. MMF induces nuclear translocation of p53. .................................................. 159 
Figure 40. MMF induces nuclear translocation of p53. .................................................. 160 
Figure 41. p53 contributes to MMF-mediated cytoprotection. ....................................... 161 
Figure 42. q-PCR time course of NQO1 and OSGIN1. .................................................. 164 
Figure 43. Protein time course of MMF-regulated proteins. .......................................... 165 
Figure 44. MMF inhibits cell proliferation. .................................................................... 168 
Figure 45. Loss of OSGIN1 does not significantly induce apoptosis. ............................ 169 
Figure 46. MMF mediated gene induction of PADI4. .................................................... 172 
Figure 47.  PADI4 is regulated by OSGIN1 and p53. .................................................... 173 
Figure 48.  PADI4 does not regulate OSGIN1 or p53. ................................................... 174 
Figure 49. OSGIN1 knockdown induces expression of TNF-alpha. .............................. 181 
Figure 50. Potential mechanism of action of OSGIN1 mediated cellular protection. .... 182 
Figure 51. Potential mechanism of action of OSGIN1 mediated cellular protection. .... 183 
 
 xix 
 
LIST OF ABBREVIATIONS 
AATF ................................................................ apoptosis antagonizing transcription factor 
ABCA1 ........................................ ATP-binding cassette, sub-family A (ABC1), member 1 
ACTB .................................................................................................................... actin, beta 
AD ......................................................................................................... Alzheimer’s disease 
ADP................................................................................................... adenosine diphosphate 
AKR1B8 ............................................................. aldo-keto reductase family 1, member B8 
ALS ........................................................................................ Amyotrophic lateral sclerosis 
ALS2 ................................................................... Amyotrophic lateral sclerosis 2 (juvenile) 
APOE .......................................................................................................... apolipoprotein E 
APP .............................................................................................. amyloid precursor protein 
ARE......................................................................................... antioxidant response element 
ATG2A ............................................................................................... autophagy related 2A 
ATP ................................................................................................... adenosine triphosphate 
BACH1 ................. BTB and CNC homology 1, basic leucine zipper transcription factor 1 
BDGI ...................................................................................... bone derived growth inhibitor 
BDNF ............................................................................... brain-derived neurotrophic factor 
BLAST ...................................................................... Basic Logical Alignment Search Tool 
bZIP....................................................................................... Basic Leucine Zipper Domain 
CCS .................................................................. copper chaperone for superoxide dismutase 
CDKN1A ......................................................... cyclin-dependent kinase inhibitor 1A (p21) 
cDNA .................................................................................................. complementary DNA 
 xx 
 
CKD ........................................................................... chronic inflammatory kidney disease 
CNC ................................................................................................................. Cap’n’Collar 
CNS ................................................................................................... central nervous system 
CSF ........................................................................................................cerebral spinal fluid 
CUL3.........................................................................................................................Cullin 3 
CYP ........................................................................................................... cytochrome P450 
DAQ ......................................................................................................... dopamine quinone 
DMF ......................................................................................................... dimethyl fumarate 
DNAJA3 ................................................ DnaJ (Hsp40) Homolog, Subfamily A, Member 3 
EAE ................................................................experimental autoimmune encephalomyelitis 
EdU ............................................................................................... ethynyl-2’-deoxy-uridine 
EGR2................................................................................... early growth response protein 2 
EpRE ..................................................................................... electrophilic response element 
ETC .................................................................................................. electron transport chain 
GAB1 ............................................................................ GRB2-associated-binding protein 1 
GAPDH ........................................................... glyceraldehyde-3-phosphate dehydrogenase 
GCLC ................................................................ glutamate cysteine ligase, catalytic subunit 
GCLM ............................................................... glutamate cysteine ligase, modifier subunit 
GDF15................................................................................. growth differentiation factor 15 
GFAP ....................................................................................... glial fibrillary acidic protein 
GLUL .......................................................................................... glutamate-ammonia ligase 
GSH......................................................................................................................glutathione 
 xxi 
 
GSTA2 ..................................................................................... glutathione S-transferase A2 
HAEC .................................................................................... human aortic endothelial cells 
H
+
 ..................................................................................................................... hydrogen ion 
HD ........................................................................................................ Huntington’s disease 
HCC .............................................................................................. hepatocellular carcinoma 
HCS ................................................................................................... high content screening 
HIF-1 ........................................................................................... hypoxia-inducible factor-1 
HMOX-1/HO-1 ........................................................................................ heme oxygenase 1 
HSP90 ................................................................................................. heat-shock protein 90 
HTT ....................................................................................................................... huntingtin 
H2O2 ........................................................................................................ hydrogen peroxide 
H2O ............................................................................................................................... water 
IACUC ......................................................... Institutional Animal Care and Use Committee 
IGFBP .............................................................. insulin-like growth factor binding protein 3 
IL-1 ................................................................................................................... interleukin 1 
IS ................................................................................................................. internal standard 
KEAP1 ........................................................................Kelch-like ECH-associated protein 1 
LB .................................................................................................................. lysogeny broth 
Maf ................................................................ musculo-aponeurotic fibrosarcoma oncogene 
MMF .................................................................................................. monomethyl fumarate 
MMO............................................................................................. methane monooxygenase 
MMP11 ...................................................................................... matrix metallopeptidase 11 
 xxii 
 
MPTP ........................................................... 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine 
MRI .......................................................................................... magnetic resonance imaging 
MS ............................................................................................................. Multiple sclerosis 
NADPH ............................................ nicotinamide adenine dinucleotide phosphate-oxidase 
NEP ..................................................................................................... New England Peptide 
NETO2 ............................................................... neuropilin (NRP) and tolloid (TLL)-like 2 
NF-E2 .............................................................................. nuclear-factor erythroid-derived 2 
(NF)-κB ............................... nuclear factor kappa-light-chain-enhancer of activated B cells 
NFKBIB ..................................................................................... NK-kappa-B inhibitor beta 
NGFG ....................................................................................... nerve growth factor, gamma 
NINJ1 ..................................................................................................................... ninjurin 1 
NMDAR ............................................................................... N-methyl-D-aspartate receptor 
NO ....................................................................................................................... nitric oxide 
NOS...................................................................................................... nitric oxide synthase 
NOS1................................................................................. nitric oxide synthase 1, neuronal 
NQO1 ........................................................................NAD(P)H dehydrogenase (quinone 1) 
NRF1 .................................................................. nuclear factor (erythroid-derived 2)-like 1 
NRF2 .................................................................. nuclear factor (erythroid-derived 2)-like 2 
NRF3 .................................................................. nuclear factor (erythroid-derived 2)-like 3 
NR2F6 ..................................................... nuclear receptor subfamily 2, group F, member 6 
NSG2.................................................................... neuron-specific protein family member 2 
NUDT7 ............................... nudix (nucleoside diphosphate linked moiety X)-type motif 7 
 xxiii 
 
OKL38 ............................................................................ ovary, kidney and liver protein 38 
OLIG1 ....................................................................... oligodendrocyte transcription factor 1 
OSGIN1 ............................................................ oxidative stress induced growth inhibitor 1 
OS ................................................................................................................. oxidative stress 
OXNAD1 ............................................. oxidoreductase NAD-binding domain containing 1 
PADI4 .......................................................................... peptidyl arginine deiminase type IV 
PARK7 ............................................ Parkinson disease (autosomal recessive, early onset) 7 
PCR ..............................................................................................polymerase chain reaction 
PD .......................................................................................................... Parkinson’s disease 
PDI ............................................................................................. protein-disulfide isomerase 
PINK1 ............................................................................... PTEN-induced putative kinase 1 
PRDX1 ......................................................................................................... peroxiredoxin 1 
PRDX2 ......................................................................................................... peroxiredoxin 2 
PTGS2 ..................................................................... prostaglandin-endoperoxide synthase 2 
PUFA ........................................................................................... polyunsaturated fatty acid 
P53 ............................................................................................tumor suppressor protein 53 
RACE .............................................................................. rapid amplification of cDNA ends 
RBP4 ................................................................................. retinol binding protein 4, plasma 
RIPA ............................................................................. Radio Immuno Precipitation Assay 
ROS ..................................................................................................reactive oxygen species 
RRMS ........................................................................ relapsing remitting multiple sclerosis 
SF ...................................................................................................................... sulforaphane 
 xxiv 
 
SIAH1 ...................................................................................... seven in absentia homolog 1 
SIRT1 ....................................................................................................................... sirtuin 1 
SLC1A2 ......... solute carrier family 1(glial high affinity glutamate transporter), member 2 
SNAI1 .......................................................................................... zinc finger protein SNAI1 
SNpc ..................................................................................... substantia nigra pars compacta 
SOD..................................................................................................... superoxide dismutase 
SQSTM1 ............................................................................................... sequestosome 1/p62 
SRXN1 ............................................................................................................ sulfiredoxin-1 
STRA6 ............................................... stimulated by retinoic acid gene 6 homolog (mouse) 
TNFα .......................................................................................... tumor necrosis factor alpha 
TXNRD1 ..................................................................... thioredoxin reductase 1, cytoplasmic 
UBC .................................................................................................................... ubiquitin C 
VEGFA ....................................................................... vascular endothelial growth factor A 
uORF ....................................................................................... upstream open reading frame 
UFP ........................................................................................................... ultrafine particles 
3-NP ..................................................................................................... 3-nitropropionic acid 
6-OHDA ................................................................................................ 6-hydroxydopamine 
8-OHdG........................................................................................ 8-Oxo-2'-deoxyguanosine
1 
 
 
 
CHAPTER I                                                                                               
INTRODUCTION 
 
1. OXIDATIVE/ELECTROPHILIC STRESS 
 Reactive oxygen species (ROS) and electrophiles are normal intermediates and/or 
byproducts produced during various physiological and pathophysiological processes. 
Although these molecules are known to play important roles in cellular and xenobiotic 
metabolism (Federico et al., 2012; Zangar et al., 2004), cell signaling (Finkel et al., 
2009), immune defense (Mittal et al., 2014) and enzymatic reactions (Pendyala et al., 
2010), uncontrolled production can have detrimental effects on cell homeostasis. Under 
normal conditions, the presence of ROS/electrophiles is regulated through intrinsic 
defense pathways that limit the highly reactive nature of these molecules; however, when 
this balance is disrupted and oxidative/electrophilic insult surpasses the cellular defense 
capacity, these toxic species can damage cells leading to oxidative and/or electrophilic 
stress (OS/ES) (Sies et al., 1985; Sies et al., 2014). This imbalance in the normal 
homeostatic state is associated with various forms of human disease and can cause 
disruptive modifications in lipids, proteins and nucleic acids, leading to cellular 
dysfunction and eventually cell death (Brieger et al., 2012).  This section will provide an 
overview of intracellular sources and functions of ROS and electrophiles, as well as 
discuss their role specifically in neurodegenerative disease. 
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1.1 Sources of ROS and Electrophiles 
Reactive oxygen species (ROS) are a collection of molecules and ions that are highly 
reactive based on the presence of an unpaired electron group (free radical) or the ability 
to generate these free radicals through various chemical reactions.  The most common 
molecules that are considered to possess the characteristics of ROS and contribute to 
oxidative stress are listed in Table 1 (Sies et al., 2014; Melo et al., 2011). Although the 
classification of ROS does not tend to include electrophiles, positively charged species 
that are attracted to electrons, the high reactivity of ROS can initiate the production of 
molecules with electrophilic properties (Kansanen et al., 2011). A common example of 
electrophile production in the presence of ROS is via lipid peroxidation, which can result 
in the production of electrophiles such as 4-hydroxynonenal (4-HNE) and 
malondialdehyde (MDA) following oxidation of cell membrane lipids via oxygen free 
radicals (Table 1) (Vila et al., 2008; Kansanen et al., 2011). This process not only has the 
capability to propagate oxidative stress, but also to initiate electrophilic stress (Jacobs et 
al., 2010). As mentioned above, the molecular species that contribute to these types of 
stress are also generated during various physiological processes that are important for cell 
function; however, their production under normal conditions is tightly controlled in order 
to protect the cell from the reactive chemistry of these molecules (Dasuri et al., 2012). 
Therefore, understanding how and why endogenous pathways such as cellular 
metabolism, cell signaling and immune defense generate ROS and electrophiles is 
essential for identifying potential sites of disruption in cellular mechanisms that may 
contribute to oxidative and/or electrophilic stress.    
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Table 1. Reactive Oxygen Species and Electrophiles 
OXYGEN FREE RADICALS superoxide anion •O ‾2 
 hydroxyl radical •OH 
 alkoxy/peroxy radicals RO• / ROO• 
REACTIVE SPECIES hydrogen peroxide H2O2 
 hypochlorous acid HOCL 
 peroxynitrite ONOO
-
 
 singlet oxygen O2
*
 
 nitric oxide NO 
ELECTROPHILES 4-hydroxynonenal C9H16O2 
 malondialdehyde C3H4O2 
   
 
1.1.1 Cellular metabolism 
 A major source of ROS in cellular systems arises from endogenous metabolic 
processes such as oxidative phosphorylation in mitochondria, an aerobic pathway used 
for energy generation/recycling in the form of adenosine triphosphate (ATP) (Federico et 
al., 2012). During oxidative phosphorylation, protein complexes within the inner 
mitochondrial membrane transfer electrons from reducing agents (electron donors) to 
oxidizing agents (electron acceptors) in an oxidation-reduction reaction (redox reaction) 
(Figure 1). Together, these protein complexes create an electron transport chain (ETC) 
that generates energy from these redox reactions to transport protons into the 
intermembrane mitochondrial space. The shuttling of protons into the intermembrane 
space of the mitochondria generates a proton gradient and an electrical potential across 
the membrane that can be utilized by the ATP synthase, allowing proton passage back 
into the inner membrane which results in rotation of the enzyme and the ability to 
generate ATP from adenosine diphosphate (ADP) through a phosphorylation reaction. 
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This process is then repeated to continuously provide ATP as an energy source for the 
cell (Fernandez-Vizarra et al., 2009). 
A common electron acceptor in oxidative phosphorylation is molecular oxygen 
(O2), a strong oxidizing agent, which becomes negatively charged following acceptance 
of electrons in the electron transport system. The acceptance of four electrons by 
molecular oxygen normally reacts with four hydrogen ions (H
+
) to be reduced to water 
(H2O) in this system; however, in some instances, partially reduced intermediates can 
also be generated when only one or two electrons are transferred, resulting in the 
production of reactive oxygen species including superoxide anion (•O2
-
) (Lass et al., 
1997; Bryla et al., 1965) (Figure 1). The probability of superoxide anion production 
increases during oxidative phosphorylation when the proton concentration gradient 
generated from the ETC is disrupted (Apostolova et al., 2011). This can slow down 
electron transport and increase the half-life of reactive intermediates that generate 
superoxide. In most cases, mitochondrial generation of superoxide anion is rapidly 
neutralized by the enzyme superoxide dismutase (SOD), which breaks down superoxide 
to hydrogen peroxide (H2O2) and molecular oxygen (O2) (Deby et al., 1990). Although a 
product of superoxide breakdown, H2O2 itself is a significant contributor to oxidative 
damage if not properly eliminated due to the ability of this molecule to easily penetrate 
cell membranes and induce damage, as well as decompose into the highly reactive 
hydroxyl radical (•OH) (Miller et al., 2010). If not eliminated by certain enzymes such as 
catalase and glutathione peroxidase, H2O2 is a toxic threat to the cell (Sies et al., 2014).  
5 
 
 
Although there is an increased probability of ROS induced cell damage during 
oxidative phosphorylation, exposure of cellular components to reactive electrophiles is 
also increased during this biological process. A major example of electrophile exposure 
as a result of oxidative phosphorylation is through lipid peroxidation, or the oxidative 
degradation of lipids (Montuschi et al., 2004; Niki et al., 2008; Niki et al., 2012). As 
mentioned above, H2O2 can decompose into the reactive hydroxyl radical (•OH), which 
can initiate lipid peroxidation by “stealing” electrons from lipids, leading to the 
propagation of a vicious cycle of fatty acid radical formation due to the instability of 
these molecules. Examples of electrophiles generated during lipid peroxidation are the 
reactive aldehydes, MDA and 4-HNE, which are considered end products of lipid 
peroxidation that can damage cell membranes and have potentially mutagenic properties 
(Vistoli et al., 2013). Therefore, the endogenous pathway of oxidative phosphorylation, 
which is crucial for normal cell functioning, is also a source of reactive species that can 
potentially contribute to oxidative and electrophilic stress if not tightly regulated.   
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Figure 1. Reactive Oxygen Species Generation via the Electron Transport Chain.  
ROS production in mitochondria through the process of oxidative phosphorylation by the 
electron transport chain (ETC). Leakage of electrons from the ETC can reactive with 
oxygen to generate superoxide and hydrogen peroxide leading to oxidative damage. 
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1.1.2 Xenobiotic metabolism 
Another metabolic source of ROS is through the metabolism of exogenous 
xenobiotics; substances that are foreign to an organism. This process involves the 
deactivation and breakdown of chemicals, such as pharmaceutical agents and toxins, into 
products that are more easily eliminated through excretion; however, similar to oxidative 
phosphorylation, xenobiotic metabolism can also produce reactive intermediates that can 
be further damaging to cells (Zangar et al., 2004).   
Xenobiotic metabolism of foreign substances occurs predominantly in the liver 
and can be divided into three phases: modification, conjugation and excretion (McKinnon 
et al., 1996). The first phase of xenobiotic metabolism, modification, utilizes enzymes to 
alter the structure of foreign compounds for detoxification and subsequent removal (Li et 
al., 2011). One common example of this is methane monooxygenase (MMO) reactions 
catalyzed by a family of heme proteins referred to as cytochrome P450 (CYP) enzymes. 
MMOs utilize molecular oxygen to incorporate one oxygen atom into a substrate to form 
a hydroxyl group and the other oxygen atom to water (Zangar et al., 2004). Since the 
reaction involves electron input as well as activated oxygen there are various leakage 
points for the production of ROS, including the release of superoxide anion radical due to 
oxygen release that does not couple to the substrate (Gorsky et al., 1984; Kuthan et al., 
1982). The complex mechanisms of P450 enzymes can also result in other leakage points 
that generate H2O2 and other ROS during the breakdown of various endogenous and 
exogenous compounds, identifying this pathway as a potential contributor to cellular 
levels of ROS (Rashba-Step et al., 1994). 
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1.1.3 Cell signaling 
A current focus of ROS and electrophilic research has been to understand the 
involvement of these reactive molecules in cellular signaling. Although ROS are largely 
described as toxic byproducts of cellular pathways, recent data suggests that ROS, as well 
as electrophiles, can be generated during normal physiological signaling and play an 
important role in cell regulation (Finkel et al., 1998; Moller et al., 2010; Mittler et al., 
2011). The rapid production and scavenging of ROS, as well as the varying molecular 
properties of different reactive species make them ideal signaling molecules. 
Furthermore, the strong link between cell homeostasis and metabolism may also make 
ROS favorable signals for monitoring alterations in metabolic pathways (Ray et al., 
2012). 
In mitochondria, production of ROS is a controlled byproduct of metabolism; 
however, there is also evidence that production of ROS in these organelles may be 
induced by ligand binding and contribute to apoptotic signaling (Vernon et al., 2013). 
Cytokines such as tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1), which 
play important roles in immune responses, have been shown to induce mitochondrial 
ROS production following binding to their receptors and subsequent regulation of 
apoptosis in cells; however, the mechanism is not fully understood (Han et al., 2009). 
Furthermore, there is evidence to suggest that ROS production is required for activation 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF)-κB and subsequent 
NF-κB-dependent gene transcription, which plays important roles in response to stress 
and immune regulation (Wang et al., 2002). The role of ROS in transcriptional regulation 
9 
 
 
during oxidative and electrophilic stress has recently become of particular interest due to 
emerging studies that support ROS signaling as important regulators of glucose 
homeostasis, inflammation and cell survival (Kesarwani et al., 2013; Ma et al., 2010).  
Another role for ROS signaling in mitochondria is through release of ROS from 
the ETC in response to hypoxia.  In this scenario, the ETC functions as an O2 sensor that 
releases ROS as a signaling molecule to induce expression of hypoxia-inducible factor-1 
(HIF-1). HIF-1 can then regulate pathways involved with adaptive metabolic responses 
and bring cell functioning back to a normal homeostatic level, including reducing total 
ROS presence (Zepeda et al., 2013). The induction of HIF-1 activity is particularly 
important during tissue hypoxia, as this factor induces angiogenesis resulting in increased 
oxygen delivery to the deprived tissue to diminish hypoxia (Hadjipanayi et al., 2013). 
One of the most investigated free radicals that functions as a cell signaling 
molecule is nitric oxide (NO). NO is synthesized in the body from the amino acid L-
arginine by nitric oxide synthases and is an important regulator of various pathways in 
the immune system, nervous system and in cardiovascular functioning (Forstermann et 
al., 2012; Kobayashi et al., 2010). The most interesting role for NO involves the synthesis 
of this radical in the brain as a neuromodulator (Stefano et al., 2009). Potential roles for 
NO in the nervous system include nerve-mediated gut relaxation during digestion, 
neuronal immune response of macrophages and S-nitrosylation, a form of post-translation 
protein modification (Groneberg et al., 2011; Mouaward et al., 2013; Liu et al., 2013). 
NO mediated S-nitrosylation of the N-methyl-D-aspartate receptor (NMDAR), a 
predominant glutamate receptor in neurons involved in synaptic plasticity, may increase 
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neuronal survival during periods of excitotoxicity by inactivating this receptor (Qu et al., 
2012). However, as with all ROS, the presence of NO in the nervous system can be 
detrimental and has been linked to various neurodegenerative diseases which will be 
discussed at the end of this section. 
1.1.4 Immune defense 
  The production and signaling of ROS plays an important role during both aspects 
of immunological defense: innate and adaptive immunity (Matsuura et al., 2012). During 
innate immunity, one of the first defenses against environmental pathogens is through 
oxidative burst of activated phagocytes, which rapidly release ROS to non-specifically 
degrade pathogens that have been internalized (Forman et al., 2001). The release of ROS 
via immune cells is accomplished by nicotinamide adenine dinucleotide phosphate-
oxidase (NADPH) oxidase, an enzyme that generates superoxide which can interact with 
other molecules to form free radicals (McGeer et al., 2002). The presence of ROS is also 
important during the second phase of immune defense, adaptive immunity, which is 
necessary for immunological memory. During this phase of immune defense, phagocytes 
present pathogen-specific antigens to T lymphocytes, which mount an immune response 
that specifically targets pathogens with the identified antigens (Langsdorf et al., 2012). 
ROS are important during this aspect of the immune response since free radicals continue 
to be released by phagocytes, which can enhance the intracellular signal transduction 
cascades within T lymphocytes (Nathan et al., 2013). The importance of ROS production 
during both aspects of immune response is supported by studies showing that individuals 
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who are deficient in ROS production are more susceptible to infection against various 
forms of bacterial invasion compared to healthy individuals.   
The role of ROS in physiological signaling has expanded our understanding of the 
diversity of these compounds; however, further research is needed to thoroughly 
appreciate the importance of ROS in these pathways and to determine whether or not 
their functional role during signaling surpasses the potentially harmful nature of their 
structure. 
 
1.2 The Role of Oxidative and Electrophilic Stress in Neurodegenerative Disease 
The harmful effects of ROS and electrophiles can include damage to 
macromolecules such as proteins, lipids, polysaccharides and nucleic acids, as well as 
lead to the inactivation of enzymes (Schieber et al., 2014). Many studies have suggested 
that these damaging effects of oxidative stress are strongly associated with aging, most 
likely due in part to a reduced ability of cells to defend against these forms of stress 
(Szarka et al., 2014). In the brain, this loss of defense is particularly important since 
neurons are highly sensitive to oxidative and electrophilic stresses (Hamilton et al., 
2001). The high metabolic rates of neurons place increased energy demands on 
mitochondria, thus leading to increased exposure of ROS. Oxidative and electrophilic 
stress resulting from ROS accumulation can affect mitochondrial efficiency and hence 
further propagate the production of ROS (Adam-Vizi et al., 2013). The low levels of 
antioxidants in neurons as well as their reduced ability to regenerate reduce their capacity 
to defend against the propagation of these reactive molecules (Dasuri et al., 2012). 
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Furthermore, the high fatty acid content in neurons, which is functionally necessary, 
makes them prone to lipid peroxidation by ROS (Tully et al., 2013). Therefore, the 
evidence that ROS overproduction is believed to be a common pathogenic mechanism in 
aging and neurodegenerative diseases is not particularly surprising (Reynolds et al., 
2007). The last part of this section will discuss some of the evidence that links oxidative 
and electrophilic stress to neurodegenerative disease such as multiple sclerosis, 
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and amyotrophic lateral 
sclerosis (Table 2).  
 
Table 2. Characteristics of Neurodegenerative Disease 
Disease Heredity Clinical Features Pathology Misfolded 
protein 
Multiple 
Sclerosis 
Sporadic Neuroinflammation White matter lesions; 
inflammation; BBB 
breakdown 
N/A 
Parkinson’s 
disease 
Mostly 
sporadic; 
rarely 
inherited 
Movement disorder Loss of DA neurons; 
Lewy bodies/NF 
subunits 
α-
synuclein 
Alzheimer’s 
disease 
Sporadic 
(95%); 
inherited 
(5%) 
Progressive 
dementia 
Senile plaques; 
neurofibrillary 
tangles; loss of 
neurons/synapses 
β-
amyloid; 
tau 
Huntington’s 
Disease 
Inherited  Dementia; motor 
and psychiatric 
problems 
Loss of striatal 
neurons; inclusion 
bodies 
Huntingtin 
ALS Sporadic 
(90%); 
inherited 
(10%) 
Movement disorder Motor neuron death; 
Spheroids/NF 
subunits 
SOD 
* BBB-blood brain barrier; DA-dopaminergic; SOD-superoxide dismutase; ALS- 
amyotrophic lateral sclerosis; NF-neurofilament; N/A-not applicable 
References: Forman et al., 2004; Hafler et al., 2004; Dauer et al., 2003; Robberecht et 
al., 2013 
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1.2.1 Multiple sclerosis 
 As discussed in section 2.1.4 of this chapter, immune cells are known to 
contribute to endogenous ROS production and use these radicals as a first line defense 
against environmental pathogens. Multiple sclerosis (MS) is predominantly characterized 
as an inflammatory disease, and many suggest that the loss of neuronal myelin, the 
defining feature of MS, is due in part to destructive immune cells (Hohlfeld et al., 2004; 
Hafler et al., 2004). The resident immune cells in the brain, microglia, can release ROS 
during inflammation, which are toxic to oligodendrocytes, the cells that are responsible 
for myelin production in the CNS (Hafler et al., 2005). The demyelination associated 
with MS leads to nervous system damage and subsequent disruption in nerve 
communication.  
One source of ROS generation associated with MS is the excessive production of 
the free radical nitric oxide (NO), which is a precursor for the highly unstable oxidant, 
peroxynitrite (ONOO
-
) (Pacher et al., 2007). NO is produced by a family of enzymes 
referred to as nitric oxide synthases (NOSs) which catalyze the formation of NO from the 
amino acid L-arginine (section 2.1.3). Four forms of NOS exist; neuronal (nNOS), which 
is produced in nervous tissue, inducible (iNOS), located in mitochondria and microglia 
for production of NO during inflammation, and endothelial (eNOS), produced in 
endothelial cells during various physiological conditions (Forstermann et al., 2012). The 
diverse production of NO is important for various signaling pathways; however, this 
diversity also creates more opportunities for excessive production of this biological 
molecule that can be toxic (Szabo et al., 2007). During periods of increased production, 
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NO can rapidly react with superoxide to produce ONOO
-
 and increase the production of 
further downstream reactive molecules (Beckman et al., 1996). Oligodendrocytes are 
particularly sensitive to ONOO
-
 and thus are vulnerable to damage induced by the 
presence of this oxidant (Jack et al., 2007). This can be exemplified by administration of 
ONOO
-
 directly into the rat corpus callosum, which resulted in the destruction of myelin 
and damage to neuronal axons similar to destruction seen in MS (Touil et al., 2001). 
In experimental autoimmune encephalomyelitis (EAE), an animal model of brain 
inflammation that shares similarities with MS pathology, ONOO
-
 production can be 
detected early and correlates with the severity of disease activity (van der Veen et al., 
1997). Furthermore, during periods of remission, where no disease symptoms are 
apparent, the presence of ONOO
-
 is undetectable in this model. The importance of this 
molecule in disease progression was confirmed experimentally when an ONOO
-
 catalyst 
used to neutralize its activity resulted in reduced disease severity and inflammation in this 
model (Cross et al., 2000). Although the presence of ONOO
-
 in the EAE model may be 
due in part to infiltrating immune cells, evidence suggests that ONOO
-
 may be a very 
early response to disease in this model. This is supported by studies that found ONOO
-
 
production to occur before the infiltration of immune cells, resulting in damage to 
mitochondrial proteins and subsequent mitochondrial dysfunction (Li et al., 2011). These 
findings suggest that alterations in cell metabolism and mitochondrial membrane 
potential, which lead to ROS production, may be induced by ONOO
- 
synthesized directly 
from neuronal cell types.  
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In humans, gadolinium-enhancing lesions, which are indicative of damaged brain 
regions, have been shown to correlate with increased levels of NO metabolites identified 
in the cerebral spinal fluid (CSF) of MS patients (Rejdak et al., 2004; Rejdak et al., 
2007). Furthermore, the presence of peroxynitrite has been identified in MS lesions, as 
well as the presence of reactive astrocytes that express high levels of the antioxidant, 
peroxiredoxin V (Cross et al., 1997; Holley et al., 2007). The damaging effect of these 
reactive molecules has also been detected in MS lesions, which show characteristics of 
oxidative damage including disruptions in mitochondrial DNA and enzymes (Van 
Horssen et al., 2008). These findings suggest that there is a continuous response to 
oxidative stress within brain lesions of MS patients.  
1.2.2 Parkinson’s disease 
Parkinson’s disease (PD) is a degenerative disorder of the CNS that results from 
the loss of dopamine-producing neurons within the substantia nigra leading to disruption 
in motor movements (Dawson et al., 2003). Literature suggests that mitochondrial 
dysfunction and oxidative stress may be important for the pathogenesis of PD and these 
factors may underlie the death of dopaminergic neurons in this disease (Jenner et al., 
2003). Evidence for this is supported by findings using the MPTP (1-methyl 4-phenyl-1, 
2, 3, 6-tetrahydropyridine) animal model, which specifically inhibits complex I of the 
electron transport chain and induces dopaminergic neuron loss. MPTP is first converted 
to toxic MPP
+ 
in astrocytes followed by release into the extracellular space. MPP
+
 is then 
transported into dopaminergic neurons via the dopamine transporter, DAT, and inhibits 
complex I function. This inhibition leads to the buildup of free radicals and the death of 
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neurons within the substantia nigra similar to that observed in PD patients (Fox et al., 
2010). Interestingly, complex I activity has been shown to be decreased specifically in 
the substantia nigra of postmortem patients with sporadic PD (Dexter et al., 2013). 
Furthermore, the inhibition of NOS, the catalyst for NO production, has been shown to 
slow progression of disease in the MPTP model and NOS-deficient mice are significantly 
more resistant to MPTP compared to controls (Kurosaki et al., 2002). These data suggest 
that mitochondrial dysfunction and free radical production are important factors in PD 
progression.  
Further support for the importance of oxidative stress in PD stems from increased 
iron accumulation found in PD postmortem brains compared to healthy controls, 
specifically within dopaminergic neurons of the substantia nigra (Zecca et al., 2005). This 
increase in iron presence may be due to dysfunctional iron transport in the mitochondria 
and can be detrimental to dopamine neurons as iron can interact with H2O2 to generate 
toxic hydroxyl radicals (Mochizuki et al., 2012). The contribution of these free radicals to 
the disease state is further supported by the observation that antioxidant levels, including 
glutathione (GSH) and peroxiredoxin 2 (PRDX2), are reduced or altered in the substantia 
nigra of postmortem PD brains, leaving dopaminergic neurons more susceptible to the 
damaging effects of free radicals (Sofic et al., 2006).  
A final example linking oxidative stress to PD, is genetic mutations that have 
been associated with familial PD, such as PTEN-induced putative kinase 1 (PINK-1), 
Parkinson disease (autosomal recessive, early onset) 7 (PARK7/DJ-1) and parkin, all of 
which are associated with mitochondria. Mutations in these genes have been shown to 
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result in mitochondrial mitophagy and increased oxidative stress (Geisler et al., 2010; 
Chien et al., 2012; Priyadarshini et al., 2013; Joselin et al., 2012). 
 
1.2.3 Alzheimer’s disease 
 One of the more highly studied neurodegenerative disorders associated with 
oxidative stress is Alzheimer’s disease (AD). AD is the most common form of dementia 
that presents early with short term memory loss and advances to symptoms of confusion, 
mood swings and long term memory loss (Querfurth et al., 2010). Eventually, the disease 
progresses to loss of bodily function and ultimately death. The pathology associated with 
AD includes the loss of neurons and synapses in the cerebral cortex and the presence of 
protein accumulations of amyloid beta (plaques) and hyperphosphorylated tau 
(neurofibrillary tangles) (Tannenberg et al., 2006; Loewen et al., 2010). Although the 
exact mechanisms associated with protein misfolding and aggregation are not fully 
understood in AD, various studies have correlated the disruption of these proteins with 
the presence of oxidative stress (Hoozemans et al., 2005; Lopez Salon et al., 2000; Behl 
et al., 1994). In postmortem AD patient brains, investigators found increased 
nitrosylation of proteins in areas of amyloid beta plaque formation (Honjo et al., 2010). 
Furthermore, the nitrosylation of heat-shock protein 90 (HSP90) was found to be 
increased in AD postmortem brains (Honjo et al., 2010). This alteration in protein 
structure due to NO has been shown to inhibit the ATPase activity of HSP90 and 
interrupt its chaperone function, which may be associated with the accumulation of tau 
amyloid.  
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Further evidence that oxidative damage may contribute to AD disease pathology 
can be found in transgenic animals and cell lines that overexpress beta amyloid or 
hyperphoshorylated tau as disease models for AD. In APP (amyloid precursor protein) 
transgenic mice that overexpress amyloid beta, increases in amyloid beta production 
correlated with defects in antioxidant defense systems, elevated levels of hydrogen 
peroxide and nitric oxide, as well as increased oxidative modification of proteins and 
lipids (Li et al., 2004; Nishida et al., 2006). Interestingly, these defects in antioxidant 
defense could be reversed by administration of antioxidants, suggesting that oxidative 
stress may play a role in amyloid beta induced toxicity (Lim et al., 2011). In regards to 
hyperphosphorylated tau, animal models that overexpress tau have shown increased 
susceptibility to oxidative stress (Stamer et al., 2002). For example, cortical neurons from 
a transgenic rat model overexpressing a human mutated tau variant, exhibited increased 
ROS levels compared to control and the administration of antioxidants to these animals 
protected neurons against ROS accumulation (Cente et al., 2006; Cente et al., 2009). 
Furthermore, P301S and P301L transgenic mouse models with human tau gene mutations 
that exhibit defects in tau and promote neurodegeneration, exhibit mitochondrial 
dysfunction, increased ROS production and reduced activity of the antioxidants 
(Yoshiyama et al., 2007; David et al., 2005; Dumont et al., 2011; Elipenahli et al., 2012).   
Evidence of oxidative stress in human AD patients has been identified following 
analysis of markers for oxidative damage in postmortem brains. These markers include 3-
nitrotyrosine, a product of peroxynitrite damage, protein carbonyls, which are products of 
protein oxidation, as well as the markers for oxidative damage of DNA (8-
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hydroxydeoxyguanosine (8-OHdG)) and RNA (8-hydroxyguanosine) (Nunomura et al., 
1999; Gabbita et al., 1998; Butterfield et al., 2001). Lipid peroxidation products, 
including MDA and 4-HNE have also been shown to be increased in AD brains as well as 
alterations in antioxidant production, such as SOD and catalase (Marcus et al., 1998; 
Omar et al, 1999; Furuta et al., 1995). These markers for oxidative damage also tend to 
be more localized to neuronal synapses and have been correlated to disease severity 
(Ansari et al., 2010).  
1.2.4 Huntington’s disease 
 Another neurodegenerative disease that has been correlated with oxidative stress 
is Huntington’s disease (HD). HD is caused by an autosomal dominant mutation resulting 
in a CAG repeat extension in the huntingtin gene (HTT) and is characterized by 
disruptions in muscle coordination, cognitive decline and depletion of spiny neurons 
within the striatum (Dorsey et al., 2013). Evidence from postmortem studies of HD 
patients show accumulation of oxidative markers such as 3-nitrotyrosine and the lipid 
peroxidation marker, MDA, in the striatum and cortex compared to non-diseased controls 
(Browne et al., 1999). There is also evidence that levels of lipid peroxidation in HD 
patient plasma correlates with HD disease severity (Klepac et al., 2007; Chen et al., 
2007). In experimental models using transgenic mice with mutated HTT, investigators 
found increases in DNA oxidative damage by measuring 8-OHdG in the brain and 
plasma, and also detected increased levels of 8-OHdG and lipid peroxidation markers 
(MDA, 4-HNE) in the striatum of these mice (Bogdanov et al., 2001, Lee et al., 2011). 
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These data suggest that metabolic dysfunction leading to oxidative stress in the CNS may 
be a contributor to HD pathogenesis.  
 A major piece of evidence that supports a role for oxidative damage via 
mitochondrial disruption in HD is the selective inhibition of succinate dehydrogenase in 
medium spiny neurons of the striatum by 3-nitropropionic acid (3-NP) and malonate. The 
damage induced by 3-NP and malonate has been described as sharing similar pathologic 
events as HD in animal models, including loss of locomotor function and selective striatal 
degeneration (Brouillet et al., 2005, Kumar et al., 2010). These compounds are 
mitochondrial inhibitors since they disrupt the transfer of electrons in the electron 
transport chain at complex II; therefore, a major factor of toxicity associated with these 
compounds is cellular and mitochondrial stress due to metabolic disruption. Use of these 
toxins both in vivo and in vitro results in increased oxidative damage.  
1.2.5 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig’s disease, is a 
motor neuron disease that is characterized by muscle atrophy and rapid progressive 
weakness (Turner et al., 2013). Although there is not a strong correlation between ALS 
and oxidative damage in sporadic cases of this disease, approximately 20% of familial 
ALS cases are associated with a mutation in the superoxide dismutase-1 (SOD1) gene 
(Hand et al., 2002). SOD1 is an important antioxidant in the body that protects against the 
damaging effects of superoxide. Although the exact mechanisms behind motor neuron 
dysfunction induced by SOD1 mutations is not clear, researchers have suggested that free 
radicals may accumulate based on a loss of function of this gene (Saccon et al., 2013). 
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This theory is supported by studies with transgenic mice expressing mutant SOD1 that 
exhibit high rates of peroxynitrite damage in spinal cord motor neurons (Bruijn et al., 
1997). Furthermore, other studies have indicated that oxidative damage may mediate 
mutant SOD1 toxicity. This is based on increased exposure of the active copper site in 
mutant SOD1 to external stimuli, which may induce copper-mediated conversion of 
hydrogen peroxide to hydroxyl radicals (Vehvilainen et al., 2014). Although there is data 
that support a loss of function role for SOD1, recent studies suggest SOD1 mutations 
may alternatively be associated with a gain of function mechanism (Vehvilainen et al., 
2014). Therefore, further research is necessary to understand the involvement of SOD1 
and other potential sources of oxidative damage in ALS pathology.  
 
2. THE NRF2 PATHWAY IN RESPONSE TO STRESS 
As exemplified in section two of this chapter, reactive oxygen species (ROS) and 
electrophiles possess unique properties that are beneficial for various physiological 
functions of the cell, including cell signaling, immune defense and metabolic processes. 
However, if not properly regulated, the reactive characteristics that make 
ROS/electrophiles ideal contributors to these pathways can also induce damage to the cell 
leading to a state of oxidative or electrophilic stress. This disruption has been described 
to play a role in neurodegenerative disease pathology which was reviewed in section 2.2 
of this chapter. In order to maintain a homeostatic balance between ROS production and 
removal, cells have evolved various mechanisms to sense the presence of these molecules 
as well as regulate their existence.  The primary cellular stress response pathway that 
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assists in maintaining cell homeostasis when threatened with oxidative and electrophilic 
stress is the Nrf2 (nuclear factor-erythroid 2-related factor 2) pathway (Miao et al. 2005; 
Nguyen et al., 2009). Initial activation of this pathway is mediated through redox sensing 
that initiates transcriptional activation of various genes involved with neutralization and 
removal of potentially harmful molecules.  
2.1 The NF-E2 Family of Transcription Factors  
Nrf2 is encoded by the NFE2L2 gene and is a member of the NF-E2 (nuclear-
factor erythroid-derived 2) family of basic region leucine-zipper (bZIP) transcription 
factors that possess a Cap’n’Collar (CNC)-type structure (Itoh et al., 1995). The CNC 
subfamily of bZIP transcription factors also includes the protein p45 NF-E2 (nuclear-
factor erythroid-derived 2) and two other NF-E2 related transcription factors, Nrf1 
(nuclear factor-erythroid 2-related factor 1) and Nrf3 (nuclear factor-erythroid 2-related 
factor 3). Although these family members share conserved domains that are distinct from 
other bZIP families, they also contain regions that make them functionally unique from 
one another (Toki et al., 1997).  
The p45 NF-E2 transcription factor plays an important role in development, 
where it is specifically required for the proper development of platelets, and is the only 
one of these CNC genes to be hematopoietic specific (Shivdasani et al., 1995). In contrast 
to p45 NFE2, the three Nrfs are ubiquitous with partially overlapping expression patterns 
and functional characteristics (Sykiotis et al., 2010). Although all three Nrfs can be 
activated under conditions of stress, their roles as transcription factors are not 
functionally redundant based on phenotype results from mouse knockout studies (Table 
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3). In these studies, Nrf1-/- knockout mice were found to be embryonic lethal due to 
defects in erythropoiesis, while Nrf2-/- and Nrf3-/- were not required for development 
(Chan et al., 1998; Chan et al., 1996; Chen et al., 2003). Susceptibility to oxidative stress 
was exacerbated in both Nrf1-/- and Nrf2-/- mice, with no phenotypic changes observed 
in the absence of Nrf3 (Derjuga et al., 2004). In Nrf1-/- and Nrf2-/- double knockout 
studies, the loss of Nrf2 exacerbated embryonic lethality and susceptibility to oxidative 
stress in the absence of Nrf1, suggesting that Nrf2 may partially compensate for the loss 
of Nrf1 (Leung et al., 2003). The absence of Nrf2-/- and Nrf3-/- together was not reported 
to alter the phenotype of the Nrf2-/- mouse (Derjuga et al., 2004). Interestingly, Nrf2-/- 
single knockout mice also exhibited age related phenotypes including a lupus-like 
autoimmune syndrome that was observed in females and a distinct neurodegeneration 
characterized by myelin destruction in the CNS (Yoh et al., 2001; Ma et al., 2006; Hubbs 
et al., 2007). These findings support non-redundant functions for each of these 
transcription factors, specifically in regards to Nrf1 and Nrf2. Although there is evidence 
that both Nrf1 and Nrf2 function through an antioxidant response, the finding that the 
absence of Nrf2 is not compensated by Nrf1 suggests that Nrf2 itself is critical for 
defense against oxidative stress and is the major defense pathway against stress induction 
amongst these three transcription factors.  
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Table 3. Nrf knockout phenotypes 
Genotype Phenotype Reference 
Nrf1-/- Mid to late embryonic lethal; defective 
erythropoiesis; oxidative stress 
Chan et al., 
1998; Chen et 
al., 2003 
Nrf2-/- Viable and fertile; sensitivity to oxidative and ER 
stress; aged related neurodegeneration and lupus-like 
autoimmune syndrome 
Hubbs et al., 
2007; Yoh et 
al.,2001;Chan 
et al.,  1996 
Nrf3-/- No observable phenotype Derjuga et 
al., 2004 
Nrf1-/-, Nrf2-/- Enhancement of Nrf1-/- phenotype; early embryonic 
lethal; increases oxidative stress 
Leung et al., 
2003 
Nrf2-/-, Nrf3-/- Viable and fertile Derjuga et 
al., 2004 
 
 
 
  
2.2 Nrf2 
Since the discovery of Nrf2 through cloning experiments in 1994 by Moi et al., 
research has continuously provided evidence for this transcription factor as the major 
regulator of gene expression in response to oxidative/electrophilic stressors (Maher et al., 
2010; Nguyen et al., 2009; van Muiswinkel et al., 2005). Early studies demonstrating 
Nrf2 to be an important regulator of the antioxidant response came from in vitro analysis 
of the ARE-driven regulation of the detoxification enzyme, NAD(P)H dehydrogenase 
(quinone 1) (NQO1) (Venugopal et al., 1996). In these studies, overexpression of Nrf2 
cDNA was found to upregulate expression and induction of the NQO1 gene, which 
contains an antioxidant response element (ARE) in its promoter region. ARE sequences 
are found in the promoter regions of various detoxification enzymes and possess 
structural as well as biological characteristics that define their ability to respond to 
various forms of stress (Rushmore et al., 1993). Direct interaction of Nrf2 with the ARE 
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sequence was confirmed in 2005 via chromatin immunoprecipitation that demonstrated a 
direct interaction between endogenous Nrf2 and the ARE (Nguyen et al., 2005). Over the 
years, other ARE-driven genes under the control of Nrf2 have been identified which will 
be discussed in further detail in section 3.3.3.   
Later studies investigating the role of Nrf2 in response to oxidative and 
electrophilic stress were conducted in vivo utilizing Nrf2-/- mice. ARE-dependent gene 
regulation both at the basal level and in the presence of an inducing agent was found to 
be severely impaired in these knockout mice, confirming that Nrf2 is responsible for both 
constitutive and inducible expression of ARE-driven genes (Itoh et al., 1997; Chanas et 
al., 2002). Subsequent studies have shown that Nrf2 is crucial for cells to cope with 
oxidative stress and that transcriptional induction via Nrf2 may be differentially regulated 
in specific cell types.  This is in contrast to early theories that suggested activation of the 
Nrf2 pathway was cell intrinsic, where each cell regulates its own internal Nrf2 to control 
transcription of ARE-driven genes (Lee et al., 2004). Although this is apparent for certain 
cell types, there is little data supporting Nrf2 regulation in specific cells such as neurons. 
Recent studies propose that Nrf2-mediated neuronal protection is through a bystander 
effect where support is provided primarily by local astrocytes (Bell et al., 2011; Miao et 
al., 2011; Vargas et al., 2008; Vargas et al., 2009). This can be seen in studies where 
neuron-rich cultures lack the ability to activate Nrf2 in the presence of oxidative stress 
and Nrf2-activating compounds, resulting in cellular death (Li et al., 2009; Murphy et al., 
2001). In contrast, activation of Nrf2 in mixed neuronal/astrocyte cultures can be 
localized to astrocytes leading to protection of neighboring neurons, suggesting that Nrf2 
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neuronal protection is mediated through astrocytes (Braun et al., 2009). This can be 
further demonstrated in studies conducted by Carole Escartin et al. where Nrf2 activation 
is shown to increase production of the antioxidant glutathione (GSH) by astrocytes, 
which is then released into the extracellular space and cleaved to cysteine. Since neurons 
cannot take-up extracellular GSH, free cysteine is collected through the Nrf2-activated 
EAAT3 (excitatory amino acid transporter 3) transporter to initiate de novo synthesis of 
GSH (Escartin et al., 2011). These data suggest that the protection inferred by Nrf2 
regulation is broad and may have different functions across cell types.   
The broad functions of Nrf2 also expand outside of its ability to regulate 
transcription of antioxidant related genes. Investigation into the diversity of Nrf2 has 
uncovered the ability of this protein to cross-talk with other signaling pathways involved 
in biological processes such as differentiation, proliferation and apoptosis (Li et al., 
2012). Studies using Nrf2-/- mice show that Nrf2 protects against tumor formation in 
various tissues based on the increased susceptibility of Nrf2-null mice to chemical 
inducers of cancer compared to control mice (Ramos-Gomez et al., 2001; Xu, et al., 
2006; Osburn et al., 2007). Furthermore, humans with a single nucleotide polymorphism 
(SNP) in the Nrf2 promoter region exhibit reduced Nrf2 expression that correlates with 
an increased risk of lung cancer (Suzuki et al., 2013). In contrast to the latter studies, 
elevated levels of Nrf2 in cancer cells have also been shown to promote cell proliferation 
(Mitsuishi et al., 2012). Together, these findings suggest that Nrf2 may play multiple 
roles within the cell, especially in regard to cell cycle regulation. Further evidence for 
Nrf2 contribution to cellular proliferation and differentiation arises from the Nrf2-
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dependent transcriptional regulation of the cell cycle regulators p21 (cyclin-dependent 
kinase inhibitor 1) and OSGIN1 (oxidative stress induced growth inhibitor 1), as well as 
the autophagy protein, SQSTM1/p62 (sequestosome/nucleoporin 62), which is also 
important for the formation of bone cells (DeNicola et al., 2012, Rea et al., 2013; Yan et 
al., 2014; Lau et al., 2010). The identification of these non-classical Nrf2 target genes 
sparks interest in the multifunctional aspects of this transcription factor and the 
probability that characteristics within the conserved domains of Nrf2 may contribute to 
these functions. 
2.2.1 Functional domains of Nrf2 
 There are seven known functional domains within the 605 amino acid protein of 
Nrf2 that contribute to its biological activities (Itoh et al., 1999) (Figure 2; Table 4). The 
first defined domain, Neh1, also known as the DNA binding domain, contains the CNC-
type bZIP region that characterizes the NF-E2 family of transcription factors.  The 
presence of a bZIP domain is common amongst DNA binding proteins and allows 
transcriptional regulators, such as Nrf2, to mediate sequence specific DNA binding as 
well as dimerization of DNA binding regions (leucine zipper) to regulate transcription. 
This region is where Nrf2 can heterodimerize with Maf recognition elements (MARE) 
within small Maf transcription proteins which have been identified as co-regulators of 
Nrf2-mediated gene regulation. The characterization of Nrf2 as a CNC-type bZIP 
transcription factor is defined by the presence of a 43-amino acid CNC domain that is 
conserved across multiple species, including worms, insects, fish, birds and mammals, 
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and has functional roles in development and homeostatic maintenance (Mohler et al., 
1991).  
The Neh2 domain is a negative regulatory domain located towards the N-terminus 
of this protein where Nrf2 binds to its specific repressor, Keap1 (Kelch-like ECH-
associated protein 1). The Neh6 domain is also important for the role of Nrf2 repression 
since it represents a second negative regulatory domain which mediates Keap1-
independent degradation of Nrf2 (Chowdhry et al., 2013; Rada et al., 2012). The 
functional and structural importance of Keap1 will be discussed in more detail in section 
3.3. 
The Neh3, Neh4 and Neh5 domains are considered transactivation domains that 
enhance transcriptional regulation of Nrf2 due to the ability of these regions to interact 
with components of the transcriptional apparatus. The Neh3 domain, located on the 
carboxy-terminal of Nrf2, is required for Nrf2 transcriptional activation and has been 
shown to interact with CHD6 (a chromo-ATPase/helicase DNA binding protein family 
member), which may function as a transcriptional co-activator to induce Nrf2-dependent 
gene regulation (Nioi et al., 2005). The Neh4 and Neh5 domains also act as 
transactivation domains, but act synergistically to bind the protein CBP (cAMP Response 
Element Binding Protein). This protein functions as another transcriptional co-activator 
and possesses intrinsic histone acetyltransferase activity, which is important for 
enhancing gene expression (Katoh et al., 2001) 
In 2013, a seventh domain, Neh7, was identified and shown to contain a 
recognition site for retinoid X receptor alpha (RXRα). These studies verified that RXRα 
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can bind to Nrf2 and repress ARE-driven gene expression; therefore, the Neh7 domain is 
considered a negative regulatory region of the Nrf2 protein (Wang et al., 2013). 
 
 
 
Figure 2. Conserved domains of human Nrf2.  
There are seven functional domains of human Nrf2 summarized in Table 4 below. 
 
 
 
 
 
Table 4. Conserved domains of human Nrf2. 
DOMAIN FUNCTION 
Neh1 CNC-bZIP domain that allows Nrf2 to heterodimerize with small Maf 
proteins 
Neh2 Allows Nrf2 binding to its cytosolic repressor Keap1 
Neh3 Potential role in Nrf2 stability; may act as a transactivation domain 
Neh4 and Neh5 Transactivation domain; binds cAMP Response Element Binding 
Protein (CREB) 
Neh6 May play a role in Nrf2 degradation 
Neh7 Regulatory region for RXRα interaction 
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2.3 Activation of the Nrf2 Pathway 
Under normal physiological conditions, constitutively expressed Nrf2 is 
sequestered in the cytoplasm by the actin-associated Keap1 (Kelch-like ECH-associated 
protein 1). Keap1 targets Nrf2 for ubiquitination and subsequent proteasomal degradation 
via a Cullin 3 (Cul3) ubiquitin ligase complex (Itoh et al., 2003; Kobayashi et al., 2004). 
Under steady state conditions Nrf2 is not readily detected in the cytoplasmic pool based 
on its continual degradation; however, this allows Nrf2 protein to be quickly accessed 
when needed (Itoh et al., 2003) (Figure 3). During periods of stress when reactive 
molecules can inhibit the degradation of Nrf2 by interacting with cysteine residues 
located on the Keap1 protein, resulting in an allosteric conformational change in Keap1 
that alters the binding capacity of the Nrf2-Keap1 complex (Dinkova-Kostova et al., 
2002). This alteration in Keap1 disrupts ubiquitin tagging of Nrf2, which allows Nrf2 to 
translocate into the nucleus. Once inside the nucleus, Nrf2 dimerizes with members of the 
small Maf (musculo-aponeurotic fibrosarcoma oncogene) family of transcription factors 
to regulate gene transcription. These small Maf-Nrf2 dimers bind to specific sequences 
located in the promoter region of cytoprotective genes referred to as Antioxidant and 
Electrophilic Response Elements (ARE/EpRE), leading to the regulation of specific 
genes involved in the induction of a Phase II antioxidant response (Itoh et al., 1997; 
Nguyen et al., 2003) (Figure 4). This tightly controlled pathway allows Nrf2 to be 
utilized rapidly under periods of stress and exemplifies the critical role of Nrf2 in 
maintaining basal and inducible expression of antioxidant defenses. 
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Figure 3. Nrf2 degradation under homeostatic conditions 
Under basal conditions, constitutively expressed Nrf2 is sequestered in the cytoplasm by 
the protein Keap1 through dimeric binding via two motifs within the N-terminal domain 
of Nrf2 referred to as the “ETGE” (E) and “DLG” (D) motifs. In collaboration with a 
Cul3-ubiquitin ligase system, Keap1 targets Nrf2 for ubiquitination and subsequent 
proteasomal degradation.  
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Figure 4. Activation of the Nrf2 pathway. 
In the presence of electrophiles or reactive oxygen species (ROS), these molecules 
interact with the cysteine residues on Keap1 leading to an allosteric protein modification 
and the inability of Keap1 to bind to the “DLG” (D) motif of Nrf2. Nrf2 is less degraded, 
leading to accumulation of Nrf2 and its ability to translocate to the nucleus. Once inside 
the nucleus, Nrf2 works with other cognate transcription factors such as Maf to induce 
the transcriptions of various cellular defense genes.  
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2.3.1 Keap1 
Nrf2 is predominantly regulated by the protein Keap1, which is a substrate for a 
Cul3-containing E3 ubiquitin ligase and was identified to be a regulator of Nrf2 
following deletion of the Neh2 domain of Nrf2 by Itoh et al. in 1999. Itoh et al. 
discovered that this deletion resulted in increased Nrf2 activity and initiated the proposal 
that this region negatively regulated Nrf2 via a repressor. Using protein-protein 
interaction studies with the Neh2 domain as bait, a mouse protein homologous to the 
Drosophila protein Kelch was identified and named Keap1 (Itoh et al., 1999). Further 
studies using Keap1-deficient (Keap1-/-) mice confirmed the importance of Keap1 due to 
the constitutive activation of Nrf2 in these mice following loss of Keap1 as well as 
embryonic lethality (Wakabayashi et al., 2003). 
The Keap1 protein contains four discrete domains (Figure 5). The N-terminus 
contains a BTB (Broad complex, Tramtrack and Bric-á-Brac) domain through which 
Keap1 forms a homodimer and can interact with Cul3 to target Nrf2 for ubiquitination 
(Zipper et al., 2002). Within this domain, Keap1 binds to Nrf2 to form a RING E3-
ubiquitin ligase with Cul3/Rbx1 which leads to the proteasomal degradation of Nrf2 (Itoh 
et al., 2003).  The BTB domain is particularly important since it contains the cysteine 151 
residue (Cys151) that has been implicated as a major Keap1 cysteine important for stress 
sensing (Yamamoto et al., 2008). The intervening region (IVR) of Keap1 which is 
particularly cysteine-rich contains eight cysteine residues, including Cys273 and Cys288. 
These two cysteine’s, like Cys151, have been implicated as stress sensors (Holland et al., 
2008; Yamamoto et al., 2008). The DGR (double glycine repeat) domain of Keap1 is a 
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Kelch domain which is composed of six Kelch motifs that fold together to create a β-
propeller structure that aids in protein-protein interactions. In collaboration with the CTR 
(C-terminal region) domain, the DGR forms a region specific for Nrf2 binding termed the 
DC domain (Bryan et al., 2013).   
As mentioned above, Nrf2 is primarily localized in a complex with Keap1 under 
basal conditions that consists of one Nrf2 molecule bound to two Keap1 molecules. In 
this complex, monomeric Nrf2 binds to dimeric Keap1 via two motifs within the N-
terminal Neh2 domain of Nrf2 referred to as the “ETGE” and “DLG” motifs (Figure 3/4) 
(Tong et al., 2006). Studies investigating the importance of these regions found that both 
motifs were required for Keap1-mediated ubiquitination of Nrf2 by Cul3–Rbx1 and that 
Keap1 affinity for the ETGE motif was 200-fold greater than for the DLG motif 
(McMahon et al., 2006; Tong et al., 2006). Original theories of the Keap1-Nrf2 
degradation pathway believed that Nrf2 was either bound to Keap1 and degraded or 
unbound following conformational changes in Keap1 that no longer supported Nrf2 
binding (Kang et al., 2004). However, studies conducted by Baird et al. in 2013 found 
that the Keap1-Nrf2 complex existed in two distinct conformations (Baird et al., 2013). 
The first conformation consists of the “ETGE” motif of Nrf2 bound to Keap1, referred to 
as the “open” state, and the second where both the “DLG” and “ETGE” motifs are bound 
to the Keap1 dimer, referred to as the “closed” state. When the complex is in the closed 
state, Nrf2 is in the correct orientation to be targeted by the Keap1-dependent E3 ligase 
for ubiquitination, which is the orientation that is predominant under basal conditions 
(McMahon et al., 2006; Tong et al., 2006). In the presence of electrophiles or compound 
35 
 
 
inducers, these molecules react with Keap1 cysteine residues to alter the conformation of 
the Keap1-Nrf2 complex and switching Keap1 from a closed to an open state (Holland et 
al., 2010). These data suggest that Nrf2 is not released from Keap1 following alteration 
of the complex but instead blocks the binding of newly synthesized Nrf2 which can then 
translocate to nucleus (Li et al.; 2012, Baird et al.; 2013, Eggler et al., 2005). 
Although classical activation of the Nrf2-Keap1 pathway is believed to be 
modulated through electrophilic and reactive compound modifications of cysteine 
residues, there is evidence that alternate Keap1 binding partners as well as Keap1-
indepenent mechanisms exist to activate Nrf2. Sequestosome 1 (p62/SQSTM1) has been 
shown to interact with the Nrf2-binding site on Keap1 to inhibit its interaction with Nrf2 
during selective autophagy to facilitate regulation of Nrf2 (Jain et al., 2010, Lau et al., 
2010, Copple et al., 2010, Ichimura et al., 2013). In Keap1-independent mechanisms, 
Nrf2 has been shown to be phosphorylated by protein kinases that assist in Nrf2 release 
from Keap1 and subsequent activation of the ARE. Studies have identified 
phosphorylation of Nrf2 by protein kinase C (Huang et al., 2002), mitogen-activated 
protein kinase (MAPK) (Yu et al., 1999), phosphoinositide 3-kinase (PI3K) (Lee et al., 
2001) and protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) (Cullinan 
et al., 2003), leading to increased Nrf2 activity; however, the mechanisms behind this 
Keap1-independent pathway is unknown. Furthermore, Nrf2 has been shown to be 
activated independently of Keap1 by caspase-3 cleavage (Ohtsubo et al., 1999), oncogene 
activation (DeNicola et al., 2011) and blockage by miRNA’s (Sangokoya et al., 2010). 
Finally, other transcription factors, such as nuclear factor kappa-light-chain-enhancer of 
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activated B cells (NF-kB) can affect the expression of Nrf2 mRNA (Rushworth et al., 
2012; Miao et al., 2005; Ramachandran et al., 2008; Nair et al., 2008). Thus, control of 
Nrf2 basal expression and stability is highly complex and involves multiple pathways that 
translate to diverse functions.  
 
 
 
Figure 5. Human Keap1 protein domains.  
BTB=Broad complex, Tramtrack and Bric-a-Brac; IVR=Intervening Region; 
DGR=Double Glycine Repeat; CTR=C-Terminal Region. 
   
 
2.3.2 Nrf2 targets genes  
Following Nrf2 accumulation via Keap1-dependent or independent mechanisms, 
Nrf2 is able to translocate to the nucleus where it can regulate the transcription of many 
genes involved in the antioxidant response (Itoh et al., 1997) (Table 5). Subsequent 
studies confirmed that Nrf2 binding to ARE/EpRE elements regulates basal expression 
and coordinates induction of numerous antioxidant response genes that possess a core 
ARE (Nguyen et al., 2003). Interestingly, Nrf2 also possesses an ARE sequence in its 
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promoter region that may allow Nrf2 to activate its own transcription to enhance the 
cellular defense response against stress (Nguyen et al., 2003). 
Nrf2 induction of ARE-driven genes includes the transcription of the direct 
antioxidants NAD (P) H-quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO-1) 
and thioredoxin (TXNRD1), which are important for the neutralization of reactive 
molecules (Alam et al., 1999). Along with direct antioxidants, Nrf2 mediates the 
expression of other detoxifying enzymes including aldo-keto reductases (AKRs) and 
Uridine Diphosphoglucuronosyltransferases (UGTs) (Nishinaka et al., 2005; Paonessa et 
al., 2011). One major downstream product of the Nrf2 pathway is the biosynthesis of 
glutathione (GSH), an antioxidant that is expressed ubiquitously throughout the CNS and 
periphery. GSH serves as an electron donor during the reduction of peroxides by 
glutathione peroxidases and is believed to play an important role in cellular protection 
against oxidative damage (Liu et al., 2009; Dringen et al., 2000). Nrf2 is responsible for 
inducing a number of genes involved with glutathione synthesis and regeneration such as 
glutamate cysteine ligase (GCL), the first rate limiting step in glutathione synthesis (Wild 
et al., 1999), glutathione-s-transferases (GST) (Hayes et al., 2000), glutathione reductase 
(GSR) (Shih et al., 2003) and glutathione peroxidase (GPX) (Thimmulappa et al., 2002). 
Each of these genes described in Table 5 are considered classical targets of Nrf2 and 
emphasize the importance of Nrf2 induction during periods of oxidative and electrophilic 
stress.  
As previously mentioned, the activation of ARE-driven genes has been shown to 
include Nrf2 heterodimerization with small Maf proteins (MafG, MafK and MafF) as 
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well as heterodimerization with Jun proteins (c-Jun, Jun-D and Jun-B) (Li et al., 1992; 
Dhakshinamoorthy et al., 2000). Interestingly, Maf-Nrf2 heterodimers have also been 
shown to repress ARE-mediated expression and induction of antioxidant enzymes, 
suggesting an additional level of Nrf2 gene regulation that may be controlled through 
transcriptional complexes of Nrf2 (Nguyen et al., 2000, Dhakshinamoorthy et al., 2000). 
Therefore, although Nrf2-mediated induction of ARE gene regulation is well established, 
further investigation into the transcriptional machinery of Nrf2 is necessary to fully 
understand how heterodimeric partners regulate Nrf2 function.  
Although Nrf2 is considered the “master regulator” of the antioxidant response, 
evidence supporting transcriptional regulation of genes involved in disparate processes 
also exists.  These include immune and inflammatory processes, carcinogenesis and 
tissue remodeling. There is even evidence for a role of Nrf2 in cognition and addiction. 
This divergence in Nrf2 target gene functions may provide insight into the numerous 
diseases that share oxidative damage as a common pathogenesis. Even though the 
downstream targets of Nrf2 associated with these pathways will not be discussed in detail 
in this section, it is important to understand that there are diverse targeted pathways of 
Nrf2 that have a physiological significance and may be contributing to the progression of 
different diseases. 
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Table 5. Classical Nrf2-regulated genes 
Classical Nrf2-regulated Genes 
Target Genes Function 
NAD(P)H dehydrogenase (quinone 1) 
(NQO1) 
Direct antioxidant; catalyzes 2-electron 
reduction of quinones to hydroquinones 
Heme oxygenase-1 (HO-1) Direct antioxidant; catalyzes the 
degradation of heme 
Aldo-Keto Reductases (AKRs) NAD(P)H-dependent reduction of 
aldehydes 
Ferritin Direct antioxidant; sequesters free iron 
Uridine 
Diphosphoglucuronosyltransferases 
(UGTs) 
Encode enzymes that directly inactivate 
oxidants or electrophiles 
Glutathione S-transferases (GSTs) Encode enzymes that directly inactivate 
oxidants or electrophiles 
Glutathione Reductase Increase GSH synthesis and regeneration; 
catalyzes the recycling of GSH 
γ-Glutamylcysteine Ligase (GCL) Increase GSH synthesis and regeneration; 
catalyzes rate limiting step in GSH 
synthesis 
χ-CT (creatine transporter) Increase GSH synthesis and regeneration; 
transporter that aids in GSH synthesis 
malic enzyme Stimulates NADPH synthesis 
Glutathione peroxidase 2 (GPX2) Antioxidant enzyme; detoxification of H202 
and peroxynitrite  
peroxiredoxin Antioxidant enzyme; detoxification of H202 
and peroxynitrite 
Multi-Drug Resistance Associated Protein 
(MRP) 
Role in multidrug resistance  
Sulfotransferases (SULFs) Catalyze sulfation of xenobiotics sulfation 
of xenobiotics  
Phosphogluconate Dehydrogenase  Stimulates NADPH synthesis 
G6PD Provides NADPH to GSH reductase for 
GSH reduction 
Metallothioneins Protection against metal toxicity 
Thioredoxin reductases/thioredoxins Direct antioxidants; reduce proteins by 
cysteine thiol-disulfide exchange 
NADPH- nicotinamide adenine dinucleotide phosphate; GSH-glutathione 
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3. THE ROLE OF NRF2 IN DISEASE  
3.1 Nrf2 and CNS-independent Diseases 
As previously mentioned, oxidative and electrophilic stressors have become 
increasingly recognized as contributing factors to various forms of disease. Since Nrf2 is 
the central mediator of antioxidant balance within the cell, alterations in the functionality 
of this pathway are likely to play a role in diseases that exhibit oxidative damage. 
Chronic inflammation, cancer and cardiovascular diseases can all be induced by 
biological, physical and chemical factors that are associated with an increased risk to 
overall oxidative stress (Wohlgemuth et al., 2014, Csiszar et al., 2007, Martien et al., 
2007). These diseases have been associated with increased production of 
ROS/electrophiles and/or a diminished antioxidant capacity which in some cases have 
been correlated with an impaired activation of Nrf2 (Singh et al., 2006). For example, 
genetic mutations in Keap1 and Nrf2 that inhibit the formation of the Nrf2-Keap1 
complex have been observed in various tumor types (Abazeed et al., 2013; Sato et al., 
2013). In CKD, severe oxidative stress indicated by oxidized lipid burden is markedly 
correlated with suppression of Nrf2 activity and its gene targets (Kim et al., 2011, Kim et 
al., 2009). Furthermore, several downstream Nrf2 target genes have been implicated in 
protection against the pathogenesis of each of these diseases, suggesting that this pathway 
may be impaired (Joshi et al., 2012).  
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3.2 Nrf2 and models of neurodegenerative disorders 
3.2.1 Dysfunction of Nrf2 in human neurodegenerative disorders 
Based on the unifying aspect of oxidative stress in neurodegenerative disorders, 
the role of the Nrf2 pathway in the CNS is of particular interest. As previously described 
in section 2.2, the high prevalence of oxidative damage observed in postmortem tissues 
of diseased patients is due in part to the brain being particularly vulnerable to oxidative 
and electrophilic stressors. This vulnerability is not only a result of reduced antioxidant 
levels, high lipid content and increased oxygen consumption within the brain, but also the 
imbalance of oxygen defense abilities across cell types (Hamilton et al., 2001). In the 
CNS, activation of the Nrf2 pathway and subsequent GSH production is preferentially 
regulated in astrocytes compared to neurons, leaving neurons highly dependent upon 
neighboring astrocytes for protection during periods of stress (Escartin et al., 2011). A 
loss of function of Nrf2 has been described in the pathogenesis of various 
neurodegenerative disorders which may contribute to the specific neuronal loss that is 
characteristic of these diseases (Itoh et al., 2009, Johnson et al., 2008).  
In post-mortem tissues of AD patients, significant increases in the expression of 
the Nrf2 target genes, HO-1 and NQO1, have been identified in cortical and hippocampal 
regions compared to controls. Furthermore, the expression of Nrf2 itself was found to be 
predominantly localized within the cytoplasm of AD hippocampal neurons from post-
mortem tissue (Schipper et al., 2006, Ramsey et al., 2007). These findings spark interest 
based on their partially contradictory results. The accumulation of antioxidants would 
suggest that activation of the Nrf2 pathway is functional in AD brains but the oxidative 
42 
 
 
load exceeds the capabilities of detoxifying agents. However, the localization of Nrf2 to 
the cytoplasm and not the nucleus of hippocampal neurons of AD patients suggests that 
translocation of Nrf2 is hindered leading to a dysfunctional pathway. Additional evidence 
that Nrf2 may be dysregulated in AD comes from measurement of SQSTM1/p62 levels 
in AD postmortem tissue where expression of this gene and its cytoplasmic levels were 
found to be significantly reduced in the frontal cortex. As previously mentioned 
SQSTM1/p62 can interact with the Nrf2 binding site on Keap1 and inhibit the Nrf2-
Keap1 complex (Salminen et al., 2012). Therefore, a decline in the level of SQSTM1 
protein could potentially inhibit the signaling pathway of Nrf2 leading to increases in 
oxidative stress and impaired neuronal survival. 
Similar to AD, post-mortem analysis of PD brain tissue has identified increases in 
NQO1 and HO1 to be predominantly localized to reactive astrocytes (van Muiswinkel et 
al. 2004, Schipper et al. 2004). However, in contrast to the latter AD brain analysis, Nrf2 
was localized predominantly within the nucleus of PD brain tissue astrocytes (Ramsey et 
al., 2007).  These findings correlate better with an overall state of oxidative stress which 
is consistent with the mitochondrial dysfunction identified within dopaminergic neurons 
of PD post-mortem brains (Alam et al., 1997, Clements et al., 2006).  Interestingly, 
analysis of postmortem brain tissue from the primary motor cortex and spinal cord of 
ALS patients identified overall reductions in Nrf2 mRNA and protein expression, 
suggesting that Nrf2 may be dysregulated in ALS (Pehar et al., 2007). Alterations in Nrf2 
regulation across CNS disorders elicits further understanding of the role of Nrf2 in 
disease pathogenesis, some of which has been made clear through research models.  
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3.2.2 Nrf2 and Models of Neurodegenerative Disorders 
Although analysis of postmortem brain tissue has given insight into the Nrf2 
pathway during neurodegeneration, most of the knowledge regarding Nrf2 and 
neurodegenerative disorders stem from in vivo/vitro research models. The following 
section will individually present evidence for Nrf2 dysregulation in experimental models 
that mimic PD, AD, HD, ALS and MS; diseases that exemplified oxidative burden as a 
unifying pathology in section 2.2.  
i. Nrf2 and Models of Parkinson’s Disease  
A previously described, PD is characterized by the loss of dopaminergic neurons 
within the substantia nigra pars compacta as well as increases in mitochondrial 
dysfunction. This pathology exacerbated in Nrf2-/- mouse models in the presence of the 
neurotoxic dopamine analogues 6-hydroxydopamine (6-OHDA) and MPTP (Chen et al., 
2009, Innamorato et al., 2010). The damaging effects of these toxins could be rescued via 
astrocyte specific over-expression of Nrf2 in these models (Chen et al., 2009). Activation 
of the Nrf2 pathway in vitro was also able to restore metabolic deficiencies observed in 
olfactory-derived cells from sporadic PD patients (Cook et al., 2011). Furthermore, in 
Drosophila fruit fly models of PD, genetic activation of Nrf2 signaling is sufficient to 
ameliorate disease phenotypes (Misra et al., 2011).  
ii. Nrf2 and Models of Alzheimer’s Disease  
Mouse models of AD that overexpress the pathogenic protein beta-amyloid 
precursor protein (APP) exhibit reduced mRNA levels of Nrf2 and its target genes, 
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NQO1 and GCL, as well as reductions in Nrf2 protein expression (Resende et al., 2008). 
Additionally, overexpression of Nrf2 via injection of lentiviral-Nrf2 expression vector 
into the hippocampus of APP transgenic mice improved spatial learning compared to 
control animals even though it did not alter amyloid beta peptide (Aβ) levels (Kanninen 
et al., 2009). However, in vitro Nrf2 overexpression or activation of the Nr2 pathway has 
shown to significantly protect neuronal and astroglial cell lines against Aβ-mediated 
toxicity (Wruck et al., 2008). 
iii. Nrf2 and Models Huntington’s Disease Models 
Common models of HD in vivo/vitro include administration of the mitochondrial 
complex II inhibitors, 3-nitropropionic acid (3-NP) and malonate, which are particularly 
damaging to striatal neurons and result in increased oxidative damage (Beal et al., 1993, 
Briouillet et al., 1999). Various research labs have demonstrated that Nrf2-deficient mice 
are more susceptible to the damage invoked by these mitochondrial inhibitors in striatal 
tissue leading to increases in lesions within this brain region (Shih et al., 2005). The 
overexpression or activation of Nrf2 specifically in astrocytes has been shown to protect 
the striatum from these toxins and reduce lesion size. Additionally, the overexpression of 
Nrf2 in vitro has been shown to infer significant protection against 3-NP and malonate 
toxicity (Calkins et al., 2005).  
iv. Nrf2 and Models of Amyotrophic Lateral Sclerosis  
A significant percentage of familial ALS cases are caused by a toxic gain of 
function in SOD1, a potent scavenger of free radicals (Rosen et al., 1993). Rodent models 
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that express the mutant form of SOD1 (mSOD1) share many features with ALS including 
mitochondrial dysfunction and oxidative stress; however, the decreased expression of 
Nrf2 demonstrated in ALS postmortem tissue is not paralleled in rodent mSOD1 models 
(Ischiropoulos et al., 2003; Kraft et al., 2007). Despite this discrepancy, there is 
supporting evidence that Nrf2 activation is protective against the toxicity induced within 
mSOD1. For example, astrocytes isolated from transgenic mSOD1 animals are toxic to 
neurons in co-culture, a phenomenon that can be reversed by overexpressing Nrf2 in 
these astrocytes (Vargas et al., 2006). Furthermore, over-expression of Nrf2 in vivo in 
mSOD1 rodents delays the onset of disease and prolongs lifespan in this model (Vargas 
et al., 2008). Therefore, it is possible that Nrf2 is expressed in mSOD1 mouse astrocytes 
but may not be functional.  
v. Nrf2 and Models of Multiple Sclerosis  
One of the most widely studied in vivo models of MS is the inflammatory EAE 
(experimental autoimmune encephalomyelitis) model, which is characterized by severe 
demyelination and inflammation. Induction of EAE pathology in Nrf2-/- mice has been 
shown to exacerbate the development and severity of EAE characteristics (Linker et al., 
2011). These include increased myelin loss, increased immune cell infiltration into the 
spinal cord, as well as altered expression of proinflammatory, cytokine and chemokine 
genes compared to control mice.  
The combined evidence from both human postmortem tissues and experimental 
models of neurodegeneration, identify the Nrf2 pathway as an important response 
mechanism during disease. This correlates with the evidence presented in section 2.2 that 
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oxidative stress is a unifying factor across neurodegenerative disorders and 
neuroinflammation and strengthens the notion that Nrf2 is important for protection 
against these stresses. Thus, activation of the Nrf2 pathway may be a suitable therapeutic 
target that could be utilized across multiple disease types, especially in regards to 
neurodegenerative disease (Copple et al., 2012).  
 
4. COMPOUNDS THAT REGULATE NRF2  
As previously described in detail (section 3, Chapter 1), cells sense and adapt to 
the presence of oxidants and electrophiles through a combined Nrf2-Keap1 mechanism. 
In this pathway, the key signaling protein that senses and transduces the effects of 
electrophiles is Keap1. Through modifications of Keap1 cysteine residues, electrophiles 
alter the conformation of this protein leading to changes in the binding affinity of Keap1 
for Nrf2 and subsequent accumulation of Nrf2 protein (Cooper et al., 2002). These steps 
are important to ensure that Nrf2 has a longer half-life and is free to translocate to the 
nucleus and induce gene transcription. Some of the most interesting research regarding 
the Nrf1-Keap1 pathway identifies various naturally occurring and synthetic compounds 
that can regulate the Nrf2 transcription factor most likely through interactions with Keap1 
cysteine residues (Balogun et al., 2003; Garg et al., 2008; Chen et al., 2005; Juge et al., 
2007; Nquyen et al., 2000;  Kraft et al., 2004). The discovery of these compounds has 
sparked considerable interest in using these molecules to regulate the Nrf2 pathway as a 
potential therapeutic target molecule. 
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4.1 Naturally Occurring Compounds 
The first molecules that were investigated as potential activators of stress 
signaling pathways were derived from plant products, including the broccoli extract 
sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] (Matusheski et al., 2004). 
Sulforaphane (SF) was originally isolated using bioassays based on its ability to induce 
NQO1, which was later identified to be one of the classical transcriptional targets of Nrf2 
(Tarozzi et al., 2013) (Table 6). Further studies confirmed that SF regulated the Nrf2 
pathway by modifying multiple Keap1 domains leading to increased expression of Nrf2-
mediated cytoprotective genes (Juge et al., 2007; Angeloni et al., 2009; Dinkova-Kostova 
et al., 2002). The ability of SF to interact with Keap1 stems from its electrophilic 
chemistry and thus functions in a similar manner as endogenous electrophiles to regulate 
Nrf2. Activation of ARE-dependent genes by SF can be exemplified in cell lines where 
the addition of this compound leads to the increased production of HO1, NQO1 and 
glutathione (GSH) related precursors (Negi et al., 2011; Mas et al., 2012). More 
specifically, SF prevented oxidative-stress induced cytotoxicity in striatal neuronal 
cultures by increasing GSH levels following Nrf2-induced expression of γ-
glutamylcysteine ligase (GCL) (Mizuno et al., 2011). Furthermore, activation of Nrf2 by 
SF was shown to be localized within astrocytes compared to neurons in primary mixed 
cultures of astrocytes and neurons, even though this lead to the protection of both cell 
types in the presence of oxidative and excitotoxic stressors (Kraft et al., 2009; 
Innamorato et al., 2008).  
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The protective effects of SF have also been demonstrated against chronic 
neurodegeneration using in vitro and in vivo models. AD in vitro models have been used 
to demonstrate the ability of SF to protect neuronal cells from Aβ-induced cytotoxicity as 
well as increase proteasomal activities, suggesting that SF may aid in proteasomal 
degradation of Aβ accumulation (Park et al., 2009; Gan et al., 2010). These findings were 
extended in in vivo mouse models of AD where SF ameliorated cognitive impairment of 
Aβ toxicity (Kim et al., 2013). In PD models, SF has been demonstrated to protect 
dopaminergic neurons from the toxic effects of 6-OHDA in various in vitro cultures (Han 
et al., 2007; Yoon et al., 2010; Siebert et al., 2009). Furthermore, the loss of neurons in 
the PD Drosophila model of α-synucleinopathy can be reduced in the presence of SF 
(Trinh et al., 2008). Finally, SF induces Nrf2 cytoprotective genes and protects against 
dopaminergic neuronal cell death and astrogliosis in the MPTP mouse model of PD 
(Jazwa et al., 2011; Morronni et al., 2013). 
Although not as potent as SF, other naturally occurring dietary antioxidants such 
as curcumin, acetyl-L-carnitine, quercetin, resveratrol and carnosine have also been 
identified as similar activators of the Nrf2 pathway (Balogun et al., 2003; Garg et al., 
2008; Chen et al., 2005) (Figure 6). These compounds have also been shown to be 
protective in various models of neurodegeneration and have been used as starting points 
for identifying therapeutic analogues that specifically target Nrf2.  
4.2 Synthetic Compounds 
Along with the above mentioned naturally occurring activators of Nrf2, synthetic 
compounds such as tert-butylhydroquinone (tBHQ) and dimethyl fumarate (DMF) have 
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also been found to modify Keap1 to activate the Nrf2 pathway (Nquyen et al., 2000;  
Kraft et al., 2004) (Figure 6). Similar to SF and other natural antioxidants, synthetic 
tBHQ can induce ARE-driven gene expression in neuronal cultures as well as protect 
these cell types from various forms of degenerating toxins. Furthermore, in vivo 
administration of t-BHQ in mouse models results in protection against dopaminergic cell 
degeneration, Aβ-induced apoptosis and traumatic brain injury. In regards to DMF, the 
next section in this Chapter will highlight DMF in detail and discuss its importance in 
activating the Nrf2 pathway.   
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Table 6. Natural and Synthetic Nrf2 Inducers 
Compound Chemical Name Source Structure 
Sulforaphane 
[1-isothiocyanato-(4R)-
(methylsulfinyl)butane] 
cruciferous 
vegetables 
 
Curcumin (1E,6E)-1,7-Bis(4-
hydroxy-3-
methoxyphenyl)-1,6-
heptadiene-3,5-dione 
turmeric 
spice 
 
Acetyl-L-
carnitine (R)-3-Acetyloxy-4-
trimethylammonio-
butanoate 
acetylated L-
carnitine 
      
Quercetin 
2-(3,4-dihydroxyphenyl)-
3,5,7-trihydroxy-4H-
chromen-4-one 
plant 
pigment 
   
Carnosine 
(2S)-2-[(3-Amino-1-
oxopropyl)amino]-3-(3H-
imidazol-4-yl)propanoic 
acid 
animal 
protein 
 
Resveratrol 
3,5,4'-trihydroxy-trans-
stilbene 
grapes 
 
tBHQ 
2-(1,1-Dimethylethyl)-
1,4-benzenediol 
synthetic 
 
DMF 
dimethyl (E)-
butenedioate 
synthetic 
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5. DIMETHYL FUMARATE 
 
5.1 Origins of Dimethyl Fumarate  
In the 1950’s the German chemist W. Schweckendiek discovered that topical 
application of fumaric acid esters (FAE) improved the outcome of his psoriatic lesions. 
Schweckendiek theorized that psoriasis was due to an underlying metabolic disorder 
caused by disruptions in the citric acid cycle that could be corrected with FAEs 
(Schweckendiek et al., 1959). Years later, DMF was combined with three fumaric acid 
esters, monoethyl fumarate-calcium (MEF-Ca), monoethyl fumarate-magnesium (MEF-
Mg) and monoethyl fumarate-zinc (MEF-Zn), and licensed as an oral therapy for the 
treatment of psoriasis under the name Fumaderm (Altmeyer et al., 1994). More than a 
decade following the approval of Fumaderm, DMF as a single therapy was advanced 
through clinical trials for the treatment of relapsing-remitting MS (RRMS). 
5.2 Structures and Interactions of DMF 
Dimethyl fumarate (DMF) (trans-1, 2-ethylenedicarboxylic acid dimethyl ester) is 
the di-methylester of fumaric acid. It is a αβ-unsaturated compound that is highly 
electrophilic and rapidly reacts with nucleophiles in a Michael addition reaction. Upon 
oral administration, DMF is believed to be rapidly metabolized by intestinal esterases to 
its bioactive metabolite monomethyl fumarate (MMF) (Litjens et al., 2004). MMF is 
more resistant to metabolism by esterases and thus can be absorbed and distributed 
throughout the body, including across the blood brain (BBB) into the brain. Eventually 
MMF is metabolized to fumaric acid within cells, which fuels the citric acid cycle leading 
to increased CO2 expiration (Litjens et al., 2004) (Figure 6).   
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Figure 6. Metabolites of dimethyl fumarate and monomethyl fumarate. 
Dimethyl fumarate (DMF) is rapidly metabolized by intestinal esterases to its bioactivate 
metabolite, monomethyl fumarate (MMF) in vivo. MMF is more slowly metabolized in 
vivo within cells to fumaric acid, which fuels the citric acid cycle leading to increased 
CO2 respiration.  
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5.3 Therapeutic Effect of DMF in Multiple Sclerosis 
More than a decade following the approval of fumarates for use in psoriasis, 
Fumaderm was administered to patients with RRMS in a small magnetic resonance 
imaging (MRI)-based study (Schimrigk et al., 2006). In this trial, oral intake of 
Fumaderm was able to reduce the total number of gadolinium-enhancing lesions as well 
as reduce lesion volume. Although the MRI endpoint of this initial study was remarkable, 
tolerability was mainly reduced due to gastrointestinal side effects. To increase the 
tolerability of fumarate administration, an oral formulation containing only DMF in an 
enteric-coated tablet (BG-12) was developed and investigated in a multicenter, 
randomized, double-blind phase-II trial (Kappos et al., 2008). This phase II clinical trial 
significantly reduced new gadolinium-enhancing lesions and new T2-hyperintense 
lesions compared to placebo controls. Both of these lesion types are representative of 
damaged cell tissue indicated by MRI analysis (Kappos et al., 2012, MacManus et al., 
2011).  
Following these promising results from phase II trials, BG-12 was further 
investigated clinically in RRMS in a phase III trial that lasted 2 years and included 
clinical measurement of relapse rate (Gold et al., 2012). Completion of this trial resulted 
in a 51% reduction in relapses in the highest dose group, increased the overall time 
between relapses for patients and significantly reduced the number of gadolinium-
enhancing and T2-hyperintense lesions. In 2013, BG-12 was approved as a monotherapy 
for the treatment of RRMS and marketed under the name Tecfidera.   
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5.4 Preclinical Studies and the Mechanism of Action of DMF 
5.4.1 Anti-inflammatory effects of DMF 
Early studies investigating the therapeutic potential of DMF were conducted with 
a focus on understanding the effects of this compound on the immune system. 
Experimental studies both in vitro and in vivo determined that DMF could induce a shift 
in cytokine production from a Th1/Th17 to a Th2 pattern (Ockenfels et al., 1998, Zoghi et 
al., 2011). This pattern shift is characterized by the loss of interferon-gamma and tumor 
necrosis factor alpha (TNF-α) production to an increase in interleukin (IL)-4 and IL-5 
(Oreja-Guevara et al., 2012). These findings correlate with Th2 cytokine patterns being 
associated with reduced inflammation and symptom improvement in MS patients while 
expression of Th1 cytokines have been shown to increase inflammation (Murphy et al., 
2002, Segal et al., 2003, Sharief et al., 1991, Miller et al., 2004, Imitola et al, 2005).  
Further evidence that supports a role for DMF in anti-inflammatory effects stems from 
the ability of DMF to inhibit the translocation of the transcription factor NF-κB. This 
suppression results in the reduction of NF-κB target genes leading to a reduction in pro-
inflammatory cytokines and adhesion molecules, as well as a reduction in apoptotic 
induction (Mrowietz and Asadullah 2005; Stoof et al., 2001). Additional in vivo studies 
utilizing the EAE rodent model of MS resulted in amelioration of disease onset and 
reductions in overall clinical score, particularly in later stages of the disease, following 
DMF treatment (Linker et al., 2011). This amelioration of disease was correlated with a 
reduction in infiltrating macrophages into the spinal cord, which may be due in part to the 
reduction of NF-κB mediated cytokine expression described above (Schilling et al., 
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2006). However, the mechanisms behind the anti-inflammatory effects of DMF are still 
under investigation.  
Recently, studies conducted by Chen et al. have identified the hydroxycarboxylic 
acid receptor 2 (HCA2) as a contributor to the protective effects of DMF in the EAE 
model. In these studies investigators compared the treatment effect of DMF in HCA2-/- 
and wild-type animals induced with EAE and found HCA2 to be necessary for the 
therapeutic potential of DMF (Chen et al., 2014). Since the HCA2 is a Gi-coupled 
membrane receptor expressed on immune cells such as macrophages and neutrophils, and 
infiltration of these immune cells is reduced in DMF-treated EAE animals, the activation 
of this receptor may be an important mediator of the ant-inflammatory effects of DMF. 
Further investigation into this receptor and how it is regulated by DMF are needed to 
better understand the mechanisms behind DMF and inflammation.  
5.4.2 DMF and the Nrf2 pathway 
Along with its anti-inflammatory effects, DMF has also been identified as a 
regulator of the Nrf2 pathway. In vitro studies using both DMF and its bioactive 
metabolite, MMF, show Nrf2 stabilization and increased antioxidant protein expression 
of Nrf2 targets including NQO1 and HO-1 (Scannevin et al., 2012). These findings were 
identified in various cell types including human astrocyte and oligodendrocyte cultures. 
Furthermore, treatment of cell cultures with DMF and MMF resulted in direct 
modifications of Keap1 cysteine residues, confirming that DMF/MMF activate the Nrf2 
pathway through a similar mechanism as other electrophilic compounds (Linker et al., 
2011, Liu et al., 2007). Most interestingly, administration of DMF/MMF was shown to 
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induce cytoprotection in cultures of neurons and astrocytes challenged with oxidative 
insults, an effect that was lost in the absence of Nrf2 (Scannevin et al., 2012). Lastly, in 
vivo experiments using the EAE model of MS displayed increased levels of Nrf2 in the 
CNS following DMF treatment. These alterations in Nrf2 levels correlated with the 
ability of DMF to ameliorate EAE symptoms as well as preserve myelin, axons and 
neurons.  In Nrf2-deficient mice, DMF was unable to protect against the disease course of 
EAE (Gold et al., 2006, Linker et al., 2011).  
Taken together, these studies support regulation of the Nrf2 pathway as an 
important mechanism of action for DMF, especially in regards to neuroprotection. 
However, although there is strong evidence that DMF increases cellular levels of Nrf2 
resulting in antioxidant gene up-regulation, it is not known how these changes result in 
protection of neurons or if DMF solely functions through this pathway or another. 
Therefore, understanding the specific sequence of events involved with Nrf2-mediated 
cellular protection is crucial for delineating the endogenous pathways that are in place to 
protect neurons and will assist in determining the role DMF and other potential 
neuroprotective compounds play in these pathways. 
Transcriptional profiling studies conducted within our lab have begun to uncover 
the diverse functions of the Nrf2 pathway across tissue types in response to DMF 
treatment; which will be discussed further in Chapter III. These studies have begun to 
unveil the mechanisms associated with DMF-mediated regulation of the Nrf2 pathway, 
particularly in regards to the CNS. One potential pathway that has been identified 
involves the induction of oxidative stress induced growth inhibitor 1 (OSGIN1), which 
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has been observed to be uniquely regulated in the CNS following DMF treatment. The 
evidence for OSGIN1 involvement in DMF mediated protection will be addressed in 
detail in Chapters IV; however, an introduction to OSGIN1 will first be presented in the 
next section.  
 
6. OSGIN1    
6.1 Background  
6.1.1 Characterization of the OSGIN1 gene 
Oxidative stress induced growth inhibitor 1 (OSGIN1), also referred to as bone 
marrow stromal cell (BMSC)-derived growth inhibitor 1 (BDG1) or ovary, kidney and 
liver protein 38 (OKL38), was first identified in 2001 by Huynh et al. as a novel induced 
pregnancy complementary DNA (cDNA) from a human ovary cDNA library. Huynh 
originally named the gene OKL38 based on the predominant expression of its protein 
product in ovary, kidney and liver and its predicted size of around 38 kDa (Huynh et al., 
2001). However, additional aliases arose from identification of different isoforms of this 
gene that resulted in the discovery of a 52 kDa and a 61 kDa protein product from the 
same gene (Wang et al., 2005). For simplicity, we will refer to this gene and its protein 
product as OSGIN1 throughout this discussion and reference the individual isoforms by 
size.  
The human OSGIN1 gene is located on chromosome 16, spans approximately 
eighteen kilo-base pairs (kb) and contains eight exons and seven introns (Figure 7). Multi 
Tissue Expression array (MTE) and Multi Tissue Northern blot (MTN) analysis indicated 
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that OSGIN1 was ubiquitously expressed across all tissue types, with higher expression 
in specific tissues such as the liver and kidney (Ong et al., 2004). Two conserved 
domains have been found within the OSGIN1 protein (Marchler-Bauer et al., 2013); a 
NAD (P)-binding Rossmann-like domain and a Bthiol_YpdA domain. These two 
domains overlap within the C-terminal region of OSGIN1 and are associated with 
oxidoreductase protein families. The NAD(P)-binding Rossmann-like domain is found in 
the putative NADP oxidoreductase coenzyme F420-dependent proteins and/or NAD-
dependent glycerol-3-phosphate dehydrogenase-like proteins, while the Bthiol_YpdA 
domain is found within a protein family of oxidoreductases present only in bacteria 
(Marchler-Bauer et al., 2013, Huang et al., 2004). The presence of these conserved 
oxidoreductase domains within OSGIN1 support a role of this gene in response to 
oxidative stress.  
6.1.2 Transcripts (Splice Variants) of OSGIN1 
In addition to OSGIN1~38kDa, researchers had identified two additional 
transcripts by northern blot analysis; however, whether these transcripts were precursory 
to the originally cloned transcript or arose from differential splicing from the gene was 
unknown (Huynh et al., 2001). In 2004, Ong et al. identified and cloned two transcript 
variants along with the OSGIN1 gene that correlated with the 52 and 61kDa isoforms 
(Ong et al., 2004, Wang et al., 2005). Alternative splicing of OSGIN1 was found to occur 
at the 5’ end of this gene to generate these variants and the splicing pattern was identified 
to be similar to that of the human thioredoxin reductase 1 (TXNRD1) gene (Rundlof et 
al., 2007, Osborne et al., 2001). This similarity in splicing suggests that these two genes 
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may be regulated in a similar manner and be family members, which is supported by the 
presence of similar oxidoreductase domains found in both genes (Ong et al., 2004, 
Osborne et al., 2001).  
Interestingly, two variants were also cloned in these studies that encode for the 
same open reading frame (ORF) corresponding to the 52 kDa protein product of OSGIN1 
(Ong et al., 2004). These variants were identified to be expressed from different 
promoters and therefore contain different 5’ untranslated regions (UTR). These findings 
suggest that OSGIN1 may be regulated at the translational level and that the 5’UTR may 
play an important role in regulation of OSGIN1 protein. The involvement of the 5’UTR 
in OSGIN1 regulation was further supported by Ong and colleagues in 2007 when they 
discovered that OSGIN1 could be downregulated via translational suppression involving 
the 5’UTR of OSGIN1 mRNA (Ong et al., 2007). They found that small upstream ORFs 
(uORF) were present in the 5’UTR of all three identified transcripts and that disruption of 
these small uORF’s resulted in increased OSGIN1 protein expression. These findings 
suggest that uORF’s within OSGIN1 transcripts could result in the translational 
suppression of OSGIN1 mRNA. The presence of uORF and upstream AUG (uAUG) sites 
in 5’UTR regions has previously been described to decrease the frequency of AUG starts 
sites to initiate transcription in the main ORF (Morris and Geballe, et al., 2000), 
suggesting that OSGIN1 expression could potentially be regulated by weaker upstream 
AUG starts. 
Over the years a total of seven potential OSGIN1 transcripts have been identified; 
six of which have evidence for protein encoding. Interestingly, the originally identified 
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OSGIN1-38kDa transcript is not recognized in genome browsers such as Ensembl as a 
known splice variant of the cloned full length OSGIN1, suggesting that the originally 
identified cDNA was incomplete. Although original experimental analysis has included 
the 38 kDa form, more recent investigation has focused on the two isoforms that encode 
for 52 and 61 kDa ORFs. However, the presence of other identified transcripts suggests 
that the regulation of the OSGIN1 gene may be complex and result in differential 
biological functions downstream.  
 
 
 
Figure 7. Genomic structure and protein isoforms of OSGIN1.  
A, genomic structure of OSGIN1 with eight labeled exons. B, translated protein products 
of OSGIN1 correlating (by color) with transcribed exons. Currently there is no strong 
evidence supporting the 38 kDa protein product as an isoform of OSGIN1. *there are two 
identified OSGIN1 transcripts that encode for the same 52 kDa protein product (see 
section 6.1.2 of introduction) 
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6.2 OSGIN1 Function 
6.2.2 OSGIN1 balances cell growth, differentiation and death 
As mentioned above, OSGIN1 was originally identified as a novel pregnancy 
gene. Studies by Huynh and colleagues localized OSGIN1 to rat breast epithelial cells 
and found that it was induced during pregnancy and lactation. Further analysis of 
OSGIN1 in human breast cancer cell lines found that expression of this protein was 
abnormally low in these cells. To investigate the importance of this loss, human breast 
cancer cells overexpressing the 38 kDa isoform of OSGIN1 were administered to mice 
and monitored for tumor formation.  Interestingly, the researchers found that OSGIN1 
overexpression reduced tumor formation in these mice, suggesting that this protein may 
play an important role in the differentiation and growth of cells (Huynh et al., 2001). 
Further studies by Ong et al. found that overexpression of the 52 kDa OSGIN1 isoform 
protein could also inhibit cell proliferation, induce cell death and reduce the migration of 
multiple cancer cell lines (Ong et al., 2004). Furthermore, comparison studies between 
the three identified isoforms found that the 52 kDa form was more potent at inducing cell 
death than the 38 kDa or 61 kDa forms and was lethal to certain cell types, suggesting 
that these variants may have divergent functions (Ong et al., 2004, Wang et al., 2002). 
The 61 kDa isoform is now considered to be the canonical OSGIN1 transcript sequence; 
however, expression of the 52 kDa isoform is most recognized in the literature. 
Further investigation into the specific pathways associated with OSGIN1 
mediated cell cycle regulation found that OSGIN1 specifically induces cell cycle arrest in 
the S phase resulting in the induction of apoptosis in breast cancer cells (Wang et al., 
62 
 
 
2004).  In 2008, Yao et al. expanded upon these findings in experiments involving DNA 
damage and confirmed that OSGIN1 regulates apoptosis through mitochondrial 
localization and cytochrome C release that involves the transcriptional control of tumor 
suppressor protein (p53) and peptidylarginine deiminase 4 (PADI4) (Yao et al., 2008) 
(Figure 8). In these studies, OSGIN1 and p53 levels were found to be repressed before 
DNA damage which correlated with high PADI4 expression at the OSGIN1 promoter. In 
contrast, increased DNA damage resulted in increased p53 at the OSGIN1 promoter, 
increased OSGIN1 expression and suppression of PADI4.  Previous data has identified 
PADI4 to suppress the transcriptional activity of p53 by counteracting protein arginine 
methyltransferase co-activators of p53 via deimination (Li et al., 2008). Together, PADI4 
and p53 may alternately regulate the expression of OSGIN1 to mediate apoptosis during 
periods of cell damage (Figure 8). 
 In 2012, Hu et al further investigated the role of OSGIN1 and p53 on regulating 
mitochondrial structure and function (Hu et al., 2012). In these studies, the 
overexpression of OSGIN1 was found to co-localize with p53 within mitochondria, 
suggesting that p53 can both transcriptionally regulate OSGIN1 as well as mediate its 
function at a protein level. Together, p53 and OSGIN1 were found to induce changes in 
mitochondrial morphology and increase ROS levels within the cell, as well as induce 
apoptosis via a cytochrome C release dependent mechanism (Figure 8). These findings 
provide evidence that OSGIN1 plays an important role in regulating pathways involved 
with cell cycle regulation and induction of cell death. 
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Figure 8. Regulation of OSGIN1. 
 A, p53 binds to the promoter of OSGIN1 to regulate transcription of this gene. 
Translated OSGIN1 protein can then interact with p53 in the cytoplasm to regulate 
apoptosis via cytochrome c release from mitochondria (Hu et al. 2012). B, PADI4 can 
also bind to the promoter of OSGIN1, but works to suppress OSGIN1 expression (Yao et 
al. 2008). 
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6.2.1 OSGIN1 as a regulator of inflammation 
 Along with mediating cell cycle, OSGIN1 has also been shown to be an important 
regulator of inflammation.  Using primary human epithelial cells, OSGIN1 was found to 
be a major hub gene that regulates major pathways in response to oxidized 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine (Ox-PAPC), a product of lipid oxidation that 
tends to accumulate in atherosclerotic lesions and other chronic inflammatory sites 
(Romanoski et al, 2011, Yia-Herttuala et al., 1989). In these studies, the loss of OSGIN1 
was found to increase the expression of interleukin-8 (IL-8), activating transcription 
factor 4 (ATF-4) and kruppel-like factor 4 (KLF4), all molecules previously identified to 
be involved in the endothelial inflammatory response (Romanoski et al., 2010, Irizarry et 
al., 2003). These data support a protective role for OSGIN1 against the induction of 
inflammation in the presence of Ox-PAPC and potentially oxidative stress due to the 
generation of Ox-PAPCs by oxidation reactions. Furthermore, loss of OSGIN1 was also 
shown in these studies to increase the levels of HO-1 induced by Ox-PAPC, suggesting a 
close relationship between these molecules in regulating responses to Ox-PAPC 
(Romanoski et al., 2011).  
 
6.3 OSGIN1 and Disease  
6.3.1 OSGIN1 and cancer 
A large portion of data supporting OSGIN1 as a regulator of cell cycle stems from 
studies investigating tumorigenesis. Some of the first investigations of OSGIN1 found 
OSGIN1 to be down-regulated in 70% of kidney tumors using cancer gene profiling 
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arrays (Ong et al., 2004). These finding were also paralleled in hepatocellular carcinoma 
(HCC) where the loss of OSGIN1 correlated with advanced tumor stages of HCC (Ong et 
al., 2005). This was also confirmed by Liu et al in 2014 when they analyzed 400 paired 
HCC and adjacent non-tumor tissues and found OSGIN1 to be down regulated or altered 
in human HCC’s. Lower expression levels of OSGIN1 in these tissues correlated with 
decreased survival times and disease-free states in patients. Further investigation of these 
tumors also identified amino acid substitutions in OSGIN1 that were retained in tumor 
tissues. These altered forms of OSGIN1 protein resulted in a reduced ability to 
translocate to mitochondria and induce apoptosis compared to the common form (Liu et 
al., 2014). On the contrary, one study reported OSGIN1 transcripts to be overexpressed in 
HCC and adjacent benign tissue compared to tissues from healthy normal controls; 
however, supporting protein analysis was not included in this study (Riou et al., 2002). 
Many studies investigating the importance of OSGIN1 in tumorigenesis have 
been conducted using breast cancer cell lines (Hu et al., 2012, Ong et al., 2004, Yao et 
al., 2008). As previously mentioned, OSGIN1 was originally identified as an important 
gene regulated during pregnancy and is believed to contribute to mammary gland cell 
growth and death needed during stages of lactation (Huynh et al., 2001). This role 
suggests that fluctuations in the OSGIN1 gene may be required for the cellular changes 
that transition a cell from a normal to a malignant state. The fluctuations of OSGIN1 in 
breast cells contrasts with the more stable expression of this gene in other tissue types, 
suggesting dysregulation of OSGIN1 in this tissue type may be causative of disease. This 
can be exemplified in breast cancer cell lines treated with the natural compound Taheebo 
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(inner bark of the Tabebuia avellandae tree), which is shown to have anti-proliferative 
effects in cancer cell lines. Global gene expression profiling conducted on cancer cells 
treated with Taheebo identified cell growth arrest and initiation of apoptosis in these cells 
to be correlated with increased OSGIN1 expression (Mukherjee et al, 2009). These 
studies indicate OSGIN1 as a tumor suppressor and thus a potential therapeutic target in 
cancer.  
6.3.2 OSGIN1 and cardiovascular disease 
Less investigation has been conducted on the role of OSGIN1 in non-carcinogenic 
diseases; however, some studies target OSGIN1 as regulated during models of 
cardiovascular disease (Omura et al, 2009). Exposure to ultrafine particles (UFP), 
associated with ambient air pollution, has been shown to be associated with 
cardiovascular disease (Kumar et al., 2008). Microarray studies showed OSGIN1 to be 
upregulated upon exposure to diesel exhaust particles which can adversely affect health 
(Omura et al., 2009). These findings were confirmed in a study by Li et al in 2010 that 
showed that UFP induced superoxide and resulted in increased OSGIN1 expression in 
human aortic endothelial cells (HAEC) (Li et al., 2010). Further research is necessary to 
understand the role of OSGIN1 in cardiovascular disease as well as other unstudied 
diseases.  
 
6.4 OSGIN1 as a Transcriptional Target of Nrf2  
Of particular interest to this discussion is the identification of OSGIN1 as a 
transcriptional target of Nrf2. In 2006, Li et al. suggested that OSGIN1 was regulated via 
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an oxidative signal induced by Ox-PAPC since these lipid oxidation products could 
induce expression levels of OSGIN1 that correlated with superoxide production. This 
theory was strengthened by the finding that the presence of superoxide scavengers 
prevented Ox-PAPC induced expression of OSGIN1 (Li et al, 2006). Involvement of 
Nrf2 was also identified in this scenario when siRNA knockdown of Nrf2 resulted in the 
inability of Ox-PAPC to induce OSGIN1, suggesting that this gene is a direct target of 
the Nrf2 pathway. These finding were confirmed by Yan et al. in endothelial cells 
showing that OxPAPC can induce OSGIN1 and is an Nrf2 mediated target (Yan et al., 
2014).  
Recently, new data suggests that miRNAs may be involved with the 
transcriptional control of OSGIN1. MiR-320a was recently found to regulate induction of 
the Nrf2 target genes HO-1, GCLM, and OSGIN1 by electrophilic molecules in 
endothelial cells and this miRNA was shown to be critical for regulating Nrf2 
transcriptional induction by OxPAPC (Schrottmaier et al., 2014). 
The identification of OSGIN1 as a gene regulated in response to stressful stimuli 
as well as in biological pathways such as cell cycle, suggests that this gene is important 
for not only endogenous pathway regulation but also stress. Whether OSGIN1 is 
controlled by Nrf2 in all of its functions or its transcripts are differentially regulated by 
different transcriptional regulators (suggested by differential promoter usage) is unknown 
and warrants further research. 
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7. RESEARCH HYPOTHESES 
The activation of the Nrf2 pathway plays a crucial role in the defense against 
oxidative and electrophilic stress; however, the mechanisms that lead to Nrf2-mediated 
cytoprotection are still under investigation. Using the known Nrf2 regulators, DMF and 
MMF, the primary aim of the research set forth in this dissertation was to identify the 
molecular mechanisms of Nrf2 regulation and subsequent cellular protection conferred by 
activation of this pathway. Using in vivo transcriptional profiling studies, the differential 
regulation of DMF-target genes was assessed across time and dose followed by 
confirmation of Nrf2 involvement. Following identification of the Nrf2-transcriptional 
target gene OSGIN1 in the CNS, further experiments attempted to elucidate the role of 
this gene and its importance in defending against oxidative damage. These proposed 
experiments allow for a broader understanding of endogenous cellular protection in the 
present of oxidative stress and how it can be used to combat various disorders of the 
CNS. This research is defined by three major hypotheses:   
 1: Activation of the Nrf2 pathway via DMF/MMF results in differential regulation of 
Nrf2 target genes across tissue types.  
 2: OSGIN1 is an Nrf2 transcriptional target that is important for the cytoprotective 
properties of MMF.  
 3: Alternative splicing of the OSGIN1 gene results in unique biological functions. 
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CHAPTER II                                                                                                       
MATERIALS AND METHODS 
 
1. MATERIALS 
1.1 Animals 
 All procedures involving animals were performed in accordance with standards 
established in the Guide for the Care and Use of Laboratory Animals as adopted by the 
U.S. National Institutes of Health. All animal protocols were approved by the Biogen 
Idec Inc. Institutional Animal Care and Use Committee (IACUC), which is accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care 
International. 
1.1.1 C57BL/6 wild type mice  
6-8 week-old male C57BL/6 wild-type mice were used for experimentation. Mice were 
purchased from Jackson Laboratories (Bar Harbor, ME) and maintained on a 12-hour 
light/dark cycle and given access to food and water ad libitum.  
1.1.2 Transgenic Nrf2 -/- knockout mice 
Transgenic Nrf2-/- knockout mice were obtained from Masayuki Yamamoto at the 
University of Tsukuba (Tsukuba, Japan). Generation of these mice was obtained by a 
target vector designed to replace the b-Zip region of the Nrf2 gene with a SV40 nuclear 
localization signal (NSL)-β-galactosidase (lacZ) recombinant gene. To select for 
transformants a neomycin resistance (neo) gene was inserted downstream of the NSL-
lacZ gene. The diphtheria toxin gene was placed upstream of the Nrf2 gene for negative 
70 
 
 
selection against non-homologous recombinants (Itoh et al., 1997). Heterozygote males 
were shipped to Jackson Laboratories (Bar Harbor, ME), bred to female C57Bl/6J and 
maintained on the 6J background. 6-8 week-old male Nrf2-/- and aged matched C57BL/6 
wild-type mice from the same colony were used for all experimentation.  
1.2 Antibodies 
All purchased and custom generated antibodies used for experimentation are listed and 
described in Table 7. 
 
Table 7. Antibodies  
ANTIBODY  MANUFACTORER CATALOG 
NUMBER 
DILUTION 
β-ACTIN MP Biomedicals 69100 1:5000 
BDNF Abcam ab108383 1:5000 
GCLC Abcam ab41463 1:500 
NQO1 Epitomics 2618-1 1:1000 
NRF2 Epitomics 2178-1 1:1000 
OSGIN1 NEP Custom* 1:200 
OSGIN1-1a/2a NEP Custom* 1:1000 
OSGIN1-2b NEP Custom* 1:500 
OSGIN1 C-terminal Abcam ab173766 1:250 
OSGIN1 N-terminal Abcam ab90128 1:1000 
PADI4 Abcam ab96758 1:500 
P53 Cell Signaling 9282 1:1000 
SQSTM1 Abcam ab56416 1:250 
TXNRD1 Abcam ab124954 1:1000 
NEP-New England Peptide; *please see section 1.2.1 of Materials and Method 
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1.2.1 Generation of OSGIN1 isoform-specific antibodies 
Three isoform specific rabbit polyclonal antibodies were generated by New 
England Peptide (NEP) based on the sequences identified and cloned by Ong et al. (Ong 
2004). Peptides were generated against human specific sequences in the OSGIN1 38 kDa, 
52 kDa and 61 kDa protein regions (Figure 9). Based on the methods of NEP, antibodies 
were generated and affinity purified using OSGIN1 isoform-specific peptides. Due to the 
overlapping homology of the sequences only the longest 61 kDa peptide sequence 
resulted in a unique antibody (Figure 9).  
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Figure 9. Epitope locations of human OSGIN1 isoform-specific antibodies.  
Boxes represent translational start sites of each OSGIN1 isoform labeled with the 
corresponding amino acid length protein; 560aa (OSGIN1~61kDa), 477aa 
(OSGIN1~52kDa) and 375aa (OSGIN1~38kDa). Colored amino acids indicate region of 
peptide generation for antibody creation; blue: OSGIN1~61kDa, red: OSGIN1~52kDa 
and green: OSGIN1~38kDa. 
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1.3 Human siRNA constructs 
Human siRNA constructs were purchased from OriGene technologies (Rockville, MD) or 
Invitrogen (Grand Island, NY) and are listed and described in Table 8. For all siRNA 
transfection studies, constructs were transfected into cells at a final concentration of 
10nM. If multiple duplexes were used, the total addition of combined duplexes equaled 
10nM. 
 
Table 8. siRNA constructs.  
siRNA MANUFACTORER CATALOG 
NUMBER 
DUPLEX 
USED 
OSGIN1 OriGene SR309301 A and C* (5nM 
each) 
PADI4 OriGene SR308375 A,B,C* (3.3nM 
each) 
Trilencer-27 Scrambled 
Negative Control 
OriGene SR30004 10nM  
Scrambled Negative Control 
Stealth RNA 
Invitrogen 13750-047 10nM 
p53 Pos Control Stealth RNA Invitrogen 13750-047 10nM 
NRF2 OriGene SR303156 A,B,C* (3.3nM 
each) 
*A, B, C represent different siRNA duplexes from Origene used for transfection. 
 
 
1.4 Primers and Probes 
1.4.1 Purchased primer/probe sets 
All manufactured primer/probe sets were purchased from Life Technologies (Grand 
Island, NY) at a concentration of 20X and are listed in Table 9.  
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Table 9. Taqman Primer/Probe Assays 
Gene Species Taqman Assay 
ID 
 Gene Species Taqman Assay 
ID 
AATF Mouse Mm00498160_m1  NINJ1 Mouse Mm00479014_m1 
ACTB Mouse Mm00442646_m1  NOS1 Mouse Mm00435175_m1 
ACTIN Human Hs01060665_g1  NQO1 Human Hs02512143_s1 
AKR1B8 Mouse Mm00484314_m1   Mouse Mm01253561_m1 
ALS2 Mouse Mm01255664_m1  NR2F6 Mouse Mm01340321_m1 
APOE Mouse Mm01307193_g1  NSG2 Mouse Mm00476554_m1 
ATG2A Mouse Mm01212087_m1  NUDT7 Mouse Mm01240093_m1 
BDNF Mouse Mm04230607_s1  OLIG1 Mouse Mm00497537_s1 
CCS Mouse Mm00444148_m1  OSGIN1 Human Hs00203539_m1 
CDKN1A Mouse Mm04205640_g1   Mouse Mm00660947_m1 
DNAJA3 Mouse Mm00469723_m1  OXNAD1 Mouse Mm00520913_m1 
EGR2 Mouse Mm00456650_m1  PADI4 Human Hs00202612_m1 
GAB1 Mouse Mm00491216_m1  P21 Human Hs00355782_m1 
GAPDH Human Hs02758991_g1  PRDX1 Mouse Mm01621996_s1 
 Mouse Mm99999915_g1  PTGS2 Mouse Mm00478374_m1 
GCLC Human Hs00155249_m1  P53 Human Hs01034249_m1 
 Mouse Mm00802655_m1  RBP4 Mouse Mm00803264_g1 
GCLM Mouse Mm00514996_m1  SIRT1 Mouse Mm00490758_m1 
GDF15 Mouse Mm00442228_m1  SLC1A2 Mouse Mm00441457_m1 
GFAP Mouse Mm01253033_m1  SNAI1 Mouse Mm00441533_g1 
GLUL Mouse Mm00725701_s1  SOD1 Mouse Mm01344233_g1 
GSTA2 Mouse Mm03019257_g1  SQSTM1 Mouse Mm00448091_m1 
HMOX1 Human Hs01110250_m1  SRXN1 Human Hs00607800_m1 
 Mouse Mm00516005_m1   Mouse Mm00769566_m1 
IGFBP Mouse Mm01187817_m1  STRA6 Mouse Mm00486457_m1 
MMP11 Mouse Mm00485048_m1  TNF-α Human Hs01113624_g1 
NETO2 Mouse Mm01245002_m1  TXNRD1 Human Hs00182418_m1 
NFKBIB Mouse Mm00456849_m1   Mouse Mm00443675_m1 
NGFG Mouse Mm01203825_gH  UBC Mouse Mm02525934_g1 
    VEGFA Mouse Mm01281449_m1 
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1.4.2 Custom primer/probes sets 
Custom primers for 5’UTR analysis were generated using primer express software to 
distinguish between two nucleotide substitutions identified within the 5’UTR of two 
human OSGIN1 transcripts (Table 10; section 2.4 of results). These transcripts were 
identified from RACE analysis and encode for the same protein. Generated primers and 
probes were analyzed using BLAST (Basic Logical Alignment Search Tool) to confirm 
specificity. 
 
Table 10. Primer and probe sets for 5’UTR transcript variants of OSGIN1. 
 Forward Primer Reverse Primer Probe 
WT CTTCCCTCTGGCCTCT-
CAGA 
GAGATCGGGACACCCAT-
TACC 
CCTCTTGGATC-
CCC 
ALT AATGGGTGTCCCGAT-
GTCA 
CCGGCCAAGTTGTGCAC-
TA 
ACTCTGTGATC-
CGTGTTC 
WT-Represents canonical sequence; ALT-represents nucleotide alteration identified in 
5’RACE 
 
 
1.4.3 Primers for 3’ and 5’ RACE 
All primers for RACE were generated against the human OSGIN1 sequence and were 
analyzed using BLAST (Basic Logical Alignment Search Tool) to confirm specificity.  
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Table 11. Primers for 3’ and 5’ RACE. 
3’ RACE Primers 
Primer Sequence 
GSP1 GCTCCCGGACCTGGAGGT 
Nested GSP2 ACTGGATGCAGAAGAAGCGA 
5’ RACE Primers 
Primer Sequence 
GSP1 CGCTTCTTCTGCATCCAGTCC 
GSP2 GCATCCAGTCCTTGACCTCCA 
Nested GSP3 TGACCTCCAGGTCCGGGAGC 
 
 
 
 
2. METHODS 
2.1 Pharmacokinetic Measure of MMF Exposure 
Whole blood and tissues (brain, liver, kidney, jejunum and spleen) were collected in a 
separate cohort of mice 30 minutes after dosing. Whole blood was collected via cardiac 
puncture and collected in lithium heparin tubes (Fisher Scientific, Cambridge MA) with 
an addition of 10 mg sodium fluoride. Tubes were immediately inverted several times 
and stored on wet ice until processed (no longer than 30 min). Whole blood was then 
centrifuged (15 minutes @ 1500xg, 4 ºC), and plasma was immediately collected and 
stored on dry ice until transfer to 
-
80°C for storage. Tissues of interest were also collected 
at 30 minutes after dosing, snap frozen and stored at 
-
80°C. A liquid chromatography–
mass spectrometry/mass spectrometry (LC-MS/MS) based bioanalytical assay was used 
to determine MMF concentration levels in plasma and tissue samples.  Stable isotope 
labeled 14C-MMF was employed as an internal standard (IS).  Study samples were 
thawed on ice and MMF, as well as the IS, were extracted from plasma samples using 
protein precipitation followed by separation from endogenous components using a liquid 
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chromatography column. Detection was conducted by mass spectrometry using negative 
electrospray and the multiple reaction monitoring mode. Concentrations of MMF in study 
samples were calculated using peak area ratios of MMF to the IS against the standard 
curve relating the peak area ratios to spiked MMF concentrations. 
 
2.2 Acute Oral Administration of DMF in vivo 
2.2.1 Time course in wild type C57BL/6 mice 
Wild type mice were dosed with a single suspension of 100 mg/kg DMF in 0.8% 
hydroxypropyl methylcellulose (HPMC) or vehicle solution alone. 100 mg/kg was 
selected based on previous animal studies with DMF. Drug was delivered by oral gavage 
at 10 μL/gram and dosed at 5 minute intervals to ensure proper timing and reduction of 
RNA variability following tissue collection. Tissues were harvested 2, 4, 6, 8, 12.5, 16.5, 
23 or 37.5 hours after dosing with each time point including a vehicle control group and 
DMF group with an n of 6 animals. 
2.2.2 Dose response in wild type C57BL/6 mice 
Experimental procedures for the DMF dose response study parallel those stated 
for the time course study unless noted otherwise. Wild type C57BL/6 mice were dosed 
with a suspension of 50, 100, 200, 400 or 600 mg/kg DMF in 0.8% HPMC or vehicle 
solution alone. Drug was delivered by oral gavage and tissues harvested 7 hours after 
dosing. This time point was selected following analysis of the DMF time course data. 
2.2.3 Modified time course in transgenic Nrf2-/- knockout mice 
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Wild type and Nrf2-/- mice were dosed with a single suspension of 100 mg/kg DMF in 
0.8% HPMC or vehicle solution alone. 100 mg/kg was selected based on previous animal 
studies with DMF. Drug was delivered by oral gavage at 10 μL/gram and dosed at 5 
minute intervals to ensure proper timing and reduction of RNA variability following 
tissue collection. Tissues were harvested at 4, 8, 16 and 32 hours post-dose with an n of 6 
per group. The time points for the Nrf2-/- study were selected following analysis of the 
first time course study in wild type mice. Tissue samples were also collected for protein 
analysis at 6 hours post DMF administration in Nrf2-/- and wild type mice based upon 
gene regulation changes identified in the latter study. 
2.2.4 Tissue harvest 
Animals were exposed to CO2 and whole blood collected via cardiac puncture. Two 100 
µl aliquots of whole blood were collected in 1.5 ml microcentrifuge tubes and snap 
frozen in liquid nitrogen. Peripheral (liver, spleen, kidney and jejunum) and CNS brain 
(cerebellum, hippocampus, striatum and cortex) tissues were harvested and snap frozen in 
liquid nitrogen with special care taken to collect tissues of similar size and from the same 
location. Two samples were collected for each tissue, one for RNA extraction and one for 
protein extraction, and protein tissue samples were weighed in pre-tarred tubes before 
snap freezing. All samples were stored at 
-
80°C until RNA and protein extraction was 
conducted (see sections 2.5 and 2.11 of Materials and Methods).  
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2.3 Cell Culture 
2.3.1 Primary human spinal cord astrocytes 
Primary cultures of human spinal cord astrocytes were purchased from ScienCell 
Research Laboratories (Carlsbad, CA) and grown in Astrocyte Medium (AM; ScienCell). 
Cultures were maintained according to the supplier specifications. Cells for plate based 
assays were seeded into clear-bottom poly-D-lysine tissue culture 12-or 24-well plates 
(BD Biosciences, San Jose, CA). 
2.3.2 Reverse transient transfection  
Human spinal cord astrocytes were transfected with X-tremeGENE siRNA transfection 
reagent (Roche, Indianapolis, IN) using the reverse transfection method. siRNA 
complexes were created according to the manufacturer’s protocol and consisted of 1.5ul 
of X-tremeGENE transfection reagent and 10nM of either OSGIN1 siRNA (Origene), 
PADI4 siRNA (Origene), Nrf2 siRNA (Origene), p53 siRNA (Invitrogen) or scrambled 
siRNA (Origene, Invitrogen). Using the reverse transfection method, complexes were 
added to poly-d-lysine coated 24-well tissue culture plates (BioCoat) and astrocytes were 
added on top of the complex at a concentration of 60,000 cells/well in human spinal cord 
astrocyte medium (ScienCell). Cells were incubated with complex for 12 hours at 37ºC 
followed by replacement of complex media with fresh human astrocyte media. 
Knockdown was assessed at 48 hours post-transfection for q-PCR analysis (see section 
2.6.1 of Materials and Methods) and western blotting (see section 2.12 of Materials and 
Methods). For analysis with MMF, cells were treated with a titration of MMF 24 hours 
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post-transfection and analyzed in plate-based assays as described in section 2.4 of 
Materials and Methods.  
 
2.4 Plate-based Cellular Assays 
2.4.1 Compound handling 
MMF was prepared in 100mM solutions of DMSO, titrated in DMSO, and then diluted 
into normal growth media for cell treatments. The final concentration of DMSO (0.03%) 
was consistent for all treated cells.  
2.4.2 H202 in vitro stress response assay 
24 hours post-transfection, human astrocytes were treated with 0, 10 or 30uM of MMF 
compound in DMSO for 20 hours at 37ºC with 5% CO2. Since DMF is rapidly 
metabolized to its bioactive metabolite, MMF, following oral administration, cells will 
likely be exposed to MMF rather than DMF. Therefore, we used MMF in these in vitro 
studies. Following 20 hour treatment with MMF compound, media was removed from 
human astrocytes and replaced with 0, 200 or 300uM of hydrogen peroxide (H2O2) 
diluted in Hanks balanced salt solution plus 20 mM HEPES, pH 7.4. Astrocytes were 
challenged with hydrogen peroxide for 2 hours at 37ºC with 5% CO2 followed by 
recovery for 20 hours in human astrocyte media. Following 20 hour recovery from 
oxidative challenge, cellular viability was assessed using a LIVE/DEAD viability stain 
according to the manufacturer’s protocol (Invitrogen). LIVE stain was quantified by 
fluorescence intensity from calcein AM fluorescence in live cells (excitation wavelength, 
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488 nM; emission wavelength, 525 nM) and in parallel by counting Hoechst-labeled 
nuclei using automated imaging and counting (see section 2.14 of Materials and 
Methods). In the LIVE/DEAD assay, dead cells were labeled with ethidium homodimer 
and appear red in fluorescent images (excitation wavelength, 550 nM; emission 
wavelength, 575 nM). Live images from LIVE/DEAD labeled cells were imaged as 
above. Cell nuclei from Hoechst dye labeled cells were quantitated in an automated 
fashion on the Thermo ArrayScan VTi platform (Thermo Fisher Scientific). 
2.4.3 EdU proliferation assay 
Human astrocytes were treated with a titration of MMF and incubated for 20-24 hours at 
37ºC with 5% CO2. Cells were incubated with EdU to measure proliferation according to 
the manufacturer protocol outlined for the Click-iT
®
 EdU HCS Assay (Invitrogen). EdU 
was added to cells at a 1:1000 fold dilution in growth media and pulse labeled for 1 hour. 
Following EdU incorporation, cells were fixed in 4% paraformaldehyde (PFA)/4% 
sucrose in PBS and EdU detected by immunostaining according the manufacturer. 
Immunostained plates were quantitated for EdU incorporation using an automated 
fashion on the Cellomics ArrayScan VTI platform and correlating algorithm analysis (see 
section 2.14 of Materials and Methods). 
2.4.4 TiterTACS
TM
 Assay for Apoptosis 
Human astrocytes were transfected with siRNA according to the protocol in section 2.3.2 
of this chapter. Following 20-24 hours incubation with MMF, cells were fixed in 4% 
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PFA/4% sucrose and the HT TiterTACS
TM 
Assay Kit (Trevigen, Gaithersburg, MD) was 
used to detect cellular apoptosis according to the manufacturer’s protocol.  
2.4.5 Cellular extract preparation and Nrf2/p53 activity assays 
For Nrf2 and p53 activity assays, human astrocytes were treated for 6 or 24 hours with 
MMF. Cytosolic and nuclear extracts were prepared by using a nuclear extract kit from 
Active Motif Inc. (Carlsbad, CA). TransAM Nrf2 and TransAM p53 assays (Active 
Motif Inc.) were used according to the manufacturer’s instructions.  
 2.4.6 Immunocytochemistry  
Localization of p53 signal and OSGIN1 positive staining were analyzed via 
immunocytochemistry following treatment with MMF after 24 hours. Cells were fixed in 
4% PFA/4% sucrose, permeabilized in .1% Triton X-100 and labeled with primary anti-
p53 antibody or NEP antibodies generated against the 52 kDa and 61 kDa isoforms of 
OSGIN1 (see section 1.2 of Materials and Methods). Primary labeled cells were tagged 
with a secondary fluorescence antibody and DAPI nuclear stain. Images were acquired 
using the Thermo HCS Arrayscan VTI platform and an algorithm generated to measure 
p53 nuclear versus cytoplasmic signal and total OSGIN1 positive puncta (see section 
2.11 of Materials and Methods).   
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2.5 RNA Extraction 
2.5.1 Tissue RNA extraction 
For RNA preparation, frozen tissues were placed in 2 mL RNAse-free 96-well blocks 
with 1.5 ml QIAzol Lysis Reagent (QIAgen) and a 3.2 mm stainless steel bead (BioSpec 
Products, Bartlesville, OK). Tissues were disrupted for four cycles of 45 seconds in a 
Mini-Beadbeater (Biospec Products). RNA was extracted in chloroform and the aqueous 
phase was mixed with an equal volume of 70% ethanol. Extracted RNA was applied to 
RNeasy 96 plates and purified by the spin method according to the manufacturer’s 
protocol (RNeasy 96 Universal Tissue Protocol, QIAgen, Hilden Germany). 
2.5.2 Whole blood RNA extraction (RBC and PBMC) 
RNA extraction from whole blood was conducted using the Agencourt RNAdvance 
Blood kit according to the manufacturer’s protocol (Beckman Coulter, CA). To begin, 
frozen whole blood samples were arranged on dry ice in a 96-well tube rack and 520 μl 
Proteinase K/Lysis buffer was added to each blood aliquot. Samples were then 
simultaneously inverted at room temperature until all were mixed directly into solution. 
Agencourt RNAdvance Blood protocol was then followed using the Agencourt SPRIPlate 
96R Super Magnet Plate (Beckman Coulter) for RNA extraction. 
2.5.3 RNA extraction from whole cells 
Total mRNA was isolated from cells using an RNeasy kit (QIAGEN) according to the 
manufacturer’s protocol for spin technology.   
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2.5.4 Measure of RNA integrity, purity and quantity 
For initial optimization of RNA extraction and all transcriptional profiling studies, RNA 
was analyzed for purity and integrity by capillary electrophoresis on an Agilent 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). For optimized studies 
 
2.6 Quantitative Real-Time Polymerase Chain Reaction (PCR) 
2.6.1 Quantitative Real-Time PCR using the Qiagen QuantStudio 12K-Flex 
qPCR was performed from total mRNA isolated from tissues and reverse-transcribed into 
cDNA according to manufacturer protocols (Life Technologies, Carlsbad, CA). For in 
vivo Nrf2-/- analysis (see section 2.2.3 of Materials and Methods), target gene mouse 
primers (see section 1.4.1 of Materials and Methods) and 6-FAM™ dye-labeled 
TaqMan® MGB™ probes (Applied Biosystems) were custom dried onto 384-well PCR 
plates and mixed with 10 μl of cDNA and 10 μl 2X Taqman Universal Master Mix II, no 
ung (Applied Biosystems), to yield a final reaction volume of 20ul. For all other studies, 
qPCR was performed using 20X Taqman target gene human primer/probe sets (see 
section 1.4.1 of Materials and Methods) mixed with cDNA and 2X Taqman Universal 
Master Mix II, no UNG, to a final volume of 20 μl. All final reactions contained 100 ng 
of cDNA, 900 nM of each primer, and 250-nM TaqMan® probes and were cycled on a 
QuantStudio™ 12K Flex system (Life Technologies) once for 10 minutes at 95°C, 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. All samples were 
measured in duplicate using GAPDH or β-Actin as a normalizing gene. Final analysis 
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was performed using the comparative CT method to calculate fold changes and samples 
were normalized relative to vehicle control conditions within each data set. 
2.6.2 Fluidigm BioMark
TM
 Real-Time PCR 
RNA was analyzed for purity and integrity by capillary electrophoresis using the Agilent 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Total RNA (125 ng) was 
DNase-treated for 15 minutes at room temperature and EDTA heat inactivated at 65°C 
for 10 minutes using Dnase I Amp Grade from Invitrogen. Samples were then reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit according to the 
manufacturer’s protocol (Applied Biosystems). High-throughput qPCR was conducted to 
study gene expression in 5 ng cDNA using 96.96 Dynamic Arrays for the microfluidic 
BioMarkTM System (Fluidigm Corporation, CA, USA). A panel of 48 genes measured in 
duplicate, were selected based on previous DMF gene profiling studies conducted in vivo 
and in vitro, as well as published experimental and computational literature of identified 
Nrf2 regulated genes (Table 12). Real time PCR probe sets were designed using Primer 
Express 3.0 (Applied Biosystems) with TaqMan MGB Quantification default settings. A 
20X Assay stock of the primer probe set of each gene to be investigated was made (900 
nM for primers and 200 nM for Probe in 1X TE Buffer [10 mM Tris pH 8 (Ambion), 1 
mM EDTA pH 8 (Sigma)]) and then diluted to a 0.2X assay pool. 2 µl of 0.2X assay pool 
was combined with 2ul of the reverse-transcribed total RNA and 4ul of 2x Taqman® 
PreAmp Master Mix (Applied Biosystems) for a final reaction volume of 8ul. Pre-
amplification of cDNA was performed in the Tetrad thermocycler [at 95°C for a 10 
minute activation step followed by 10 cycles: 95°C, (15 s), 60°C, (4 minutes)]. Following 
86 
 
 
pre-amplification, 32 µl 0.1X TE Buffer was added to each sample and then mixed at an 
11:9 ratio of 2X Taqman® Gene Expression Master Mix (Applied Biosystems) with 1% 
20X GE Sample Loading Reagent (Fluidigm) to create the Sample Mix. In a separate 
mixture, 2X of Assay Loading Reagent (Fluidigm) was mixed with each pre-made 20X 
Assay at a 1:1 ratio to yield a 10X Assay mix. 5 µl of each Sample Mix and 5 µl of each 
10X Assay Mix were loaded and mixed into dedicated wells of a 96.96 Dynamic Array 
using the Integrated Fluidic Circuits (IFC) Controller HX (Fluidigm). The loaded 
Dynamic Array was then transferred to the BioMark™ real-time PCR instrument and the 
Fluidigm GE 96x96 Standard v1 PCR Thermal Protocol was run [Thermal Mix at 50°C 
(2 minutes), 70°C (30 minutes), and 25°C (10 minutes); UNG and Hot Start at 50°C (2 
min), and 95°C (10 minutes); cycling was performed using 95°C (15 second), and 60°C 
(1 minutes) for 40 cycles]. Samples were measured in duplicate and normalized to 
Gapdh, Actb and Ubc housekeeping controls. Final analysis was performed using the 
comparative CT method to calculate fold changes and samples were normalized relative 
to vehicle control conditions within each data set. 
2.7 Northern Blotting 
2.7.1 RNA probe generation 
RNA probes were generated using primers that covered the primer/probe sequence of the 
OSGIN1 Taqman assay used for q-PCR analysis (see section 1.4 of materials and 
methods). PCR was conducted using human spinal cord astrocyte cDNA as a template 
and PfuUltra II Hotstart PCR Master Mix according to the manufacturer’s protocol 
(Agilent). PCR products were separated on 2% SeaKem® LE Agarose DNA gels 
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(Lonza), appropriate bands excised and purified using QIAquick Gel Extraction Kit 
(Qiagen). Purified DNA was digested, re-purified and inserted into a pBluescript II KS+ 
Vector using a Quick Ligation Kit (Invitrogen). The vector-DNA ligation was then 
transformed into One Shot Chemically Competent E. coli (Invitrogen) by heat shock at 
42ºC for 30 seconds. Transformed cells were spread on ampicillin resistant selection 
plates and incubated overnight at 37ºC. Following overnight incubation, eight colonies 
were collected in lysogeny broth (LB) medium plus ampicillin and shaken for eight hours 
at 37ºC. Plasmid DNA was then purified using the Nucleospin 8 Plasmid Kit according to 
the manufacturer’s protocol (Machery-Nagel, Bethlehem PA). Purified plasmid was 
checked for correct insertion by restriction digest and submitted for DNA sequencing. 
Plasmid DNA containing the appropriate insert was linearized and transcribed into RNA 
probes using a MAXIscript in vitro Transcription Kit (Invitrogen) according to the 
manufacturer’s protocol. Unincorporated nucleotides were removed by column 
purification using NucAway Spin Columns (Ambion) and biotin labeled using a 
BrightStar Psoralen-Biotin Kit (Ambion).  
2.7.2 Northern blot analysis 
Northern blot analysis was conducted using the Ambion
®
NorthernMax
®
-Gly Kit (Life 
Technologies) according to the manufacturer’s protocol. RNA was transferred to Ambion 
BrightStar Plus Membranes (Ambion) using an iBlot Transfer System (Invitrogen) and 
detection was accomplished using the BrightStar BioDetect Kit (Ambion). 
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2.8 Rapid Amplification of cDNA Ends (RACE) 
2.8.1 3’ RACE 
3’ RACE was conducted using the Invitrogen 3’ RACE Kit (Invitrogen) with the primers 
listed in section 1.4 of Materials and Methods. The manufacturer’s protocol was followed 
other than for target cDNA amplification which was accomplished using Platinum PCR 
Supermix (Invitrogen). 3’ RACE products were separated by gel electrophoresis, excised 
and inserted into a TOPO vector. Generated plasmids were transformed into bacteria and 
purified according to the protocol mentioned in section 2.7.1 of Materials and Methods. 
Purified DNA was checked by restriction digest and submitted for DNA sequencing.  
2.8.2 5’ RACE 
5’ RACE was conducted using the Invitrogen 5’ RACE Kit (Invitrogen) with the primers 
listed in section 1.4 of Materials and Methods. 5’ RACE primer starting points were 
determined based on the sequence identified from 3’ RACE. 5’ RACE products were 
separated by gel electrophoresis, excised and inserted into a TOPO vector. Generated 
plasmids were transformed into bacteria and purified according to the protocol mentioned 
in section 2.7.1 of Materials and Methods. Purified DNA was checked by restriction 
digest and submitted for DNA sequencing. 
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2.9 Protein Isolation 
2.9.1 Protein isolation from tissue 
For protein extraction, frozen tissues were placed on wet ice and Radio Immuno 
Precipitation Assay (RIPA) buffer containing protease inhibitors was immediately added 
to samples at a volume of ~300 μl per 5 mg of tissue. Tissues were homogenized in 
buffer for 20 seconds using an F60 Sonic Dismembrator (Fisher Scientific) at setting 8 in 
a 4ºC walk-in fridge. Homogenized samples were incubated for 2 hours at 4ºC with 
constant agitation and then centrifuged for 20 minutes at 13,000 rpm in a microcentrifuge 
maintained at 4ºC. Following centrifugation, the supernatant was collected and the pellet 
discarded. Supernatants were analyzed for total protein concentration using the Thermo 
Scientific Pierce BCA Protein Assay Kit (Thermo Scientific) and diluted to yield equal 
concentrations of 2ug/uL. Samples were diluted 1:1 in 2X Laemmli denaturing buffer and 
boiled at 100ºC for 5 minutes. 
2.9.2 Protein isolation from cells 
For protein isolation from whole cells, cells were scraped directly in 1X Laemmli 
denaturing buffer, disrupted using an F60 Sonic Dismembrator (Fisher Scientific) and 
boiled at 100ºC for 5 minutes. 
2.9.3 Protein quantification 
Protein was quantified using the Pierce
®
 BCA Protein Assay Kit (Pierce) and samples 
diluted to equal loading volumes.  
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2.10 Western Blot Analysis 
Thirty μg of total denatured protein was loaded on Criterion™ TGX™ precast gels (Bio-
Rad Laboratories) and ran at a constant voltage of 200V for ~45 minutes. Gels were 
transferred to nitrocellulose membranes using the Invitrogen iBlot system (Invitrogen). 
Membranes were blocked in 5% milk in TBST (tris-buffered saline, tween 20) for 1 hour 
followed by incubation with primary (overnight at 4ºC) and secondary (1 hour at room 
temperature) antibodies in 5% milk in TBST. Signal was developed using SuperSignal
®
 
Chemiluminescent Substrate (Thermo Scientific). Primary antibodies can be found in 
section 1.2 of Materials and Methods. 
 
2.11 Thermo HCS Arrayscan Algorithm Creation and Analysis 
Plate-based cell assays were imaged using the Thermo HCS Arrayscan (Thermo 
Scientific) and quantified by algorithm generation. Templates were used to generate 
algorithms using HCS Studio software and included the Nuclear Translocation algorithm 
template for p53 translocation analysis and Target Activation algorithm template for 
DAPI nuclear count and the EdU proliferation assay. 
 
2.12 Data Analysis and Statistics  
Method of statistical analysis and corresponding p values are stated within individual 
figures other than for transcriptional profiling time course and dose response studies 
which are described below. 
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2.12.1 Transcriptional profiling time course and dose response studies 
Statistical analysis was performed using Wilcoxon signed-rank test using SAS software 
for the transcriptional profiling time course study, with each statistical comparison 
occurring between vehicle and DMF-treated per time point. For the transcriptional 
profiling dose response study, one-way analysis of variance (ANOVA) was performed 
with Dunnett’s multiple comparison test. Significance is indicated in Tables 13 and 14 as 
either p < .01 (dark gray) or p < .05 (light gray). 
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CHAPTER III                                                                                                        
DELAYED-RELEASE DIMETHYL FUMARATE PHARMACODYNAMIC 
RESPONSES ARE TISSUE-SPECIFIC AND NRF2-DEPENDENT 
 
1. RATIONALE 
A potential mechanism to treat neurodegenerative disease is to utilize and 
enhance the activity of existing cellular defense mechanisms to overcome the 
degenerative and toxic effects of pathogenic stimuli. Elucidating how these defensive 
signaling pathways regulate cellular protection at the molecular level can contribute to 
the development of therapeutic approaches for combating neurodegenerative disease. The 
major cellular defense system activated during periods of oxidative and electrophilic 
stress is the Nrf2 pathway, which regulates the expression of genes that are pro-survival 
in nature and enable cells to better mitigate potentially toxic stimuli. DMF is believed to 
mediate its effect, at least in part, via the Nrf2 pathway; however, the exact mechanism of 
action is unknown. Therefore, evaluating the detailed pharmacodynamic responses to 
DMF treatment would provide important insight into the molecular nature of the DMF 
mechanism of action. Although there is strong evidence that DMF regulates Nrf2 
expression resulting in target gene up-regulation, it is not known how these changes 
result in immunomodulation and/or cellular protection or if DMF activity is mediated 
solely through Nrf2, or if non-Nrf2 mechanisms exist. To begin exploring these 
possibilities, we measured transcriptional changes in wild type and Nrf2 knockout mice 
treated with DMF to compare the pharmacodynamic responses throughout the central 
nervous system (CNS) and periphery in order to understand how changes in target gene 
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expression may confer DMF functional activity, and also to determine the necessity for 
Nrf2 in these processes.   
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2. RESULTS 
2.1 DMF treatment leads to increased levels of MMF in all tissues of interest 
DMF is known to be rapidly hydrolyzed to its bioactive metabolite, MMF, within 
minutes following oral intake (Werdenberg et al., 2003). To confirm that DMF was 
present at tissue sites analyzed for gene expression, MMF concentrations were measured 
in these tissues as an indicator of compound exposure. Following a single dose of 100 
mg/kg DMF in wild type C57BL/6 mice, MMF exposure was detected in all six tissues of 
interest; liver, spleen, kidney, jejunum, brain and plasma (Figure 10). The highest level of 
MMF exposure was seen within plasma samples and the lowest levels were found to be 
in the liver. In the remaining tissues, comparable exposure levels were seen between the 
peripheral organs and the brain. These findings confirm that DMF administration can 
result in effects within the CNS and that the metabolite of MMF can cross the blood brain 
barrier to contribute to DMF-mediated mechanisms.  
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Figure 10.  MMF exposure in peripheral and CNS tissues following a single dose of 
DMF.  
A, structure and basic properties of dimethyl fumarate (DMF) and monomethyl fumarate 
(MMF).  B, drug exposure levels were measured in mouse tissue samples collected 30 
minutes post-dose of oral DMF and were analyzed for levels of MMF, the active 
metabolite of DMF. 
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2.2 DMF-induces differential gene expression across tissue types 
To determine the effects of a single 100 mg/kg DMF dose on transcription 
regulation, a detailed gene transcriptional profiling study was conducted that measured 
the expression of 48 genes (Table 12) across eight time points using the Fluidigm 
BioMark™ HD System.  This system maintains the sensitivity of classical real time PCR 
analysis while utilizing nanofluidic technology to collect larger data sets (upwards of 
9,000 data points) in a single run.  After receiving a single dose of DMF or vehicle, 
cohorts of animals were harvested at 2, 4, 6, 8, 12.5, 16.5, 23 or 37.5 hours. DMF and 
vehicle treated animals were harvested in parallel at each time point to eliminate the 
effects of diurnal variation, as all DMF samples were compared directly to time-matched 
vehicle controls to determine fold-changes in target gene expression. Data collected using 
this system identified time-dependent transcriptional changes following DMF treatment 
within peripheral (liver, spleen, kidney, jejunum and whole blood) and CNS (cerebellum, 
hippocampus, striatum and cortex) tissues. DMF-dependent transcription differed 
between the genes regulated within these tissue types as well as the onset and duration of 
the response (Figures 11-14; Table 13). 
DMF-dependent transcription differed between the specific genes regulated 
within tissue types, with each tissue exhibiting a fairly distinct profile of the 48 genes 
selected for analysis. In Figures 11 and 12, identified DMF-regulated genes in peripheral 
tissues were graphed to show the differential expression of these genes in various tissues 
types against VEGFA, a non-regulated baseline control gene. Identified genes included 
ARB18, GCLC, GDF15, NQO1, SRXN1, SQSTM1, TXNRD1, OSGIN1 and RBP4. 
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Within peripheral tissues, less regulation in these genes was seen to occur in the liver and 
spleen compared to the kidney and jejunum, with the largest number of genes being 
regulated in the kidney and the largest magnitude of response occurring within the 
jejunum (Figure 11). Classical Nrf2-regulated genes such as AKRB18, GCLC, NQO1, 
SRXN1 and TXNRD1 showed fairly universal expression across the four analyzed 
peripheral tissues compared to more localized expression in specific peripheral regions 
for GDF15, SQSTM11, RBP4 and OSGIN1 (Figures 11 and 12).  
Gene regulation following DMF treatment in CNS tissues was defined by a 
smaller subset of gene changes compared to the periphery, with gene transcription only 
affecting levels of NQO1, OSGIN1 and BDNF (Figure 13 and 14). Furthermore, as was 
seen in the periphery, the expression of these genes was differentially regulated in the 
four analyzed brain regions. NQO1 levels only changed slightly (1.5 to 2 fold) within 
brain tissues, with the exception of the striatum where no expression of NQO1 could be 
detected at the selected time points. The largest and most universal transcriptional 
changes within the brain were seen with OSGIN1 gene regulation, which expressed 
changes up to 4-5 fold above vehicle values in the hippocampus and cortex. OSGIN1 
changes could also be detected within the cerebellum and striatum albeit at lower 
expression levels. In contrast to OSGIN1 and NQO1 in the brain, BDNF expression was 
unique to the striatum following DMF treatment.  
Transcriptional changes following DMF treatment also resulted in distinct 
patterns in the onset and duration of the response. Within peripheral tissues, gene 
regulation peaked between 4 and 8 hours post-dose with the exception of OSGIN1 and 
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GDF15 in the kidney, which exhibited an earlier peak regulation of around 2 hours 
(Figure 11). For the few genes regulated within CNS tissues, gene expression also tended 
to peak at a slightly earlier time point between 2 and 6 hours following DMF dosing 
(Figures 13 and 14). For most regulated genes in most tissues, overall expression 
gradually decreased to baseline between 12 and 24 hours; however, when expressed, 
NQO1 and AKR1B8 tended to have more prolonged response in tissues. This can be seen 
in the small change in NQO1 within the CNS, as well as the more pronounced regulation 
of NQO1 and AKR1B8 within the kidney and jejunum. Although CNS regulation of 
NQO1 was slight, the prolonged expression tended to last out to 16.5 hours. In the kidney 
and jejunum prolonged expression continued past 24 hours. A unique time course 
following DMF could also be see for BDNF expression in the striatum and RBP4 in the 
spleen, with peak regulation of these genes occurring at 4 hours post-dose and then 
dropping below normal levels before returning to baseline at around 16 hours. 
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Table 12. Gene selections for Fluidigm real-time PCR. 
GO TERM GO ID Gene Name Gene 
Symbol 
Autophagy GO:0006914 ATG2 autophagy related 2 homolog A  ATG2A 
  sequestosome 1 (p62) SQSTM1 
Cell cycle GO:0007049 cyclin-dependent kinase inhibitor 1A (P21) CDKN1A 
  growth differentiation factor 15  GDF15 
Cell differentiation GO:0030154 vesicular endothelial growth factor VEGFA 
Cellular matrix 
organization 
GO:0030198  matrix metallopeptidase 11 (stromelysin 3)  MMP11 
Cell migration GO:0016477 snail homolog 1 SNAI1 
Cholesterol homeostasis  
ATP-binding cassette, sub-family A (ABC1), 
member 1  
ABCA1 
Developmental growth GO:0048589 
stimulated by retinoic acid gene 6 homolog 
(mouse)  
STRA6 
Dopamine receptor 
signaling pathway 
GO:0007212 neuron-specific protein family member 2 NSG2 
Glutamine biosynthesis 
process 
GO:0005642 glutamate-ammonia ligase  GLUL 
L-glutamate transport GO:0015813 solute carrier family 1, member 2 (EAAT2) SLC1A2  
Metabolic process GO:0008152 glutathione S-transferase alpha 2  GSTA2 
Myelination GO:0042552 early growth response 2  EGR2 
Negative regulation of 
apoptotic process 
GO:0043065  
DnaJ (Hsp40) homolog, subfamily A, member 
3  
DNAJA3 
  apoptosis antagonizing transcription factor  AATF 
  nerve growth factor-γ NGFG 
Negative regulation of 
cell  growth 
GO:0008083 Oxidative stress induced growth inhibitor 1 OSGIN1 
  nitric oxide synthase 1 NOS1 
  sirtuin 1 SIRT1 
Neuron development GO:0048666  
nuclear receptor subfamily 2, group F, member 
6 
NR2F6 
Neuron fate commitment GO:0048663 oligodendrocyte transcription factor 1  OLIG1 
Nucleoside diphosphate 
metabolic process  
GO:0009132 
nudix (nucleoside diphosphate linked moiety 
X) 
NUDT7 
    
Oxidation-reduction 
process 
GO:0055114 aldo-keto reductase family 1, member B8 AKR1B8 
  copper chaperone for superoxide dismutase CCS 
  
oxidoreductase NAD-binding domain 
containing 1  
OXNAD1 
Positive regulation of 
excitatory postsynaptic 
membrane potential  
GO:2000463  neuropilin (NRP) and tolloid (TLL)-like 2  NETO2 
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Table 12 continued. Gene selections for Fluidigm real-time PCR. 
 
GO TERM GO ID Gene Name Gene 
Symbol 
Regulation of cell  growth  GO:0001558 insulin-like growth factor binding protein  IGFBP 
 
Regulation of synaptic 
plasticity 
GO:0048167 brain-derived neurotrophic factor BDNF 
Response to oxidative 
stress 
GO:0006979 amyotrophic lateral sclerosis 2 (juvenile) ALS2 
  apolipoprotein E APOE  
  GRB2-associated binding protein 1 GAB1  
  glutamate-cysteine ligase, catalytic subunit GCLC 
  glutamate-cysteine ligase, modifier subunit  GCLM 
  NAD(P)H dehydrogenase, quinone 1 NQO1 
  peroxiredoxin 1 PRDX1 
  prion protein PRNP 
  prostaglandin-endoperoxide synthase 2 PTGS2 
  superoxide dismutase SOD1 
  sulfiredoxin 1  SRXN1 
  thioredoxin reductase 1 TXNRD1 
  glial fibrillary acidic protein  GFAP 
Retinol metabolic process GO:0042574  retinol binding protein 4, plasma RBP4 
Signal transduction GO:0007165 NF-kappa-B inhibitor, beta NFKBIB 
Tissue regeneration GO:0042246  ninjurin 1 NINJ1 
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Figure 11. DMF transcriptional profiling time course in peripheral tissues: 
kidney/jejunum.  
Transcriptional changes following single 100 mg/kg oral dose of DMF in kidney (A) and 
jejunum (B), graphed as changes in selected genes over time. Data are graphed as fold 
change values normalized to vehicle treated animals, with the starting value of 1 
equivalent to the normalized baseline of vehicle animals. Graphed genes represent only 
those that were found to be regulated in peripheral tissues, with Vegfa as a baseline 
control gene. Refer to Table 13 for statistical analysis. 
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Figure 12. DMF transcriptional profiling time course in peripheral tissues: 
spleen/liver.  
Transcriptional changes following single 100 mg/kg oral dose of DMF in spleen (A) and 
liver (B), graphed as changes in selected genes over time. Data are graphed as fold 
change values normalized to vehicle treated animals, with the starting value of 1 
equivalent to the normalized baseline of vehicle animals. Graphed genes represent only 
those that were found to be regulated in peripheral tissues, with Vegfa as a baseline 
control gene. Refer to Table 13 for statistical analysis. 
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Figure 13.  DMF transcriptional profiling time course in CNS tissues: 
OSGIN1/BDNF. 
Transcriptional changes following single 100 mg/kg oral dose of DMF for two genes 
found to be regulated in the brain:  Osgin1 (A) and Bdnf (B). Data are graphed as fold 
change values normalized to vehicle treated animals, with the dashed line at 1 equivalent 
to the normalized baseline of vehicle animals. Later time points are not included since 
regulation of the graphed genes is consistent with the graphed 16.5 hour time point. Refer 
to Table 13 for statistical analysis. 
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Figure 14.  DMF transcriptional profiling time course in CNS tissues: NQO1. 
Transcriptional changes following single 100 mg/kg oral dose of DMF Nqo1 in the brain. 
Data are graphed as fold change values normalized to vehicle treated animals, with the 
dashed line at 1 equivalent to the normalized baseline of vehicle animals. Later time 
points are not included since regulation of the graphed genes is consistent with the 
graphed 16.5 hour time point. Refer to Table 13 for statistical analysis.  
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Table 13. Transcriptional profiling time course statistical analysis. 
 
Tissue Gene  P-value 
2 hrs 
P-value 
4 hrs 
P-value 
6 hrs 
P-value 
8 hrs 
P-value 
12.5 hrs 
P-value 
16.5 hrs 
P-value 
23 hrs 
P-
value 
37 
hrs 
Liver AKR1B8 0.51 0.008 0.0011 0.013 0.010 0.99 0.15 0.88 
 GCLC 0.0007 0.0005 0.0016 0.029 0.021 0.027 0.0056 0.74 
 NQO1 0.88 0.15 0.0081 0.0042 0.0015 0.14 0.0059 0.013 
 OSGIN1 0.0048 0.21 0.19 0.79 0.022 0.13 0.27 0.30 
 SRXN1 0.17 < 0.0001 < 0.0001 0.0005 0.0007 0.36 0.21 0.021 
Spleen NQO1 0.14 0.98 0.064 0.0046 0.046 0.038 0.99 0.93 
 OSGIN1 0.078 0.0012 < 0.0001 0.0039 0.29 0.44 0.31 0.76 
 SQSTM1 0.44 0.032 0.041 0.0035 0.38 0.70 0.35 0.010 
 SRXN1 0.050 0.030 0.017 0.0008 0.011 0.029 0.22 0.54 
 TXNRD1 0.0087 < 0.0001 < 0.0001 < 0.0001 0.0091 0.98 0.57 0.67 
Kidney AKR1B8 0.82 0.082 0.0061 0.0075 0.0012 0.028 0.31 0.86 
 GCLC 0.081 0.0003 0.0001 0.0026 0.019 0.098 0.14 0.028 
 GDF15 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0001 0.0041 0.038 
 NQO1 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.18 
 OSGIN1 < 0.0001 < 0.0001 0.066 0.0056 0.015 0.50 0.025 0.088 
 SQSTM1 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0047 0.19 0.84 0.45 
 SRXN1 0.0009 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0052 0.16 0.026 
 TXNRD1 0.0002 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0030 0.28 0.002 
Jejun. AKR1B8 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.22 
 GCLC < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0001 0.0007 0.060 
 NQO1 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.003 
 OSGIN1 .0002 < 0.0001 0.011 0.017 0.13 0.012 0.56 0.22 
 SRXN1 0.0029 0.0003 0.0002 0.0011 0.0051 0.037 0.28 0.31 
 TXNRD1 0.0009 < 0.0001 < 0.0001 0.0017 0.0019 0.0039 0.056 0.68 
Cortex OSGIN1 0.0019 0.0020 0.097 0.16 0.036 0.36 0.37 0.36 
Cereb. OSGIN1 < 0.0001 < 0.0001 0.0033 0.0048 0.99 0.36 0.028 0.12 
Hippo. NQO1 0.28 0.51 0.0035 0.26 0.30 0.35 0.79 0.65 
 OSGIN1 0.0005 0.012 0.0044 0.052 0.55 0.50 0.37 0.61 
Jejun. =jejunum; Cereb. =cerebellum; Hipp. =hippocampus. Gray shading representive of 
p<.01 based on Wilcoxon signed-rank test. p values calculated using vehicle control 
samples. 
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2.3 The magnitude of DMF-induced gene expression is dose-dependent 
Dose-dependent changes in DMF-induced gene expression were also measured 
against the gene panel (Table 12) analyzed in the above mentioned time course using the 
Fluidigm BioMark™ HD System. This study aimed to capture DMF-dependent 
transcriptional changes with increasing concentrations of DMF that ranged from 50 to 
600 mg/kg.  DMF concentrations were administered at a constant time point of 7 hours 
that was selected based on optimal gene regulation across tissues identified in the 
previous time course. Data from this study shows the magnitude of DMF transcriptional 
response to be dose-dependent for all genes in all tissues tested except for the BDNF 
response in striatal tissue (Figures 15-18; Table 14). In contrast to all other regulated 
genes in the periphery and CNS which showed dose-dependent expression of genes 
previously identified in the time course, BDNF expression in the striatum increased at 
lower doses of 50 and 100 mg/kg but returned to baseline at concentrations above 100 
mg/kg. 
In the presence of higher DMF concentrations, genes not identified in the time 
course study were found to be induced. The most obvious example of this is the 
expression of CDKN1A at concentrations above 100 mg/kg within the liver, kidney and 
all CNS tissues (Figures 15-18). Interestingly, the liver, which did not express large 
transcriptional changes in the time course study, amplified CDKN1A over 40-fold at the 
highest dose following DMF treatment (Figure 16B). Furthermore, AKR1B8, which had 
the most profound expression in the jejunum in the time course study, was surpassed in 
expression by GSTA2 at concentrations above 200 mg/kg (Figure 15B). Other genes that 
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increased in expression at higher doses with DMF included NETO, IGFBP3 and NINJ1 
in the spleen and GSTA2 in the jejunum. Reductions in gene expression were also seen at 
higher doses of DMF including NUDT7 in the liver and OLIG1 in the kidney (Figure 
15A and 16B).  
In the CNS, the cortex, cerebellum and hippocampus portrayed similar gene 
regulation patterns for CDKN1A, OSGIN1 and NQO1 following higher concentrations of 
DMF, with the largest magnitude of expression seen in OSGIN1 (Figures 17 and 18A). In 
contrast to the latter tissues and as seen in the time course data, the striatum continued to 
show differential regulation of genes in the presence of DMF compared to other CNS 
brain regions (Figure 18B). As mentioned above, BDNF regulation was only present in 
the striatum and only at low doses; however, there were also reductions in GAB1 and 
EGR2 seen within the striatum with increasing concentrations of DMF that reduced the 
expression of these in half. Furthermore, unlike neighboring brain regions, the striatum 
did not show dose-dependent increases in NQO1. 
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Figure 15. DMF transcriptional profiling dose-response in peripheral tissues: 
kidney/jejunum.  
Transcriptional changes following multiple doses of DMF in kidney (A) and jejunum (B), 
graphed as changes in selected genes across doses. Data are graphed as fold change 
values normalized to vehicle treated animals, with the starting value of 0 equivalent to the 
normalized baseline of vehicle animals. Graphed genes represent only those that were 
found to be regulated in peripheral tissues, with Vegfa as a baseline control gene. Refer 
to Table 14 for statistical analysis.  
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Figure 16. DMF transcriptional profiling dose-response in peripheral tissues: 
spleen/liver.  
Transcriptional changes following multiple doses of DMF in spleen (A) and liver (B), 
graphed as changes in selected genes across doses. Data are graphed as fold change 
values normalized to vehicle treated animals, with the starting value of 0 equivalent to the 
normalized baseline of vehicle animals. Graphed genes represent only those that were 
found to be regulated in peripheral tissues, with Vegfa as a baseline control gene. Refer 
to Table 14 for statistical analysis.  
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Figure 17. DMF transcriptional profiling dose-response in CNS tissues: 
cortex/cerebellum.  
Transcriptional changes following multiple doses of DMF in Cortex (A), Cerebellum (B), 
graphed as changes in selected genes across doses. Data are graphed as fold change 
values normalized to vehicle treated animals, with the starting value of 0 equivalent to the 
normalized baseline of vehicle animals. Graphed genes represent only those that were 
found to be regulated in CNS tissues, with Vegfa as a baseline control gene. Refer to 
Table 14 for statistical analysis. 
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Figure 18. DMF transcriptional profiling dose-response in CNS: 
hippocampus/striatum.  
Transcriptional changes following multiple doses of DMF in Hippocampus (A), Striatum 
(B), graphed as changes in selected genes across doses. Data are graphed as fold change 
values normalized to vehicle treated animals, with the starting value of 0 equivalent to the 
normalized baseline of vehicle animals. Graphed genes represent only those that were 
found to be regulated in CNS tissues, with Vegfa as a baseline control gene. Refer to 
Table 14 for statistical analysis. 
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Table 14. Transcriptional profiling dose response statistical analysis.  
Tissue Gene p-value 
50mpk 
p-value 
100mpk 
p-value 
200mpk 
p-value 
400mpk 
p-value 
600mpk 
Liver AKR1B8 0.2078 0.0180 0.0006 < 0.0001 < 0.0001 
 CDKN1A > 0.9999 0.9999 0.9958 0.1512 0.0019 
 GCLC 0.3035 0.1414 0.1571 0.0007 < 0.0001 
 NQO1 0.1285 < 0.0001 0.0028 < 0.0001 < 0.0001 
 NUDT7 0.6611 0.8941 0.3174 0.0006 0.0001 
 SQSTM1 0.7532 0.3684 0.1855 0.0041 0.0026 
 SRXN1 0.8096 0.0288 0.0502 0.0149 0.0006 
  Spleen GDF15 0.9999 0.9957 0.9179 0.0373 0.0006 
 GLUL 0.9946 0.5730 0.4302 0.0019 < 0.0001 
 NINJ1 0.6906 0.0910 0.0240 < 0.0001 < 0.0001 
 NQO1 0.9579 0.5392 0.3811 0.0632 0.0088 
 OSGIN1 0.9673 0.8205 0.0392 < 0.0001 < 0.0001 
 SQSTM1 0.9997 0.2289 0.3902 0.0081 < 0.0001 
 SRXN1 0.9922 0.4780 0.5188 0.0456 0.0022 
 TXNRD1 0.9997 0.1512 0.2418 0.0005 < 0.0001 
  Kidney GCLC 0.5500 0.0357 0.1326 < 0.0001 0.0002 
 GCLM 0.0159 0.0004 0.0003 < 0.0001 < 0.0001 
 GDF15 0.9164 0.2127 0.1689 0.0002 < 0.0001 
 GSTA2 0.7974 0.0005 0.0260 0.0040 < 0.0001 
 NQO1 0.0183 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 OSGIN1 0.7770 0.5161 0.0548 < 0.0001 < 0.0001 
 PRDX1 0.1131 0.0086 0.0307 0.0012 0.0036 
 PRNP 0.2796 0.1519 0.1220 0.0046 0.0410 
 SQSTM1 0.1257 0.0044 0.0008 < 0.0001 < 0.0001 
 SRXN1 0.8774 0.1240 0.1268 < 0.0001 < 0.0001 
 TXNRD1 0.0692 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Jejunum AKR1B8 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 CDKN1A 0.9997 0.9813 0.5640 0.0921 0.0104 
 GCLC 0.8189 0.0265 0.0142 < 0.0001 < 0.0001 
 GCLM 0.3128 0.0194 0.0005 < 0.0001 < 0.0001 
 GDF15 0.9054 0.8633 0.9174 0.2186 0.0036 
 GSTA2 0.9806 0.3975 0.1193 < 0.0001 0.0037 
 NQO1 0.0186 0.0002 < 0.0001 < 0.0001 < 0.0001 
 OSGIN1 0.5395 0.3733 0.0596 < 0.0001 0.0003 
 SRXN1 0.4836 0.1905 0.0461 0.0047 0.0007 
Light grey=p<.05 and dark grey=p<.01 based on one-way analysis of variance 
(ANOVA) performed with Dunnett’s multiple comparison test. p values calculated 
using vehicle control samples. (Table continued on page 113) 
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Table 14 continued. Transcriptional profiling dose response statistical 
analysis.   
Tissue Gene P-value 
50mpk 
P-value 
100mpk 
P-value 
200mpk 
P-value 
400mpk 
P-value 
600mpk 
Jejunum TXNRD1 0.0717 0.0050 0.0015 < 0.0001 < 0.0001 
Cortex CDKN1A 0.9867 0.9984 0.9786 0.0358 0.0003 
 GCLC 0.3499 0.5443 0.4165 0.0060 0.0002 
 IGFBP3 0.9981 0.8788 0.9918 0.0358 0.0006 
 NQO1 0.9914 0.0036 0.0008 < 0.0001 < 0.0001 
 OSGIN1 0.9949 0.9763 0.1509 0.0062 0.0321 
Cerebellum CDKN1A 0.9999 0.9938 0.4639 0.0002 < 0.0001 
 GAB1 0.8488 0.8932 0.6950 0.0346 0.0099 
 NQO1 0.4832 0.0133 0.1517 < 0.0001 < 0.0001 
 OSGIN1 0.6673 0.4070 0.1447 0.1406 0.0292 
Hippocampus CDNK1A > 0.9999 0.9915 0.7042 0.0002 < 0.0001 
 GAB1 0.9997 0.6539 0.7792 0.0890 0.0322 
 GCLC 0.4169 0.0009 0.2017 < 0.0001 0.0013 
 NQO1 0.3692 0.0241 0.2579 0.0091 0.0021 
 OSGIN1 0.9936 0.8693 0.6327 0.2702 0.0146 
Striatum BDNF 0.4307 0.0062 0.8007 0.9594 0.3467 
 CDKN1A 0.9999 0.9982 0.7790 0.0051 < 0.0001 
 EGR2 0.9999 0.1539 0.5928 0.0008 0.0016 
 GAB1 0.9025 0.9934 0.8852 0.0431 0.0011 
Whole Blood GCLC 0.9998 0.7210 0.0478 0.0010 0.0041 
 NINJ1 0.7168 0.9965 0.1031 0.0236 0.0006 
 NGFG > 0.9999 0.9719 0.5310 0.0098 0.0016 
 NQO1 0.9986 0.9877 0.5893 0.6577 0.0434 
 SRXN1 0.8727 0.8770 0.0374 0.0350 0.0038 
 TXNRD1 0.3182 0.4550 0.1012 0.0248 0.0260 
Light grey=p<.05 and dark grey=p<.01 based on one-way analysis of variance (ANOVA) 
performed with Dunnett’s multiple comparison test. p values calculated using vehicle 
control samples. 
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2.4 DMF transcriptional regulation in whole blood 
Gene regulation following DMF treatment in the time course and dose response 
paradigms was also measured in whole blood samples for each animal analyzed. Whole 
blood data tended to be more variable than results detected in peripheral and CNS tissues; 
however, 2-fold increases in GFAP, PRDX1, OSGIN1 and NQO1 could be detected after 
a single 100 mg/kg dose of DMF (Figure 19A). These gene expression increases peaked 
at 2 hours for OSGIN1, between 4 and 6 hours for GFAP and PRDX1, and 8 hours for 
NQO1. Differential gene regulation in whole blood could also be detected with higher 
concentrations of DMF (Figure 19B) in a dose-dependent manner at a single 7 hour time 
point. Increased expression of GCLC and NINJ1 were detected at concentrations ≥ 200 
mg/kg and decreased expression of NFKBIB and NSG2 were also identified at higher 
concentrations of DMF. 
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Figure 19. DMF transcriptional profiling dose-response in whole blood.  
Transcriptional changes following a single dose of 100 mg/kg DMF across 8 time points 
in whole blood samples (A). Data are graphed as fold change values normalized to 
vehicle treated animals, with the dashed line at 1 equivalent to the normalized baseline of 
vehicle animals. Transcriptional changes following multiple doses of DMF in whole 
blood (B). Data are graphed as fold change values normalized to vehicle treated animals, 
with the starting value of 0 equivalent to the normalized baseline of vehicle animals. 
Graphed genes represent only those that were found to be regulated in whole blood. Refer 
to Tables 13 and 14 for statistical analysis. 
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2.5 DMF-induced gene expression is Nrf2-dependent 
To determine if the DMF-induced transcriptional changes identified in the 
aforementioned time course and dose response studies were Nrf2-dependent, we 
measured the regulation of five of these identified genes in an Nrf2 knockout mouse. The 
panel of five genes included NQO1, AKR1B8, GDF15, OSGIN1 and BDNF, and were 
measured for transcriptional regulation at 4, 8 and 16 hours post 100 mg/kg DMF. This 
small gene panel was selected to specifically measure genes that were of particular 
interest and/or genes that had not been previously identified as classical Nrf2-regulated 
genes in the literature. In the absence of Nrf2, our results indicate a loss of NQO1, 
AKR1B8, GDF15 and OSGIN1 expression following dosing with a single concentration 
of DMF in the periphery and the CNS (Figures 20 and 21). Furthermore, the baseline 
expression of these genes in the knockout animals was decreased below endogenous 
expression levels of wild type controls in tissues where these genes could be induced by 
DMF.  
Of these five analyzed genes BDNF was the only target that did not result in a 
complete loss of DMF-induced signal (Figure 21B). Although variable, loss of Nrf2 
resulted in increased levels of BDNF expression at baseline, and in the presence of DMF 
these increases were gradually returned to the level of wild type values over time. 
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Figure 20. Transcriptional time course with 100 mg/kg DMF in Nrf2-/- and wild 
type mice: peripheral tissues.  
Transcriptional changes following single 100 mg/kg oral dose of DMF in peripheral 
tissues: Jejunum (A) and Kidney (B), graphed as changes in selected genes over time. 
Data are graphed as fold change values normalized to vehicle treated (WT-wildtype) 
animals, with the starting value of 1 equivalent to the normalized baseline of vehicle 
animals. Graphed genes represent a select panel determined based on gene regulation 
from the time course study. Refer to Table 15 for statistical analysis. 
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Figure 21. Transcriptional time course with 100 mg/kg DMF in Nrf2-/- knockout 
and wild type mice: CNS tissues.  
Transcriptional changes following single 100 mg/kg oral dose of DMF in CNS tissues: 
Hippocampus (A) and Striatum (B), graphed as changes in selected genes over time. Data 
are graphed as fold change values normalized to vehicle treated (WT-wildtype) animals, 
with the starting value of 1 equivalent to the normalized baseline of vehicle treated 
animals. Graphed genes represent a select panel determined based on gene regulation 
from the time course study. Refer to Table 15 for statistical analysis. 
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Table 15. DMF transcriptional time course in Nrf2-/- mice. 
 
Tissue Gene  P-value 
0 hrs 
P-value 
4 hrs 
P-value 
8 hrs 
P-value 
16 hrs 
Kidney AKR1B8-WT - 0.0007 0.0058 0.0286 
 
AKR1B8-KO 0.1819 0.9683 0.0915 0.8561 
 
GDF15-WT - < 0.0001 0.0053 0.3542 
 
GDF15-KO 0.0003 0.0069 0.9889 0.0020 
 
NQO1-WT - < 0.0001 < 0.0001 0.0005 
 
NQO1-KO 0.0003 0.0599 0.7960 0.0063 
 
OSGIN1-WT - 0.0400 0.0043 0.2915 
 
OSGIN1-KO 0.0083 0.6851 0.1179 0.0050 
Jejunum AKR1B8-WT - < 0.0001 0.0019 < 0.0001 
 
AKR1B8-KO < 0.0001 0.7329 0.9999 0.3252 
 
NQO1-WT - < 0.0001 0.0008 < 0.0001 
 
NQO1-KO < 0.0001 0.1502 0.9563 0.0013 
 
OSGIN1-WT - 0.0040 0.0617 0.3505 
 
OSGIN1-KO 0.2371 0.7589 0.9983 0.5581 
Striatum BDNF-WT - 0.2382 0.6817 0.6546 
 
BDNF-KO 0.1005 0.6065 0.3476 0.9858 
 
OSGIN1-WT - < 0.0001 < 0.0001 0.0133 
 
OSGIN1-KO 0.0006 0.0085 0.0004 0.0839 
Hippocampus NQO1-WT - 0.0329 0.8621 0.0711 
 
NQO1-KO 0.5377 0.4299 0.3991 0/8776 
 
OSGIN1-WT - < 0.0001 0.0027 0.0037 
 
OSGIN1-KO 0.0011 0.2886 0.0302 0.0116 
Light grey=p<.05 based on one-way analysis of variance (ANOVA) performed with 
Dunnett’s multiple comparison test. p values calculated using WT, vehicle control 
samples. 
 
 
 
 
 
 
 
 
120 
 
 
2.6 DMF transcriptional regulation translates to protein expression 
To confirm that transcriptional regulation of Nrf2 target genes translate to protein 
following DMF administration, western blot analysis was conducted to analyze protein 
levels of genes identified to be regulated following transcriptional analysis. Protein levels 
in tissue extracts from Nrf2-/- knockout and wild type mice 6 hours post 100 mg/kg DMF 
administration were analyzed for expression changes of NQOl, TXNRD1, GCLC and 
SQSTM1 in peripheral tissues (Figure 22) and NQOl and BDNF in CNS tissues (Figure 
23). Selection of proteins to be analyzed was determined based on particular interest and 
success of antibody optimization.  
Protein analysis in peripheral tissue extracts identified increased expression of 
selected proteins following DMF treatment in kidney (Figure 22A) and jejunum (Figure 
22B). In the absence of Nrf2, these protein changes were either decreased or lost 
following DMF administration. In CNS tissues, basal levels of BDNF in the striatum 
(Figure 23A) and NQO1 in the cortex (Figure 23B) were not altered in the absence of 
Nrf2; however, although variable, a trend of increased protein expression in the presence 
of DMF could be identified. 
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Figure 22. DMF induced Nrf2-dependent protein expression in peripheral tissues.  
Nrf2-/- knockout and wild type mice were treated with vehicle or 100 mg/kg DMF in 
triplicate and tissues harvested at 6 h after compound addition. Relative protein levels of 
Txnrd1, Sqstm1, Nqo1 and GCLC were assessed and actin control levels measured as an 
internal control.  Protein expression following a single 100 mg/kg oral dose of DMF in 
Kidney (A) and Jejunum (B).   
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Figure 23. DMF induced protein expression in CNS tissues.  
Nrf2-/- and wild type mice were treated with vehicle or 100 mg/kg DMF in triplicate and 
tissues harvested at 6 h after compound addition. Relative protein levels of Nqo1 and 
BDNF were assessed and actin control levels measured as an internal control.  Protein 
expression following a single 100 mg/kg oral dose of DMF in Striatum (A) and Cortex 
(B). 
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3. Discussion 
Recent studies have identified inflammation and generation of excessive oxidative 
stress as contributing factors in a number of neurodegenerative disorders. Reactive 
oxygen species (ROS), a natural byproduct of cellular metabolism, exists in all aerobic 
cells in a physiological balance with neutralizing antioxidants (Andersen et al., 2004). 
However, when this balance is disrupted and ROS production surpasses antioxidant 
capacity, toxic free radicals can damage cells leading to oxidative stress (OS) (Orient et 
al., 2007). Inflammatory processes are also linked to the generation of excessive 
oxidative stress; the release of significant ROS via a “metabolic burst” mechanism from 
activated microglia and infiltrating macrophages in the CNS. Disturbances in the normal 
redox state, either through dysregulation of normal homeostatic processes or from 
aberrant inflammatory activity in the CNS, are believed to be a common pathogenic 
mechanism in aging as well as in neurodegenerative diseases such as PD (Jenner, 2007), 
AD (Emerit et al., 2004), ALS (Carr   et al., 2003) and MS (Offen et al., 2004). Previous 
studies have suggested that targeting the Nrf2 pathway could be a promising therapeutic 
target for these diseases since this pathway is a ubiquitously expressed defense system for 
combatting against inflammatory, oxidative and electrophilic stress.  
A functional Nrf2 pathway has been shown to be required for DMF protection 
against toxic oxidative stress in vitro (Scannevin et al, 2012), and for mediating DMF 
efficacy in vivo in the EAE model (Linker et al, 2011). The primary aim of our current 
study was to further characterize DMF pharmacodynamic responses throughout the CNS 
and periphery, and also to understand the requirement for Nrf2 in mediating these 
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responses. These experiments provide further understanding of the specific genes, onset 
of expression, duration and relative magnitude of DMF pharmacodynamic responses that 
occur across many different tissues. These data will help inform the sequence of events 
involved with DMF-mediated anti-inflammatory effects and cellular protection.  
Our results indicate that DMF-induces distinct gene changes within peripheral and 
CNS tissues, with differentiation in the onset and duration of the response observed 
between genes and tissue type. These data also confirm earlier studies demonstrating that 
BG-12 activates transcription of Nrf2-dependent genes in the CNS and periphery. 
Although many classical Nrf2-dependent genes, such as NQO1, AKR1B8, GCLC, 
SRXN1 and TRXND1, were found to be regulated across many tissue types, we also 
identified many gene expression changes specific to certain tissues, including RPB4 in 
the spleen and BDNF in the striatum (Figures 12A and 13B).  
The observations of tissue-specific gene expression indicate additional levels of 
transcriptional regulation that are specific to individual mRNA and particular cells types. 
These data also suggest that the dosage of DMF and corresponding relative DMF/MMF 
exposure may potentially effect transcriptional regulation of specific genes in different 
tissue types, based on our observation that increased concentrations of DMF can induce 
unique gene regulation in tissues that were not originally detected at lower doses.  In 
addition to distinct gene changes, most transcriptional changes tended to be transient, 
with expression levels peaking between 2 and 8 hours post-dose (Figures 11-14). As there 
was differentiation in the persistence of individual mRNA, even those induced to a 
similar peak magnitude (Figure 11B. NQO1 vs GCLC), this indicates specific mRNA 
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stability may be governed by multiple pathways. It is also interesting to note that some of 
these responses persisted for an extended period of time before returning to baseline 
(Figures 11A and B; NQO1, AKR1B8). 
One of the main goals of this study was to characterize CNS gene regulation 
following DMF treatment to a greater detail.  The presented data indicate that the 
bioactive metabolite of DMF, MMF, can cross the blood-brain barrier (Figure 10) and 
induce differential gene expression in various brain regions. Although the regulation of 
genes in the CNS was not as robust in magnitude or in overall number of genes as within 
the periphery, we were able to identify small, but significant changes in the classical Nrf2 
target gene NQO1 as well as novel expression of OSGIN1 throughout all brain regions 
(Figure 13 and 14). Although one study identifies OSGIN1 as a candidate Nrf2 target, our 
analysis is the first to confirm in an in vivo model that Osgin1 expression is mediated via 
Nrf2 (Chorley et al, 2012). Current literature on OSGIN1 suggests that various splice-
variants of this gene interact with p53 to mediate cell death and survival within the cell 
(Hu et al, 2012). Although we attempted to determine OSGIN1 protein regulation 
following DMF treatment with commercial antibodies, we were unsuccessful in 
identifying immune reactive bands that were present or correlated with current literature. 
This may be due in part to differential regulation of OSGIN1 variants across tissue and 
cell types.  
BDNF was also shown to be regulated in the brain by DMF, specifically within 
the striatum; however, results from Nrf2-/- studies suggest that BDNF is not Nrf2-
dependent. Moreover, it appears that basal expression of BDNF increases in the absence 
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of Nrf2, and DMF appears to reduce expression levels back to baseline. This line of 
investigation is currently being further explored as BDNF has demonstrated neurotrophic 
properties, this may indicate a novel mechanism by which DMF exerts therapeutic 
effects. BDNF regulation is also of particular interest since the transcriptional expression 
of this gene is not within the striatum is not widely accepted. Instances where striatal 
neurons can generate their own BDNF could be significantly beneficial to the health and 
survival of these cells.  
The transcriptional profiling data compiled in this report indicates differential 
gene regulation across tissue types following treatment with DMF, which gives insight 
into the unique Nrf2-dependent pathways stimulated, or repressed, within distinct tissues 
and biofluids.  These findings spark particular interest in the regulation of genes in the 
CNS compared to peripheral tissues, especially in regards to the regulation of OSGIN1 
and BDNF in the brain.  The activation of distinct cellular genes following DMF 
treatment may give us insight into the specific pathways that mediate the anti-
inflammatory and neuroprotective actions of DMF. 
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CHAPTER IV                                                                                                                                 
OSGIN1 CONTRIBUTES TO THE CYTOPROTECTIVE PROPERTIES OF 
MONOMETHYL FUMARATE (MMF) 
 
1. RATIONALE 
Previous studies using DMF and its bioactive metabolite, MMF, show Nrf2 
stabilization and increased antioxidant protein expression following treatment of human 
astrocyte and oligodendrocyte cultures (Nguyen et al., 2009, Scannevin et al., 2012). 
Furthermore, MMF treatment in these cultures systems, as well as in primary mixed 
neuronal cultures, can protect against oxidative injury induced by hydrogen peroxide. 
This neuronal protection is also evident in the ability of DMF/MMF to improve clinical 
score and reduce neuroinflammation in the rat EAE model of MS (Linker et al., 2011). 
Although there is strong evidence that DMF/MMF increase cellular levels of Nrf2 
resulting in antioxidant gene upregulation, it is not known how these alterations result in 
cellular protection. Therefore, understanding the specific sequence of events involved 
with Nrf2-mediated cellular protection is crucial for delineating the role fumarates play in 
these pathways. Following the identification of OSGIN1 as an Nrf2 transcriptional target 
that is urpregulated in the brain following oral administration of DMF (Chapter 3), the 
importance of OSGIN1 in DMF-mediated cytoprotection was investigated. 
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2. RESULTS 
2.1 MMF induces Nrf2 target genes and is protective against oxidative insult  
 Based on current literature that suggests Nrf2 regulation in the CNS is 
predominantly via astrocytes, primary human astrocytes were measured for Nrf2 target 
gene regulation following treatment with MMF (Vargas et al., 2009, Miao et al., 2011). 
As previously mentioned, DMF is rapidly metabolized to MMF upon oral administration 
and only MMF exposure is known be detected in the CNS (Figure 10; Werdenberg et al, 
2003); therefore, to parallel in vivo studies all in vitro cultures were treated with MMF.  
To confirm that OSGIN1 is endogenously expressed in human astrocytes and confirm 
OSGIN1 induction with MMF treatment, OSGIN1 and five classical Nrf2 targets were 
analyzed via q-PCR. Following 24 hour treatment with MMF, q-PCR analysis identified 
OSGIN1 to be dose-dependently induced approximately 2 fold more than other classical 
Nrf2 target genes such as NQO1, TXNRD1, SRXN1, GCLC and HMOX1 in the 
presence of MMF (Figure 24). These results confirm previous in vivo studies that 
OSGIN1 is a MMF-regulated transcriptional target as well as confirm the regulation of 
Nrf2 target genes in the presence of MMF.   
 Since the Nrf2 pathway is considered the major cellular response pathway to 
oxidative and electrophilic stress, the effect of MMF on cellular viability in the presence 
of oxidative insult was evaluated. Previous studies investigating the cytoprotective effects 
of MMF have shown this compound to protect human astrocytes from the oxidative insult 
hydrogen peroxide (H2O2) (Scannevin et al, 2012); therefore, to confirm that MMF can 
indeed protect cells from oxidative damage, human astrocytes were treated with a 
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titration of MMF for 24 hours followed by oxidative challenge with H2O2 (Figure 25). To 
measure viability of cells following experimentation, LIVE/DEAD analysis was 
performed. Addition of 300μM H2O2 to DMSO-treated cells resulted in approximately 
85% reduction in LIVE fluorescence intensity measured by calcein-AM incorporation 
into cells. In the presence of MMF, astrocytes challenged with H2O2 were protected 
against the toxic effects of this insult resulting in only a 50% reduction in cell loss 
(Figure 25D). To confirm fluorescent intensity quantitative results, images were acquired 
from samples analyzed in the LIVE/DEAD assay (Figure 25A-C). H2O2 challenge alone 
resulted in a dramatic loss of cell number as well as an increase in dying cells (Figure 
25B). In comparison, pre-treatment with MMF was able to preserve cellular viability of 
astrocytes and reduce cell death (Figure 25C). These data confirm previous studies that 
MMF is cytoprotective against the effects of oxidative stress in vitro. Furthermore, the 
increases in OSGIN1 (Figure 25B) following MMF treatment correlate with increased 
cellular survival against H2O2, suggesting this gene may play a mechanistic role in this 
paradigm.  
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Figure 24. MMF induces Nrf2 target gene expression in human astrocytes.  
Human astrocytes were treated with either DMSO or a titration of MMF for 24 hours 
before RNA extraction and q-PCR analysis. The graph represents triplicate samples; error 
bars indicate S.D. A, q-PCR analysis of classical Nrf2 target genes. B, OSGIN1 q-PCR 
analysis. *, p<0.001 of OSGIN1 regulation compared to the other Nrf2 targets using two-
way ANOVA with Tukey’s multiple comparison’s test.  
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Figure 25. MMF protects human astrocytes from oxidative challenge.  
Human astrocytes were treated with DMSO or 30 μM MMF for 24 hours followed by 
oxidative challenge. A-C, live imaging of LIVE/DEAD labeled cells pretreated with 
MMF and then challenged with H2O2. LIVE calcein AM (green) and DEAD ethidium 
homodimer (red) labeling. A, positive control cells treated with DMSO. B, control 
DMSO-treated and 300 μM H2O2-challenged cells. C, astrocytes pretreated with 30 μM 
MMF and challenged with 300 μM H2O2. D, quantification of calcein AM fluorescence 
intensity in LIVE/DEAD labeled cells from A-C. *, p<0.001 compared to control using 
one-way ANOVA with Tukey’s multiple comparison’s test. Experiment was repeated 
three times.        
   
132 
 
 
2.2 Loss of Nrf2 abolishes MMF cytoprotection and depletes OSGIN1 
Following confirmation of MMF-mediated cytoprotection against oxidative insult, 
the importance of Nrf2 in this protection was assessed. Human astrocytes were 
transfected with siRNA targeted against Nrf2 to reduce mRNA and protein levels of this 
gene. Nrf2 siRNA transfection resulted in an approximate 80% reduction in Nrf2 mRNA 
levels and almost a complete loss of Nrf2 protein expression (Figure 26B). In the 
presence of MMF, no significant regulation of Nrf2 transcript was observed in either 
control or Nrf2 siRNA transfected astrocytes (Figure 26A). Since Nrf2 is constitutively 
expressed and degraded under normal homeostatic conditions by the protein Keap1 and 
inhibition of this interaction is believed to regulate Nrf2 protein expression (see section 
2.3 of Chapter I; Itoh et al., 1997), no effect on Nrf2 mRNA induction is expected.  MMF 
is believed to interact with the cysteine residues on Keap1 to inhibit the degradation of 
Nrf2 and allow for Nrf2 accumulation (Linker et al., 2011). Protein accumulation of Nrf2 
following MMF treatment was observed with control siRNA and these accumulations 
were lost in cells transfected with Nrf2 siRNA (Figure 26B).  These findings confirm 
previous findings that MMF regulates Nrf2 expression on a protein level to activate this 
pathway (Scannevin et al., 2012).  
To determine if the loss of Nrf2 expression in human astrocytes correlates with 
the reduction in OSGIN1 expression seen in Nrf2-/- knockout mice (see section 2.5, 
Chapter III), q-PCR analysis was conducted to measure OSGIN1 transcript levels 
following Nrf2 knockdown (Figure 27). Loss of Nrf2 reduced total OSGIN1 expression 
in astrocytes by greater than 60% and significantly reduced the ability of MMF to induce 
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OSGIN1 transcript levels. This confirms in vivo Nrf2 knockout studies where induction 
of OSGIN1 was found to be strongly regulated by Nrf2 and Nrf2 was necessary for 
MMF-mediated regulation of OSGIN1. Although other Nrf2 transcriptional targets have 
been identified to be mediated by MMF in vitro (Scannevin et al., 2012), OSGIN1 is the 
most significantly regulated Nrf2 target shown to be mediated in the presence of MMF, 
suggesting that this gene is an important target of Nrf2 (see section 2.5, Chapter III). 
In order to determine if activation of the Nrf2 pathway contributes to the 
cytoprotective properties of MMF, human astrocytes were transfected with Nrf2 siRNA 
and treated with MMF for 24 hours followed by oxidative challenge with H2O2. In the 
absence of Nrf2, MMF-mediated cytoprotection of human astrocytes was completely 
abolished, as can be seen in both LIVE/DEAD acquired images and viable nuclear DAPI 
counts (Figure 28). Nrf2-deficient astrocytes also demonstrated increased sensitivity to 
oxidative insult as seen in the reduced viability of DMSO-treated cells lacking Nrf2 
compared to control transfected cells. These results confirm previous findings from our 
lab that activation of the Nrf2 pathway is important for MMF-mediated protection against 
oxidative damage in astrocytes.  
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Figure 26. Nrf2 knockdown.  
B, q-PCR analysis of human astrocytes treated with 10 nM of control or Nrf2 siRNA and 
either DMSO or 30 μM MMF. *, p<0.001 as compared to control siRNA using two-way 
ANOVA and Tukey’s multiple comparison test. B, correlating western blot data with A. 
Actin is shown as a loading control. Experiment was repeated twice. 
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Figure 27. Loss of Nrf2 reduces OSGIN1 expression. 
Human astrocytes were transfected with scrambled (control) or Nrf2 siRNA followed by 
treatment with a titration of MMF. q-PCR analysis was conducted for OSGIN1 
transcription. Error bars represent SD and p values based on two-way ANOVA with 
Tukey’s post-test for multiple-samples comparisons. Experiment was repeated three 
times. 
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Figure 28. Loss of Nrf2 abolishes MMF-mediated cytoprotection.  
Human astrocytes were transfected with scrambled (control) or Nrf2 siRNA and treated 
with either DMSO or MMF for 24 hours then challenged with H2O2. A, cells fixed and 
stained with DAPI nuclear dye. Graph represents average cell nuclei counts in 20 fields 
per well (2 wells averaged in graph). Error bars represent standard deviation (SD) and p 
values based on two-way ANOVA with Sidak’s post-test for multiple-samples 
comparisons. B, live imaging of LIVE/DEAD labeled cells pretreated with MMF and 
then challenged with H2O2. LIVE calcein AM (green) and DEAD ethidium homodimer 
(red) labeling. Experiment was repeated three times.  
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2.3 Loss of OSGIN1 reduces MMF cytoprotection in the presence of oxidative insult 
  OSGIN1 was first identified as an Nrf2 target in in vitro studies where the loss of 
Nrf2 inhibited the ability of the oxidation product, Ox-PAPC, to induce OSGIN1 (Li et 
al, 2006). Although these studies were confirmed in 2014 by Yan et al, further 
understanding of the role of OSGIN1 as an Nrf2 target has not been thoroughly 
investigated (Yan et al, 2014). The in vivo findings presented in section 2.5 of Chapter III 
as well as the inability of MMF to induce OSGIN1 in the absence of Nrf2, suggest that 
OSGIN1 may be involved in mediating some of the protective effects of activating the 
Nrf2 pathway. To investigate the possibility of a role for OSGIN1 in MMF-mediated 
cytoprotection, human astrocytes were transfected with OSGIN1 siRNA to diminish 
OSGIN1 levels and the effect on oxidative challenge was studied as previously described 
with Nrf2 siRNA knockdown (see section 2.2 of Chapter IV).  
 siRNA knockdown of OSGIN1 resulted in greater than 70% loss of OSGIN1 
transcript levels compared to scrambled siRNA control (Figure 29A). In the presence of 
MMF, OSGIN1 induction was also significantly diminished following reduction in basal 
levels of OSGIN1 (Figure 29A). Furthermore OSGIN1 knockdown did not affect the 
level of Nrf2 transcripts, which is expected since OSGIN1 has already been identified as 
a downstream target of Nrf2 in section 2.2 of this Chapter (Figure 27B). 
To determine if OSGIN1 induction contributes to MMF-mediated cytoprotection, 
astrocytes transfected with OSGIN1 siRNA were treated with a titration of MMF for 24 
hours followed by oxidative challenge with H2O2. Knockdown of OSGIN1 resulted in a 
reduced ability of astrocytes to be protected against H2O2 following MMF treatment. This 
138 
 
 
can be visualized in the increased number of viable cells indicated by LIVE-positive 
staining and reductions in overall DEAD-positive cells in LIVE/DEAD acquired images 
(Figure 30A). These findings were further quantified by fluorescence measurement of 
LIVE-positive cells and viable nuclear DAPI count where an approximately 4 fold 
decrease in viable cells was observed in the absence of OSGIN1 (Figure 30B and C). In 
comparison to Nrf2 siRNA transfection (Figure 28), OSGIN1 knockdown did not 
completely abolish MMF-mediated cytoprotection, with approximately 10% of MMF-
mediated cytoprotection maintained. Although this could be a result of incomplete loss of 
OSGIN1 in this cellular system, it is more likely that other transcriptional targets of Nrf2 
also contribute to the protection inferred by MMF.  
Interestingly, OSGIN1 siRNA transfection in the presence of H2O2 alone tended 
to be almost 2 fold more resistant to oxidative damage compared to scrambled siRNA 
control astrocytes (Figure 30). Although there was not a significant difference observed 
in total cell count between OSGIN1 and control siRNA transfected astrocytes, this could 
still be due to increased proliferation in the absence of OSGIN1. OSGIN1 has previously 
been identified to regulate cell cycle and loss of OSGIN1 has been shown to induce 
proliferation of cancer cell lines (Ong et al., 2004; Huynh et al. 2001, Wang et al., 2005). 
These aspects of OSGIN1 will be discussed further in section 2.7 of this Chapter.  
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Figure 29. OSGIN1 siRNA knockdown.  
Human astrocytes were transfected with scrambled (control) or OSGIN1 siRNA and 
treated with either DMSO, 10 μM MMF or 30 μM MMF for 24 hours before RNA 
extraction and q-PCR analysis. A, q-PCR analysis for OSGIN1 transcriptional regulation. 
B, q-PCR analysis for Nrf2 transcriptional regulation. The graphs represent duplicate 
samples; error bars indicate SD. p values based on two-way ANOVA with Tukey’s post-
test for multiple-samples comparisons. Experiment was repeated three times. 
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Figure 30. OSGIN1 siRNA knockdown inhibits MMF-mediated cytoprotection.  
Human astrocytes were transfected with scrambled (control) or OSGIN1 siRNA and 
treated with MMF for 24 hours then challenged with H2O2. A, imaging of LIVE/DEAD 
labeled cells pretreated with MMF and then challenged with H2O2. LIVE calcein AM 
(green) and DEAD ethidium homodimer (red) labeling. B, quantification of calcein AM 
fluorescence intensity in LIVE/DEAD labeled cells from A. C, replicate plates as in A 
fixed and stained with DAPI nuclear dye. Graph represents average cell nuclei counts in 
20 fields per well (2 wells averaged in graph). Error bars represent SD and p value based 
on one-way ANOVA with Tukey’s post-test for multiple-samples comparisons. 
Experiment was repeated three times.  
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2.4 Identification of OSGIN1 isoform induction in the presence of MMF   
2.4.1 Generation of OSGIN1 isoform specific antibodies 
As discussed in Chapter I (section 6.1.2), OSGIN1 undergoes alternative splicing 
to yield various isoforms, three of which have been investigated by researchers (Ong et 
al., 2004). These include variants encoding for 52 kDa and 61 kDa ORF’s, as well as a 
third isoform encoding a 38 kDa ORF that has been researched but is not accepted as a 
likely variant. Research investigating the importance of these variants suggests that 
individual regulation of OSGIN1 isoforms may yield divergent biological functions (Hu 
et al., 2012). Therefore, following identification of OSGIN1 as a downstream target of 
Nrf2 that contributes to MMF cytoprotection, investigation into the regulation of 
OSGIN1 isoforms in the presence of MMF was pursued. To deduce whether OSGIN1 
variants are differentially regulated by MMF, three isoform-specific antibodies were 
generated using affinity purification conducted by New England Peptide (NEP) that 
recognize the following three human OSGIN1 variants; OSGIN1-38 kDa, OSGIN1-52 
kDa and OSGIN1-61 kDa. Based on the splicing characteristics of these isoforms, only 
the OSGIN1-61 kDa antibody should be unique, with the OSGIN1-52 kDa antibody 
recognizing both the 52 kDa and 61 kDa forms and the OSGIN1-38 kDa antibody 
recognizing all three variants (section 1.2.1 of Chapter II; Figure 9). 
To determine the specificity of these antibodies, peptide competition studies were 
conducted. In these studies human astrocyte cell lysates were probed with three different 
conditions; antibody alone (NP), antibody pre-incubated with antibody specific peptide 
(P) and antibody pre-incubated with non-specific control peptide (CP) (Figure 31). 
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Peptides generated against the different isoforms were used as control peptides (example: 
OSGIN1-52 kDa peptide was a control for OSGIN1-61 kDa antibody optimization). 
OSGIN1-52 kDa and OSGIN1-61 kDa antibodies detected specific immunoreactive 
bands that correlated with the appropriate predicted size of their amino acid sequence 
(Figure 31). Both of these bands were lost when the antibody was pre-incubated with an 
epitope specific peptide but not with a control peptide. Interestingly, pre-incubation of the 
OSGIN1-61 kDa antibody with the control peptide (in this case the OSGIN1-52 kDa 
peptide) resulted in depletion of a lower immunoreactive band (Figure 26B). This could 
be a result of OSGIN1-52 kDa antibody contamination in the OSGIN1-61 kDa antibody 
pool, particularly since this band runs at a similar size to the 52 kDa OSGIN1 protein. No 
immunoreactive bands were identified in the presence of the OSGIN1-38k Da antibody. 
Since this antibody should pick up all three isoforms, this antibody most likely did not 
yield successful immunoglobulin.   
Following optimization of the OSGIN1-52 kDa and OSGIN1-61 kDa antibodies, 
siRNA knockdown of OSGIN1 in human astrocytes was conducted to determine if 
immunoreactive bands associated with these antibodies were depleted in the absence of 
OSGIN1. Loss of OSGIN1 correlated with depletion of immunoreactive bands identified 
during optimization, with almost complete loss of the OSGIN1-61 kDa immunoreactive 
band (Figure 32). Abundance of the OSGIN1-52 kDa immunoreactive band seemed to be 
higher than that of OSGIN1-61 kDa; however, whether this difference was to due 
antibody specificity is unclear. However, the modest reduction observed with the 
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OSGIN1-52 kDa antibody following OSGIN1 knockdown may be indicative of 
incomplete knockdown and suggest that this isoform is truly more abundant. 
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Figure 31. Optimization of OSGIN1-52kDa and OSGIN1-61kDa antibodies. 
Human astrocyte cell lysates were probed with three antibody condition: antibody alone 
(NP), antibody pre-incubated with epitope specific peptide (P) or non-specific control 
peptide (CP). A, OSGIN1-52kDa antibody conditions. B, OSGIN1-61kDa antibody 
conditions. Experiment was repeated twice. 
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Figure 32. OSGIN1 knockdown depletes OSGIN1 isoform specific immunoreactivity 
Human astrocytes were transfected with 10nM of control or OSGIN1 specific siRNA and 
cell lysates were probed with OSGIN1 isoform-specific antibodies. β-actin is included as 
a loading control. Experiment was repeated three times.  
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2.4.2 Evidence for induction of OSGIN1-61 kDa isoform in the presence of MMF 
 
 To determine if OSGIN1 isoforms are differentially regulated in the presence of 
MMF, human astrocytes were transfected with either control or OSGIN1 specific siRNA 
followed by treatment with MMF for 24 hours. OSGIN1-52 kDa and OSGIN1-61 kDa 
antibodies were probed against cell lysates via western blot (Figure 33). Although a 
similar reduction in immunoreactivity was observed with the OSGIN1-52 kDa antibody 
similar to previous findings, no induction was seen in the presence of MMF (Figure 
33A). In contrast, control siRNA transfected astrocytes probed with the OSGIN1-61kDa 
antibody detected an increase in immunoreactivity in the presence of 30 μM MMF which 
was lost in the absence of OSGIN1 (Figure 33B). These findings suggest that addition of 
MMF to astrocytes specifically induces expression of the 61 kDa encoding OSGIN1 
ORF.  
 Overexpression of the 61 kDa encoding OSGIN1 isoform has been shown to be 
less toxic to tumorigenic cell lines, suggesting this specific variants may function 
independently of apoptotic induction and thus may be regulated differentially (Hu et al., 
2012). Since OSGIN1 is an Nrf2-regulated target gene and loss of Nrf2 reduces OSGIN1 
transcript expression, the regulation of the identified OSGIN1-61 kDa reactive band was 
examined following Nrf2 depletion. Human astrocytes were transfected with control or 
Nrf2 specific siRNA and cell lysates were probed with the OSGIN1-61 kDa antibody. 
Nrf2 knockdown resulted in depletion of OSGIN1-61 kDa immunoreactivity which 
correlated with OSGIN1 knockdown (Figure 33C), confirming the regulation of this 
isoform in an Nrf2-dependent manner. 
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 Further examination of both the OSGIN1-52 kDa and OSGIN1-61 kDa generated 
antibodies was also conducted via immunocytochemistry. Human astrocytes treated with 
MMF for 24 hours were fixed and probed with either the OSGIN1-52 kDa or OSGIN1-61 
kDa antibody. Stained cells were imaged on an automated Thermo HCS Arrayscan 
technology and immunoreactive puncta were quantified using HCS Studio algorithm 
software. Total fluorescent spot count indicated a significant increase in immunoreactive 
puncta probed with the OSGIN1-61 kDa antibody compared to no change seen following 
identification with OSGIN1-52 kDa immunoreactive puncta (Figure 34). Furthermore, 
the total fluorescent spot count was observably higher in the 52 kDa group compare to 
the 61 kDa, providing further evidence that the 61 kDa OSGIN1 isoform is less abundant 
than the 52 kDa form. However, since the antibodies generated against the OSGIN1-
61kDa and OSGIN1-52kDa variants have non-specific immunoreactivity (Figure 31), the 
absolute spot quantification may not be accurate. Therefore, generation of OSGIN1 
variant specific antibodies is necessary to fully understand the contribution of each of 
these variants to the results identified within this experiment.  
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Figure 33. The OSGIN1 61 kDa encoding isoform is regulated via MMF and Nrf2.  
Human astrocytes were transfected with either control or OSGIN1 specific siRNA 
followed by treatment with 30 μM MMF for 24 hours. A, transfected cell lysates probed 
with OSGIN1-52 kDa antibody. B, transfected cell lysates probed with OSGIN1-61 kDa 
antibody. C, human astrocytes transfected with either control or Nrf2 specific siRNA and 
probed with OSGIN1-61 kDa antibody. β-actin is included in all figures as a loading 
control. Experiment was repeated three times. 
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Figure 34.  Immunocytochemical analysis of OSGIN1-52 kDa and OSGIN1-61 kDa 
antibodies.  
Human astrocytes were treated with MMF for 24 hours, fixed and then probed with 
antibodies against OSGIN1-52 kDa and OSGIN1-61 kDa isoforms of OSGIN1. Total 
fluorescent spot count was accomplished using Thermo HCS Arrayscan technology. p 
values based on one-way ANOVA with Tukey’s post-test for multiple sample 
comparisons. 
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2.4.3 Alteration in the 5’UTR of OSGIN1 transcripts identified by RACE 
Although MMF regulation of the OSGIN1-61kDa isoform was identified via 
protein analysis, confirmation of this specific transcript was unable to be confirmed via q-
PCR based on the location of the primer/probe set within the overlapping region of the 
OSGIN1 isoforms. Therefore, Northern Blot analysis was attempted to isolate the 
transcript associated with the identified protein product. As outlined in section 2.7 of 
Chapter II, RNA probes were generated against the probe sequence used for OSGIN1 q-
PCR and probed against human astrocyte purified RNA treated with MMF. Various 
attempts were made to accurately identify OSGIN1 RNA transcripts; however, these 
studies were inconclusive. In order to overcome the challenges faced with Northern Blot 
analysis, rapid amplification of cDNA ends (RACE) was attempted. 3’ RACE was 
performed using RNA extracted from human astrocytes treated with a titration of MMF 
and probes designed based on the primer/probe sequences used for OSGIN1 q-PCR (see 
section 1.4.3 in Chapter II). 3’ RACE resulted in a 1.3kb sequence that was confirmed to 
match the 3’ end of OSGIN1 following DNA sequencing (Figure 35A). The identified 3’ 
RACE product correlated with an increase in total 3’ sequence abundance in the presence 
of MMF, confirming upregulation of this sequence following MMF treatment (Figure 
35A). 
Following confirmation of the 3’ RACE product by sequencing, primers were 
generated within the identified 3’ sequenced region for 5’RACE analysis (see section 
1.4.3 in Chapter II). Similar to 3’ RACE, RNA extracted from MMF–treated astrocytes 
treated was used as a template. 5’ RACE analysis identified a 0.6 kb sequence that was 
151 
 
 
found to match the 5’ end of the OSGIN1-52kDa encoding region following DNA 
sequencing (Figure 30B). Interestingly, the identified 5’RACE product was depleted in a 
dose-dependent manner in the presence of MMF, suggesting that the 5’ end of OSGIN1 
in the presence of MMF is differentially regulated. This could potentially be a result of 
GC enrichment in the 5’ region of the longer 61kDa encoding sequence and thus an 
inability to prime past this region. Furthermore, based on previous results suggesting that 
the 52kDa is more highly expressed than the 61kDa form, this could simply be a result of 
low abundance.  
 Further DNA sequencing analysis of the 0.6 kb 5’ RACE product identified two 
identical transcripts that differed only in two nucleotide substitutions within the 5’ region 
of OSGIN1 (Figure 35B). Alterations in the 5’UTR of OSGIN1 have been previously 
identified to regulate the protein expression of OSGIN1 (Ong 2007); therefore to 
determine if MMF differentially regulated these two transcripts, Taqman primer/probe 
sets specific for each transcript were generated (see section 1.4.2 of Chapter II) and 
analyzed against human astrocytes treated with and without MMF. q-PCR analysis 
detected a significant MMF-dependent alteration in expression of these two transcripts 
suggesting that they are not simply allele variants (Figure 36). Furthermore, MMF 
induced expression of the “ALT” transcript variant which substitutes a C for an G at 
position 59 and a G to an A at position 62 of the OSGIN1 sequence (NM_182981.2), 
which results in a potential ATG start site and a premature stop site (Figure 35B). These 
findings suggest that alterations in the 5’ region of OSGIN1 may be regulated in the 
presence of MMF, but further investigation of these alterations is necessary. 
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Figure 35. 3’ and 5’ RACE of OSGIN1 transcript.  
RNA extracted from human astrocytes treated with a titration of MMF was subjected to 
3’ and 5’ RACE. A, resulting RACE products analyzed via gel electrophoresis. B, 
sequencing of 5’ RACE products identified two transcript variants of OSGIN1 within the 
5’ UTR of the OSGIN1-52kDa transcript that differed in two nucleotide substitutions 
(indicated in red). WT=canonical sequence; ALT=identified 5’ RACE sequence with 
nucleotide substitutions. Dash lined indicates where RACE was terminated.  
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Figure 36. q-PCR analysis of identified 5’RACE transcripts. 
RNA was extracted from human astrocytes treated with DMSO or MMF for 24 hours and 
subjected to q-PCR using primer/probe sets specific to identified 5’RACE transcripts. 
WT=canonical sequence; ALT=identified 5’ RACE sequence with nucleotide 
substitutions.  *, p<0.05 and ****, p<0.0001 based on one-way ANOVA with Tukey’s 
post-test for multiple comparisons. Significance was also identified in the WT (30uM 
MMF) versus DMSO control (p<0.001). 
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2.5 p53 is downstream of OSGIN1 and contributes to OSGIN1-mediated 
cytoprotection 
Current literature investigating the role of OSGIN1 describes this gene as a 
mediator of cell cycle and apoptosis that is believed to be regulated via p53 (Hu et al., 
2012; Yao et al., 2008). p53 has been shown to bind to the promoter of OSGIN1 to 
regulate it’s transcription as well as interact with OSGIN1 in the cytoplasmic space to 
induce apoptosis (Hu et al., 2012). To determine if OSGIN1 is transcriptionally regulated 
by p53, human astrocytes were transfected with siRNA targeted against p53 or OSGIN1 
and transcript regulation analyzed. p53 knockdown resulted in an approximate 80% loss 
of p53 transcript expression (Figure 37A); however, this reduction in p53 did not affect 
basal transcriptional levels of OSGIN1 (Figure 37C). Furthermore, siRNA knockdown of 
OSGIN1 had no effect on p53 transcription (Figure 37A). These findings suggest that p53 
is not a transcriptional regulator of OSGIN1 in this cell type.  
Following 24 hour treatment with MMF, p53 transcript levels were slightly, yet 
significantly increased in human astrocytes transfected with scrambled (control) as well 
as Nrf2 siRNA (Figure 37A). This is of particular interest since p53 has been identified 
within the literature to contribute to Nrf2-mediated transcriptional control and co-regulate 
the expression of proteins involved in protection against oxidative stress (Toledano et al., 
2009); therefore, the effect of p53 knockdown on Nrf2 transcription was also analyzed in 
human astrocytes. Loss of p53 was found to have no effect on transcriptional regulation 
of Nrf2 in astrocytes (Figure 37B); however, since Nrf2 regulation is mediated at the 
protein level and p53 is also believed to be regulated in a similar manner as Nrf2, protein 
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induction of p53 was investigated (Wakabayashi et al., 2010).  In the presence of MMF, 
control transfected astrocytes exhibited a visible induction of p53 protein that was 
abolished in p53 knockdown and diminished in astrocytes transfected with OSGIN1 and 
Nrf2 siRNA (Figure 38A and C). Furthermore, knockdown of p53 did not alter the MMF-
mediated accumulation of Nrf2. These findings strongly suggest that p53 is induced 
downstream of Nrf2 and OSGIN1 in the presence of MMF. Since OSGIN1 has already 
been identified to be downstream of Nrf2 (Figure 27), regulation of p53 is most likely 
regulated via an OSGIN1-induced pathway at a protein level. 
As mentioned above, p53 protein levels are tightly regulated within cells similar 
to Nrf2. In resting conditions, p53 protein is maintained at low levels by proteasomal 
degradation and activation of p53 expression can reduce ROS levels by inducing the 
expression of anti-oxidative stress proteins (Vurusaner et al., 2012; Levine et al., 2006). 
Since MMF is known to induce Nrf2 accumulation and translocation into the nucleus, the 
effect of MMF on p53 nuclear translocation was investigated. Human astrocytes were 
treated with a titration of MMF for 24 hours followed by fixation and detection with p53 
antibody. Plates were imaged using the Thermo HCS Arrayscan and quantification of p53 
localization in the nucleus and cytoplasm was accomplished by algorithm creation using 
HCS Studio software. Addition of MMF to human astrocytes resulted in a significant 
translocation of p53 protein from the nucleus which correlated with reduced p53 protein 
levels in the cytoplasm (Figure 39). These results were also confirmed using a p53 
nuclear TransAM ELISA which measures cytoplasmic and nuclear cellular fractions in 
an ELISA with p53 specific DNA sequence bound to the ELISA plate (Figure 40). 
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Following identification of p53 nuclear translocation with MMF treatment, the 
importance of p53 in MMF-mediated cytoprotection was evaluated. Human astrocytes 
were transfected with p53-specific or control siRNA and treated with MMF for 24 hours 
followed by oxidative challenge with H2O2. MMF regulated protection was reduced in 
this model in the absence of p53 to a similar extent as observed in OSGIN1 knockdown 
cultures (Figure 41 and Figure 30). These results suggest that the nuclear translocation of 
p53 may contribute to the cytoprotective properties of MMF.  
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Figure 37. q-PCR of p53 siRNA knockdown.  
Human astrocytes transfected with either control (scrambled) or p53 siRNA followed by 
treatment with DMSO or MMF for 24 hours. A, q-PCR analysis of p53 mRNA levels. *, 
p<0.01 based on two-way ANOVA with Tukey’s post-test for multiple comparisons. B, 
human astrocytes transfected with either control (scrambled), p53 or Nrf2 siRNA and 
analyzed for Nrf2 mRNA levels. C, same as B but q-PCR directed against OSGIN1 
transcript levels. B/C, *, p<0.01 based on one-way ANOVA with Dunnett’s post-test for 
multiple comparisons. Experiment was repeated three times.  
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Figure 38. p53 protein is regulated by MMF in an Nrf2 and OSGIN1 dependent 
manner.  
Human astrocytes were transfected with 10 nM control (scrambled), p53, OSGIN1 or 
Nrf2 siRNA followed by treatment with DMSO or MMF for 24 hours. A, p53 protein 
measure in scrambled (control), p53 and OSGIN1 siRNA knockdown samples treated 
with MMF. B, Nrf2 protein measure in scrambled (control) and p53 siRNA knockdown 
samples treated with MMF. C, Scrambled (control) and Nrf2 siRNA knockdown samples 
treated with MMF and probed for p53 protein. β-actin is included in all figures as a 
loading control. Experiment was repeated twice.  
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Figure 39. MMF induces nuclear translocation of p53. 
Human astrocytes were treated with a titration of MMF for 24 hours followed by fixation 
and immunocytochemistry (ICC) analysis of p53. A, ICC images acquired using the 
Thermo HCS Arrayscan and algorithm analysis overlaid. B, Quantification of images in 
A. Each point represents 20 images from one well; n=6 wells per condition. Statistical 
analysis was performed using one-way ANOVA with Dunett’s multiple comparison post-
test (*, p<0.05). Experiment was repeated twice. 
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Figure 40. MMF induces nuclear translocation of p53. 
Human astrocytes were treated with a titration of MMF for 24 hours followed by analysis 
of nuclear and cytoplasmic cell extracts for p53 expression. A, nuclear extract 
quantification. B, cytoplasmic extract quantification. Statistical analysis was performed 
using one-way ANOVA with Dunett’s multiple comparison post-test (*, p<0.05). 
Experiment was repeated twice. 
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Figure 41. p53 contributes to MMF-mediated cytoprotection. 
Human astrocytes were transfected with scrambled (control) or p53 siRNA and treated 
with MMF for 24 hours then challenged with H2O2. A, imaging of LIVE/DEAD labeled 
cells pretreated with MMF and then challenged with H2O2. LIVE calcein AM (green) and 
DEAD ethidium homodimer (red) labeling. B, quantification of calcein AM fluorescence 
intensity in LIVE/DEAD labeled cells from A. Error bars represent SD and p value based 
on one-way ANOVA with Tukey’s post-test for multiple-samples comparisons. 
Experiment was repeated three times.  
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2.6 MMF time course of OSGIN1, p53, Nrf2 and NQO1.  
 Sections 2.1 through 2.5 of this chapter have identified OSGIN1, p53 and Nrf2 to 
contribute to the cytoprotective properties of MMF. In order to confirm the transcript and 
protein regulation patterns of these genes following MMF treatment, time course analysis 
was conducted. Human astrocytes were treated with MMF for 3, 6, 9, 12, 24 or 36 hours 
followed by RNA and protein collection. Transcript expression of OSGIN1 and the 
classical Nrf2 target, NQO1, were analyzed. Following addition of MMF, OSGIN1 was 
found to be induced early, peaking at 6 hours and remaining elevated at 36 hours post 
treatment (Figure 42A). This early, sharp response parallels in vivo studies measuring the 
OSGIN1 time course in mouse brain (Figure 13). In comparison, NQO1 transcript levels 
elevated in a more gradual manner, peaking at around 24 hours and remaining elevated in 
a more consistent pattern (Figure 42B). Peak induction of OSGIN1 was almost four fold 
higher compared to NQO1 induction following MMF treatment.  
 Since Nrf2 and p53 have only be shown to be predominantly regulated at the 
protein level, they were measured for protein expression along with NQO1 and OSGIN1 
following MMF treatment (Figure 43). Nrf2 accumulated first following MMF addition 
to human astrocytes beginning at the three hour post-dose and returning to near baseline 
levels by 36 hours. Interestingly, even though OSGIN1 transcript levels increased first, 
NQO1 protein levels increased before OSGIN1 with OSGIN1 protein accumulation not 
occurring to almost 24 hours. This suggests that alterations of OSGIN1 may occur at 
either the transcript or protein level to eventually lead to protein accumulation after 24 
hours. As suggested in section 2.6, p53 protein levels accumulated last between around 
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36 hours, confirming that p53 protein regulation occurs as a downstream target of Nrf2 
and OSGIN1. Together these findings suggest that Nrf2 is activated first in the presence 
of MMF following by OSGIN1 accumulation and eventually p53 in the nucleus. 
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Figure 42. q-PCR time course of NQO1 and OSGIN1.  
Human astrocytes were treated with 0, 10 or 30 μM of MMF and analyzed for transcript 
regulation of OSGIN1 and NQO1 over various time points. A, OSGIN1 time course. B, 
NQO1 time course. *, p<0.001 based on two-way ANOVA with Tukey’s post-test for 
multiple comparisons using vehicle controls at each time point for comparison. 
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Figure 43. Protein time course of MMF-regulated proteins. 
Human astrocytes were treated with 0, 10 or 30 μM of MMF and analyzed for protein 
regulation of OSGIN1, Nrf2, p53 and NQO1 over various time points. β-actin is included 
as a loading control. Red arrow indicates OSGIN1-61kDa immune-reactive band 
confirmed via peptide competition. 
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2.7 MMF inhibits cell proliferation: preliminary studies.  
Although OSGIN1 has been shown in the latter studies to contribute to MMF-
induced cytoprotection in an Nrf2-dependent and potentially p53-dependent manner, the 
exact mechanisms associated with the protective characteristics of OSGIN1 are unclear. 
This section will discuss preliminary data suggesting that OSGIN1 may inhibit cell 
proliferation following MMF treatment which may contribute to the cytoprotective 
properties of OSGIN1. 
2.7.1 MMF reduces cell proliferation independent of apoptosis  
 Regulation of cell cycle is considered to be major a cellular pathway controlled by 
OSGIN1 expression (Liu et al., 2014; Huynh et al., 2001; Ong et al., 2004); however, 
whether OSGIN1 contributes to cell cycle regulation in astrocytes is unknown. To 
investigate a role for OSGIN1 in cell cycle regulation, human astrocytes were transfected 
with scrambled (control) or OSGIN1 siRNA followed by 24 hour treatment with MMF. 
Astrocytes were pulse labeled with 5-ethynyl-2’-deoxy-uridine (EdU) to label dividing 
cells and analyzed using the Thermo HCS Arrayscan imaging and algorithm creation 
technology. Treatment with MMF in control transfected cells resulted in a significant, 
dose-dependent reduction in total proliferating cells (Figure 44). In the absence of 
OSGIN1, this effect on proliferation in the presence of MMF was significantly reduced 
(Figure 44). To confirm that reductions in proliferation in the presence of MMF were 
independent of apoptosis, transfected astrocytes treated with MMF were analyzed for 
apoptosis using the TiterTACS
TM
 apoptotic assay.  Knockdown of OSGIN1 or p53 did 
not significantly increase apoptosis compared to control knockdown (Figure 45). These 
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findings suggest that OSGIN1 may regulate cell proliferation.  Interestingly, loss of p53 
slightly yet significantly induced apoptosis in the presence of MMF. Since p53 plays a 
role in various cellular pathways, loss of p53 could place transfected cells in a high state 
of stress, making them sensitive to compound addition. Whether this is a direct effect of 
loss of MMF function warrants further investigation. 
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Figure 44. MMF inhibits cell proliferation. 
Human astrocytes were transfected with scrambled (control) or OSGIN1 siRNA followed 
by treatment with 0, 10 or 30 μM MMF and pulse incorporation of EdU. Cells were fixed 
and EdU incorporated cells were imaged and quantified using a Thermo HCS Arrayscan 
and HCS Studio software. A, quantification of four wells are averaged in graphs (25 
fields/well). *, p<0.05; **, p<0.01; ***, p<0.001 based on two-way ANOVA with 
Tukey’s post-test for multiple comparisons. Experiment was repeated twice. 
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Figure 45. Loss of OSGIN1 does not significantly induce apoptosis.  
Human astrocytes transfected with 10 nM scrambled (control), OSGIN1 or p53 siRNA 
for 48 hours followed by analysis of apoptotic cells using the TiterTACS
TM
 assay. A, 
siRNA transfection alone. B, siRNA transfection in the presence of MMF treatment for 
24 hours. *, p<0.01 based on one-way ANOVA with Dunnett’s post-test for multiple 
comparisons. 
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2.7.2 A potential role for PADI4  
As previously mentioned, p53 is cited in the literature to regulate OSGIN1 
expression; however, the results discussed in this chapter suggest that OSGIN1 may 
instead regulate p53 nuclear translocation (Hu et al., 2012). Another protein cited to 
regulate OSGIN1 expression is peptidyl arginine deiminase type IV (PADI4), which has 
been shown to negatively regulate OSGIN1 expression (Yao et al., 2008). Furthermore, 
PADI4 has been shown to regulate gene transcription by regulating the deimination of 
arginines on histones and antagonizing arginine methylation and may contribute to cell 
cycle control (Tanikawa et al., 2009; Chang et al., 2011). To determine if PADI4 is 
transcriptionally regulated following MMF treatment, PADI4 was measured in the 
previous time course analysis described in section 2.6 of this chapter. PADI4 was 
demonstrated to be regulated transcriptionally following MMF treatment in a similar 
manner as NQO1 (Figure 42B), with peak expression occurring at 24 hours and a more 
gradual induction of expression compared to OSGIN1 (Figure 42A). Since these findings 
demonstrated PADI4 to be regulated after OSGIN1 induction, PADI4 transcript levels 
were measured in PADI4, p53 and Nrf2 siRNA knockdown in human astrocytes to 
determine where PADI4 is targeted. q-PCR analysis of PADI4 levels following siRNA 
transfection with PADI4, OSGIN1 and p53 resulted in significant reductions in PADI4 
expression compared to control samples (Figure 47A). In contrast, Nrf2 knockdown had 
no effect on PADI4 transcript expression. Furthermore, MMF induction of PADI4 was 
abolished in the absence of OSGIN1 (Figure 47B). These findings suggest PADI4 is 
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regulated downstream of p53 since p53 has previously been identified to be regulated 
downstream of Nrf2 and OSGIN1.  
As mentioned above PADI4 has been described in the literature to negatively 
regulate transcription of OSGIN1 (Yao et al., 2008); however, in the absence of PADI4, 
no differences in OSGIN1 transcriptional expression were observed (Figure 48A). 
Furthermore, p53 transcript levels were also not altered in the absence of PADI4 (Figure 
48B). Overall, the studies outlined in this section suggest that PADI4 is regulated 
independently of Nrf2 induction but is also a downstream target of OSGIN1 and p53. 
Based on the known functions of PADI4 as a mediator of cell proliferation, PADI4 may 
function to inhibit cell division in the presence of MMF in p53 dependent manner; 
however, further research is necessary to fully understand the role of PADI4.  
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Figure 46. MMF mediated gene induction of PADI4. 
Human astrocytes were treated with 0, 10 or 30 μM of MMF and analyzed for 
transcriptional regulation of PADI4 over various time points. *, p<0.01 based on two-
way ANOVA with Tukey’s post-test for multiple comparisons using vehicle controls at 
each time point for comparison.  
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Figure 47.  PADI4 is regulated by OSGIN1 and p53. 
Human astrocytes were transfected with either scrambled (control), PADI4, OSGIN1, 
Nrf2 or p53 siRNA followed by q-PCR analysis. A, PADI4 q-PCR. *, p<0.0001 based on 
one-way ANOVA with Dunnett’s post-test for multiple comparisons. B, transfected cells 
treated with MMF for 24 hours followed by q-PCR for PADI4. p values based on two-
way ANOVA with Tukey’s post-test for multiple comparisons.  
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Figure 48.  PADI4 does not regulate OSGIN1 or p53. 
Human astrocytes were transfected with either scrambled (control), PADI4, OSGIN1 or 
p53 siRNA followed by q-PCR analysis. A, transfected cells treated with MMF for 24 
hours followed by q-PCR for OSGIN1. B, q-PCR for p53. p values based on two-way 
ANOVA with Tukey’s post-test for multiple comparisons. *, p<0.001 
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3. Discussion 
Endogenous regulation of cellular defense systems such as the Nrf2 pathway have 
become of particular interest to the field of neurodegeneration. A unifying aspect of 
nervous system disease is the accumulation of ROS leading to an overall state of 
oxidative stress. Activation of Nrf2 by small-molecule compounds such as DMF has 
shown to increase antioxidant defense genes leading to cytoprotection in various models 
of neurodegenerative disease (Linker 2011); however, the exact mechanisms underlying 
Nrf2-mediated cytoprotection are unclear. In Chapter 3, transcriptional profiling studies 
were conducted to evaluate gene regulation following oral dosing with DMF in an 
attempt to identify specific targets of this compound in the CNS. These studies identified 
the Nrf2 transcriptional target OSGIN1 to be significantly upregulated in the CNS in 
vivo. Current literature describing the biological functions of OSGIN1, describe this gene 
to be a major mediator of cell apoptosis under the control of the tumor suppressor protein, 
p53 (Yao et al., 2008; Hu et al., 2012). However, the in vitro findings in human 
astrocytes discussed in this chapter suggest OSGIN1 is significantly regulated by Nrf2 
and contributes to the cytoprotective properties of the bioactive metabolite of DMF, 
MMF, against oxidative insult in human astrocytes.  
Regulation of OSGIN1 via an Nrf2-dependent mechanism in contrast to p53-
dependent transcriptional control raised the new question of whether splice variants of 
OSGIN1 contribute to alternate biological functions of this gene. The predominant 
literature associated with OSGIN1 function has been conducted in tumor cell lines and 
have identified the shorter OSGIN1 isoforms, OSGIN1-52 kDa and the less accepted 
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OSGIN1-38 kDa, to be strong inducers of apoptosis under the control of p53 (Hu et al., 
2012; Yao et al., 2008). In contrast, the longer OSGIN1-61 kDa isoform is shown to be 
less toxic to cells and was also the major variant identified to be regulated in astrocytes in 
the presence of MMF in an Nrf2-dependent manner (Hu et al., 2012). The specific, 
cytoprotective regulation of OSGIN1-61 kDa under the transcriptional control of Nrf2 
supports a mechanism for OSGIN1 independent of the recognized function of this gene in 
tumor cell lines. These findings suggest that functional domains within OSGIN1 variants 
may result in differing biological effects regulated under specific cellular conditions. This 
correlates with findings that OSGIN1 has been identified to contribute to a diverse set of 
cellular functions other than apoptosis, including anti-inflammatory actions, regulation of 
cell cycle and protection against oxidative stress (Li et al., 2007; Li et al., 2010; Oguri et 
al., 2010).  Interestingly, we have also identified a role for OSGIN1 in anti-inflammatory 
effects based on the increased expression of TNF-α following knockdown of OSGIN1 in 
astrocytes (Figure 49). This correlates with previous findings in other labs that identify 
OSGIN1 to reduce oxidative stress and inflammation in cells challenged with Ox-PAPC 
(Romanoski et al., 2011; Li et al., 2007; Hammad et al., 2009). Although these findings 
have not yet been pursued they support a protective role for OSGIN1.  
Although the specific transcript encoding the identified OSGIN1-61 kDa protein 
product was not detected in RACE analysis, a distinct reduction in expression of the 5’-
end of the MMF-induced transcript was identified. DNA sequencing determined the 
MMF-induced transcript to encode for the 52 kDa OSGIN1 isoform; however, as 
mentioned previously, this could potentially be a result of GC enrichment in the 5’ region 
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of the known 61kDa encoding sequence or be a result of low abundance of this transcript, 
resulting in an inability to fully sequence the long form of OSGIN1. In general, these 
findings suggest that alterations splicing of the 5’ region do occur in the presence of 
MMF. This theory was further supported by identification of two nucleotide substitutions 
in the 5’ end of the identified transcript that were induced following MMF treatment in 
astrocytes. This is particularly interesting since these nucleotide substitutions resulted in a 
potential AUG start site encoding a small ORF. Although the Kozak region preceding 
this new start site was not incredibly strong, there has been evidence in the literature 
suggesting that upstream AUG sites encoding upstream open reading frames (uORFs) in 
5’UTR regions can decrease the frequency of AUG starts sites to initiate transcription in 
the main open reading frame (Morris and Geballe, 2000). Furthermore, the generation of 
OSGIN1 small encoding ORFs in the 5’UTR, have been previously identified to 
negatively control OSGIN1 protein translation (Ong et al., 2007). Therefore, in theory, 
the regulation of specific OSGIN1 transcripts by Nrf2 could potentially result in selection 
of the 61 kDa protein over the 52 kDa form through downregulation of OSGIN1-52 kDa 
protein expression independent of transcript regulation. Preliminary studies in our lab 
show evidence of reduced OSGIN1-52 kDa protein expression in the presence of MMF; 
however, further experiments are necessary to confirm these findings as well as 
thoroughly investigate this theory. Next generation sequencing analysis (RNA-seq) is 
currently underway to elucidate the various sequences that may be regulated downstream 
of Nrf2. 
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As mentioned above, p53 was not shown to regulate OSGIN1 expression in 
human astrocytes. Instead, studies with MMF in these cell types identified p53 to be a 
downstream protein target of Nrf2-regulated OSGIN1. This was exemplified by the 
inability of p53 to accumulate and translocate to the nucleus in the absence of OSGIN1, 
suggesting this molecule may activate p53-mediated transcriptional control.  Previous 
studies have suggested that p53 and Nrf2 work together to regulate gene expression in the 
presence of oxidative stress and p53 itself has also been shown to be protective against 
oxidative damage (Toledano et al. 2009; Chen et al., 2012). Thus, the activation of 
OSGIN1 by Nrf2 may be a potential mechanism through which Nrf2 regulates p53 
during periods of oxidative stress. Since OSGIN1 gene expression is activated before the 
activation of the gene expression of classical Nrf2 targets, it is possible that the role of 
OSGIN1 is to induce p53 translocation to the nucleus where it can interact with Nrf2 to 
regulate other Nrf2 target genes. Previous data from other labs have already identified the 
ability of p53 and OSGIN1 to interact in the cytoplasm, but there may also be a role for 
OSGIN1 in inhibiting degradation of p53 similar to the degradation mechanism of Nrf2. 
One way to investigate these theories would be to conduct p53 pull-down studies to 
measure the interaction of Nrf2 and OSGIN1 with p53. Furthermore, investigation into 
the interaction of OSGIN1 with the protein degradation machinery associated with p53 
could give insight into whether or not OSGIN1 inhibits p53 degradation.  
On the other hand, the translocation of p53 by OSGIN1 may also induce or 
suppress gene regulation independent of Nrf2. Evidence for this includes the regulation 
of PADI4 identified in astrocytes to be regulated by p53 but in an Nrf2-dependent 
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manner. In the preliminary studies described in this chapter, PADI4 was also identified to 
be transcriptionally regulated by OSGIN1, suggesting that OSGIN1-mediated 
translocation of p53 induces PADI4 expression. Interestingly, similar to p53, the 
regulation of PADI4 in association with OSGIN1 contrasts with current literature that 
suggests PADI4 to be a negative regulator of OSGIN1 (Yao et al., 2008). As discussed 
above, these alternate functions of OSGIN1 in MMF-treated astrocytes may be due to the 
expression of the OSGIN1-61 kDa isoform or potentially be due to cell type-specific 
signaling of OSGIN1. PADI4 has been shown to regulate DNA methylation by 
citrullination of histone residues to regulate DNA transcription and a role for p53 in this 
process has been described (Tanikawa et al., 2009). Therefore, the role of PADI4 in our 
model may be to inhibit DNA transcription in a p53-dependent manner to reduce cell 
proliferation. This process is independent of apoptosis based on the findings that MMF 
administration does not induce apoptosis but does reduce cell proliferation. Various 
studies have identified the inhibition of cell cycle entry to be a protective mechanism 
within cells, allowing conservation of energy and limiting the probability of DNA 
damage to be replicated (Price et al., 2003; Giovanni et al., 2005). Contribution of PADI4 
to cellular protection in the presence of MMF is currently being further investigated.  
Overall, these results indicate a role for the Nrf2 transcriptional target OSGIN1 in 
MMF-mediated cytoprotection in the presence of oxidative stress. Furthermore, these 
results lay the groundwork for a potential mechanism of OSGIN1-dependent protection 
(Figures 50 and 51). This mechanism involves activation of Nrf2 by MMF through 
inhibition of Keap1 degradation, resulting in the translocation of Nrf2 to the nucleus. 
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Once inside the nucleus, Nrf2 regulates the transcription of various genes including 
OSGIN1, which is one of the first Nrf2 transcribed targets. Translation of the OSGIN1-
61 kDa protein then results in the accumulation and subsequent translocation of p53 to 
the nucleus, leading to the induction of PADI4 regulation and potentially inhibition of 
cell proliferation. Whether p53 also regulates other genes independently or in 
collaboration with Nrf2 is unknown. Furthermore, the exact importance of inhibiting cell 
cycle in this paradigm is also not clear, even though there is evidence that this could be a 
protective mechanism. This inhibition could also involve proliferative inhibition of 
immune cells and a subsequent inflammatory response since loss of OSGIN1 also 
increased TNF-α levels. Although many aspects of this theoretical pathway still need 
further investigation and activation of OSGIN1 is not the sole target of Nrf2, these 
studies support an important role for OSGIN1 following Nrf2 activation in the presence 
of MMF. This suggests that Nrf2-mediated cytoprotection is not simply a result of 
antioxidant induction, but instead consists of a complicated network of pathways that 
together function to protect the cell during periods of stress.  
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Figure 49. OSGIN1 knockdown induces expression of TNF-alpha. 
Human astrocytes were transfected with scrambled (control) or OSGIN1 specific siRNA. 
Samples were analyzed for alterations in TNF-α transcript levels. *, p<0.05 based on 
student’s t test.  
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Figure 50. Potential mechanism of action of OSGIN1 mediated cellular protection. 
Interaction of MMF with cysteine residues on Keap1 results in allosteric conformational 
change in the Keap1 protein, resulting in the inability of Nrf2 to be targeted for 
ubiquitination and subsequent proteasomal degradation. This allows Nrf2 to accumulate 
in the cytoplasm and translocate to the nucleus where it can regulate the transcription of 
various genes including OSGIN1. OSGIN1 transcript expression is then translated to a 
61kDa protein that can induce the accumulation of p53 in an unknown mechanism. p53 
protein can then translocate to the nucleus and induce gene transcription.  
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Figure 51. Potential mechanism of action of OSGIN1 mediated cellular protection. 
Interaction of MMF with cysteine residues on Keap1 results in allosteric conformational 
change in the Keap1 protein, resulting in the inability of Nrf2 to be targeted for 
ubiquitination and subsequent proteasomal degradation. This allows Nrf2 to accumulate 
in the cytoplasm and translocate to the nucleus where it can regulate the transcription of 
various genes including OSGIN1. OSGIN1 transcript expression is then translated to a 
61kDa protein that can induce the accumulation of p53 in an unknown mechanism. p53 
protein can then translocate to the nucleus and induce gene transcription. 
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CHAPTER V                                                                                                         
GENERAL CONCLUSIONS 
 
1. General conclusions 
The excessive generation of ROS resulting in a state of oxidative stress is a 
unifying factor in neurodegenerative disease, which has generated a strong research 
interest in endogenous pathways that defend against these stresses. Activation of the Nrf2 
pathway has been identified as the major endogenous cellular defense system regulated in 
response to oxidative stress and various small molecules have been shown to activate this 
pathway. Dimethyl fumarate (DMF) is one such molecule recently approved for the 
treatment of relapsing forms of MS; however, the exact mechanisms behind Nrf2-
mediated cytoprotection of this compound are not well understood. The studies outlined 
in this dissertation have identified DMF to differentially regulate Nrf2-dependent gene 
expression across tissue types in both a time and dose-dependent manner. In the CNS, 
one of the few genes identified to be significantly regulated by DMF was OSGIN1, more 
specifically OSGIN1-61 kDa, which was found to be Nrf2-dependent. Further analysis of 
this gene in vitro uncovered OSGIN1 as an important mediator of MMF-mediated 
cellular protection in human astrocytes and outlined a potential mechanism for this gene 
involving regulation of p53 by the 61 kDa-encoding isoform of OSGIN1. Although 
further investigation into this gene is necessary to fully understand how OSGIN1 and its 
splice variants are regulated within the cell to confer protection, these findings contribute 
further knowledge to the complex pathway associated with Nrf2-mediated cytoprotection.  
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2. Study limitations 
 As with every research endeavor, there are study limitations that effect 
interpretation of the work presented. The major limitation associated with the research 
outlined in this dissertation was the inability to sequence the OSGIN1-61 kDa transcript 
following MMF treatment. Although evidence was presented to support the presence of 
this protein product, the q-PCR probes and siRNA constructs used targeted all variants of 
OSGIN1. It would be ideal to individually target or knockdown them each isoform 
individually to look at which one is responsible for the protective effects in the presence 
of MMF. Although RACE identified alterations in the 5’ end of the sequenced transcript, 
suggesting MMF treatment regulated differential expression or splicing of OSGIN1 
transcripts, further experiments are necessary to identify the exact Nrf2-regulated 
transcript of OSGIN1. As mentioned previously, Next Generation Sequencing is 
currently underway to assist in answering these questions.  
 Another study limitation of this research was that the OSGIN1 identified splice 
variants do not translate back to the mouse. Differential alternative splicing is believed to 
occur in the mouse that contrasts with splicing of the human OSGIN1 gene and there is 
no evidence for the long OSGIN1-61 kDa isoform in the mouse (Flicek et al., 2014). 
Therefore, the specific OSGIN1 sequences regulated in our mouse models may not 
correlate with what was identified in human cell cultures. This may result in difficulty 
analyzing this gene in vivo unless the human form is expressed. Therefore, further 
investigation is needed to understand the regulation of OSGIN1 splicing in the mouse. 
Furthermore, this may also imply that the OSGIN1-mediated cytoprotection mechanism 
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is unique in human and its in vivo validation may be difficult unless human OSGIN1 
genome knock-in mice are available for mimicking the physiological expression of 
human OSGIN1 transcript variants in vivo. 
siRNA knockdown of p53 also can be considered a study limitation. Since p53 is 
tightly regulated and is involved with various cellular pathways, general knockdown of 
this gene may result in altering pathways unassociated with Nrf2 and OSGIN1. It is 
therefore difficult to determine if knockdown alone of p53 itself reduces protection in an 
oxidative challenge model or if this effect is solely a result of loss of p53-mediated 
protection in the presence of MMF.  
 
3. Future directions 
Future studies investigating the importance of OSGIN1 in MMF-mediated 
cytoprotection will be targeted to understand the interactions of OSGIN1 and p53 in 
cellular protection. One way to approach this would be to tag OSGIN1 splice variants 
(i.e. GFP) to localize and compare if OSGIN1 variants differentially interact with p53. 
Ideally, the generation of an OSGIN1-61kDa GFP-tagged DNA would be of greatest 
interest; however, identification of the full length OSGIN1-61 kDa sequence is necessary 
to accomplish this. Nonetheless, if accomplished, these tagged proteins could then be 
investigated in various human neuronal cell lines to determine the cell-specific functions 
of OSGIN1 variants. This same experimental procedure could also be used to visualize 
Nrf2 and p53 interactions along with potential pull-down studies.  
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Investigation of the cell type-specific regulation of Nrf2 signaling is currently 
underway using a transgenic ARE-luciferase reporter mouse.  These mice have been 
treated with a single dose of DMF and are currently being analyzed via 
immunohistochemistry (IHC) to locate signal of Nrf2 activation in specific cell types. 
These studies will give further insight into the localization of Nrf2 signaling within 
different tissue types, which can be correlated with findings obtained from transcriptional 
profiling studies in Chapter 3. 
Further investigation into the role of PADI4 in OSGIN1/p53 mediated protection 
and its effects on cell proliferation are important to understand the role of PADI4 
downstream of OSGIN1. Although efforts have been made to understand if PADI4 
regulation is necessary for MMF-mediated cytoprotection, further studies are necessary 
to fully elucidate the importance of this gene in Nrf2-p53 signaling.  
In vivo analysis of OSGIN1 function would also be of particular interest. The 
importance of OSGIN1 in regards to immune cell infiltration and astrogliosis in animal 
models of MS, such as experimental autoimmune encephalomyelitis (EAE), could give 
insight into the anti-inflammatory and anti-proliferative effects associated with DMF and 
OSGIN1. Furthermore, generation of transgenic mice overexpressing the human 
OSGIN1-61 kDa and OSGIN1 knockout mouse models could give further insight into the 
important biological pathways associated with OSGIN1.  
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